diclofenac has been researched along with Osteoarthritis in 349 studies
Diclofenac: A non-steroidal anti-inflammatory agent (NSAID) with antipyretic and analgesic actions. It is primarily available as the sodium salt.
diclofenac : A monocarboxylic acid consisting of phenylacetic acid having a (2,6-dichlorophenyl)amino group at the 2-position.
Osteoarthritis: A progressive, degenerative joint disease, the most common form of arthritis, especially in older persons. The disease is thought to result not from the aging process but from biochemical changes and biomechanical stresses affecting articular cartilage. In the foreign literature it is often called osteoarthrosis deformans.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The results of 4 pivotal multicentre double-blind trials demonstrating the clinical efficacy of diclofenac/misoprostol in the treatment of rheumatoid and osteoarthritis are reviewed." | 10.17 | Diclofenac/misoprostol. A review of the major clinical trials evaluating its clinical efficacy and upper gastrointestinal tolerability in rheumatoid arthritis and osteoarthritis. ( Downie, WW, 1993) |
| "To examine elevations in levels of serum glutamic oxaloacetic transaminase (SGOT) in patients with rheumatoid arthritis (RA) and osteoarthritis (OA) taking placebo, aspirin, or diclofenac, and to seek possible explanations for the occurrence of these elevations." | 10.17 | Differential effects of diclofenac and aspirin on serum glutamic oxaloacetic transaminase elevations in patients with rheumatoid arthritis and osteoarthritis. ( Anderson, W; Furst, DE, 1993) |
| "To evaluate the efficacy and safety of intra-articular injection of diclofenac etalhyaluronate (DF-HA) in patients with osteoarthritis (OA) of the hip, ankle, shoulder, or elbow." | 9.51 | Diclofenac-hyaluronate conjugate (diclofenac etalhyaluronate) intra-articular injection for hip, ankle, shoulder, and elbow osteoarthritis: a randomized controlled trial. ( Ikegami, H; Kano, K; Kubo, T; Kumai, T; Nishii, M; Seo, T, 2022) |
| "To compare the efficacy and safety of ketoprofen plasters and diclofenac plasters after 3 weeks of administration in patients with osteoarthritis-related knee pain." | 9.41 | Comparison of the Efficacy and Safety of Ketoprofen Plaster and Diclofenac Plaster for Osteoarthritis-Related Knee Pain: A Multicenter, Randomized, Active-Controlled, Open-Label, Parallel-Group, Phase III Clinical Trial. ( Cha, JE; Ershova, O; Hyun, BJ; Kastanayan, A; Krechikova, D; Nikulenkova, N; Polyakova, S; Shvarts, Y; Vinogradova, I; Yakushin, S, 2021) |
| "Post-marketing study of combined therapy of OA of different localizations using diclofenac, aescin and original glucosamine sulfate in Russia and Ukraine demonstrated decrease of the pain severity, assessed by numeric rating scale, after 8 weeks of the treatment." | 9.17 | [Impact of combined therapy using glucosamine sulfate and anti-inflammatory agent on pain severity in patients with osteoarthritis: prospective, non-controlled postmarketing study]. ( Belen'kiĭ, DA; Borisenko, OV, 2013) |
| " Omeprazole and Diclofenac for At-Risk Osteoarthritis and Rheumatoid Arthritis Patients (CONDOR) trial showed that a haemoglobin drop ≥2 g/dL adjudicated as either of defined or presumed GI origin was the most frequent component/event for the composite GI primary end point." | 9.16 | Risk factors associated with a decrease ≥2 g/dL in haemoglobin and/or ≥10% haematocrit in osteoarthritis patients taking celecoxib or a nonselective NSAID plus a PPI in a large randomised controlled trial (CONDOR). ( Chan, FK; Goldstein, JL; Lanas, A; Li, C; Peura, DA; Sands, GH; Scheiman, JM; Wilcox, CM, 2012) |
| "To assess the clinical, biochemical, and histologic effects of topically administered diclofenac liposomal cream (DLC) in the treatment of horses with experimentally induced osteoarthritis." | 9.14 | Evaluation of topically administered diclofenac liposomal cream for treatment of horses with experimentally induced osteoarthritis. ( Frisbie, DD; Kawcak, CE; McIlwraith, CW; Pearce, GL; Werpy, NM, 2009) |
| "To evaluate efficacy and safety of aceclofenac-paracetamol combination against aceclofenac alone in patients with osteoarthritis (OA) flare-up." | 9.14 | A randomized, multicentric, comparative evaluation of aceclofenac-paracetamol combination with aceclofenac alone in Indian patients with osteoarthritis flare-up. ( Bartakke, G; Chandurkar, N; Desai, M; Kini, S; Pareek, A; Sharma, VD, 2009) |
| "To measure the efficacy and safety of diclofenac sodium gel in patients with primary hand osteoarthritis (OA)." | 9.14 | Diclofenac sodium gel in patients with primary hand osteoarthritis: a randomized, double-blind, placebo-controlled trial. ( Altman, RD; Chase, WF; Dreher, DS; Dreiser, RL; Fisher, CL; Zacher, J, 2009) |
| "A 4-week, multicentre, randomised, double-blind study has compared the effects of lumiracoxib 100 mg once daily (od) (n = 394) and ibuprofen 600 mg three times daily (tid) (n = 393) on ambulatory BP in osteoarthritis (OA) patients with controlled hypertension." | 9.14 | The effects of lumiracoxib 100 mg once daily vs. ibuprofen 600 mg three times daily on the blood pressure profiles of hypertensive osteoarthritis patients taking different classes of antihypertensive agents. ( Krammer, G; Lheritier, K; MacDonald, TM; Richard, D, 2010) |
| "To test whether treatment with celecoxib reduces the incidence of gastroduodenal ulcers compared to diclofenac in Asian patients with osteoarthritis (OA) or rheumatoid arthritis (RA) with minimal significant risk factors." | 9.14 | Incidence of gastroduodenal ulcers during treatment with celecoxib or diclofenac: pooled results from three 12-week trials in Chinese patients with osteoarthritis or rheumatoid arthritis. ( Cheng, TT; Cheung, R; Dong, Y; Feng, H; Lai, K; Lau, CS; Lin, HY; Parsons, B, 2010) |
| " To examine whether lumiracoxib 100 mg once daily would result in lower 24-h mean systolic ambulatory blood pressure than ibuprofen 600 mg three times daily in osteoarthritis patients with controlled hypertension, a 4-week, randomized, double-blind, parallel-group study was conducted in 79 centres in nine countries." | 9.13 | Effect on blood pressure of lumiracoxib versus ibuprofen in patients with osteoarthritis and controlled hypertension: a randomized trial. ( Krammer, G; Lheritier, K; Littlejohn, TW; MacDonald, TM; Rebuli, R; Reginster, JY; Richard, D, 2008) |
| " This safety study compared the GI tolerability, the blood pressure (BP) profile and the incidence of oedema with lumiracoxib and rofecoxib in the treatment of OA." | 9.13 | A 6-week, multicentre, randomised, double-blind, double-dummy, active-controlled, clinical safety study of lumiracoxib and rofecoxib in osteoarthritis patients. ( Krammer, G; Stricker, K; Yu, S, 2008) |
| "The aim of the study was to compare treatment with diclofenac sodium (Voltaren 3 x 50 mg) to occlusal splint therapy in a randomized, single-blind controlled trial of patients with a diagnosis of temporomandibular joint (TMJ) osteoarthritis (OA) in accordance with Research Diagnostic Criteria for temporomandibular disorders." | 9.13 | Diclofenac sodium and occlusal splint therapy in TMJ osteoarthritis: a randomized controlled trial. ( Mejersjö, C; Wenneberg, B, 2008) |
| "Randomized clinical trials evaluating ultramicronised diclofenac, diclofenac, celecoxib, etodolac and placebo in patients with osteoarthritis were identified." | 9.12 | Efficacy of ultramicronised diclofenac in patients with osteoarthritis - systematic review with network meta-analysis. ( Auletta, LL; de Almeida Macedo, E; de Campos, GC; Kummer, AM; Millan Fachi, M; Papaleo Rosim, M, 2021) |
| "To evaluate the efficacy and upper gastrointestinal (UGI) safety of celecoxib, compared with nonspecific nonsteroidal anti-inflammatory drugs (NSAIDs), among patients with osteoarthritis." | 9.12 | Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study. ( Agrawal, NM; Andrade-Ortega, L; Bello, AE; Eisen, GM; Fort, JG; Goldstein, JL; Hanrahan, PS; Levy, RA; Singh, G; Stenson, WF; Triadafilopoulos, G; Wallemark, C, 2006) |
| "Aceclofenac is an effective and well-tolerated drug in osteoarthritis in the Indian setting." | 9.12 | Efficacy and safety of aceclofenac in the treatment of osteoarthritis: a randomized double-blind comparative clinical trial versus diclofenac - an Indian experience. ( Chandanwale, AS; Jain, UK; Kapoor, S; Oak, J; Pareek, A, 2006) |
| " To compare the gastrointestinal (GI) tolerability, safety, and efficacy of etoricoxib and diclofenac in patients with osteoarthritis (OA)." | 9.12 | Gastrointestinal side effects of etoricoxib in patients with osteoarthritis: results of the Etoricoxib versus Diclofenac Sodium Gastrointestinal Tolerability and Effectiveness (EDGE) trial. ( Baraf, HS; Bird, S; Brzezicki, J; Curtis, SP; Fuentealba, C; Greenwald, M; Kaur, A; O'Brien, K; Polis, A; Soffer, B, 2007) |
| "To determine the cardiovascular outcomes in high risk patients with osteoarthritis treated with ibuprofen, naproxen or lumiracoxib." | 9.12 | Cardiovascular outcomes in high risk patients with osteoarthritis treated with ibuprofen, naproxen or lumiracoxib. ( Abramson, SB; Chesebro, JH; Farkouh, ME; Fuster, V; Greenberg, JD; Hochman, JS; Jeger, RV; Kirshner, H; Lay, CL; Matchaba, PT; Mellein, B; Ramanathan, K; Ruland, S; Verheugt, FW, 2007) |
| "To compare the analgesic efficacy and tolerability of a sustained-release pellet formulation of diclofenac (Olfen-100 SR Depocaps, SR-CAP, Mepha Ltd, Aesch, Switzerland) with the standard reference formulation (Voltaren retard 100, SR-TAB, Novartis Pharma AG, Basel, Switzerland), both containing 100 mg diclofenac sodium, in patients with osteoarthritis (OA) of the knee and/or hip." | 9.12 | Comparative efficacy and tolerability of two sustained-release formulations of diclofenac: results of a double-blind, randomised study in patients with osteoarthritis and a reappraisal of diclofenac's use in this patient population. ( Cambon, N; Frentzel, A; Mueller, EA; Wagenitz, A, 2007) |
| "To determine whether or not N of 1 trials with diclofenac/misoprostol (Arthrotec) are superior and cost-effective compared with standard treatment in osteoarthritis (OA)." | 9.11 | The efficacy and cost effectiveness of N of 1 studies with diclofenac compared to standard treatment with nonsteroidal antiinflammatory drugs in osteoarthritis. ( Anderson, J; Pope, JE; Prashker, M, 2004) |
| "The efficacy and safety of SKI306X, an herbal anti-arthritic agent, was compared with that of diclofenac sodium for the treatment of osteoarthritis of the knee." | 9.11 | A four-week, randomized, double-blind trial of the efficacy and safety of SKI306X: a herbal anti-arthritic agent versus diclofenac in osteoarthritis of the knee. ( Ahn, JH; Chang, DY; Cho, YB; Han, CK; Jung, KO; Jung, YK; Kim, DH; Kim, JM; Kwak, WJ; Lee, CS; Lee, MC; Lung, YB; Park, BJ; Park, YS; Roh, KJ; Seo, JG; Seong, SC; Shin, YU, 2004) |
| "In patients with OA, lumiracoxib 200 mg or 400 mg qd was associated with a significantly lower risk of gastroduodenal ulceration than ibuprofen 800 mg tid, and was similar to celecoxib 200 mg qd." | 9.11 | Gastroduodenal safety and tolerability of lumiracoxib compared with Ibuprofen and celecoxib in patients with osteoarthritis. ( Cousin, M; Fiedorowicz-Fabrycy, IF; Gitton, X; Hawkey, CC; Hoexter, G; Nasonov, EL; Pikhlak, EG; Svoboda, P, 2004) |
| " This study sought to evaluate dyspepsia-related health in osteoarthritis (OA) and rheumatoid arthritis (RA) patients taking valdecoxib compared with patients taking nonspecific NSAIDs." | 9.11 | Valdecoxib is associated with improved dyspepsia-related health compared with nonspecific NSAIDs in patients with osteoarthritis or rheumatoid arthritis. ( Goldstein, JL; Mayne, TJ; Rabeneck, L; Rublee, DA; Vu, A, 2005) |
| " Overall, the data indicate that administration of valdecoxib offers similar efficacy for the treatment of osteoarthritis but improved upper-gastrointestinal safety compared with the conventional NSAIDs, ibuprofen and diclofenac, based on the significantly lower incidence of gastroduodenal ulcers detected by endoscopy." | 9.10 | Incidence of gastroduodenal ulcers associated with valdecoxib compared with that of ibuprofen and diclofenac in patients with osteoarthritis. ( Agrawal, NM; Kent, JD; Recker, DP; Sikes, DH; Verburg, KM; Zhao, WW, 2002) |
| "A multi-centre, double-blind, randomised parallel-group study was conducted to compare the efficacy and safety between etodolac SR and diclofenac in treating patients with osteoarthritis of the knee." | 9.10 | Double-blind, randomised, comparative trial of etodolac SR versus diclofenac in the treatment of osteoarthritis of the knee. ( Hsu, PN; Liang, TH, 2003) |
| "To compare celecoxib (800 mg/day, n=1997) with diclofenac (150 mg/day, n=1996) on dyspepsia-related tolerability." | 9.10 | Dyspepsia tolerability from the patients' perspective: a comparison of celecoxib with diclofenac. ( Burke, TA; Eisen, GM; Geis, GS; Goldstein, JL; Lefkowith, J; Peña, BM, 2002) |
| ", Skokie, Illinois) administered twice daily with that of nabumetone 1500 mg administered once daily in 1203 patients with symptomatic osteoarthritis (OA) of the hip or knee." | 9.09 | Comparison of the upper gastrointestinal safety of Arthrotec 75 and nabumetone in osteoarthritis patients at high risk for developing nonsteroidal anti-inflammatory drug-induced gastrointestinal ulcers. ( Agrawal, NM; Ball, J; Bocanegra, TS; Caldwell, J; Dhadda, S; Hancock, L; Hurley, S; Kivitz, AJ; Weaver, AL, 1999) |
| "1), the rofecoxib group vs the Arthrotec group respectively reported diarrhea 6." | 9.09 | Tolerability profiles of rofecoxib (Vioxx) and Arthrotec. A comparison of six weeks treatment in patients with osteoarthritis. ( Acevedo, E; Beaulieu, AD; Caeiro, F; Casas, N; Castañeda, O; Garza-Elizondo, M; Gutierrez-Ureña, S; Hinojosa, W; Irazoque, F; Laurenzi, M; Pons-Estel, B; Rodgers, DB; Ugaz, M; Vandormael, K, 2001) |
| "The aim of this study was to evaluate the efficacy and tolerability of meloxicam compared with diclofenac in patients with osteoarthritis of the lumbar spine." | 9.09 | A comparison of the efficacy and tolerability of meloxicam and diclofenac in the treatment of patients with osteoarthritis of the lumbar spine. ( Accardo, S; Hettich, M; Lieu, PL; Reginster, JY; Valat, JP; Wouters, M, 2001) |
| "The objective of this study was to determine the long-term efficacy of misoprostol in preventing diclofenac-induced gastroduodenal ulcers in rheumatoid arthritis and osteoarthritis patients." | 9.08 | Misoprostol coadministered with diclofenac for prevention of gastroduodenal ulcers. A one-year study. ( Agrawal, NM; Erhardt, LJ; Geis, GS; Van Kerckhove, HE, 1995) |
| "To conduct the first Canadian study of the comparative efficacy and safety of nabumetone and diclofenac SR in patients with primary osteoarthritis (OA) of the hip, knee and shoulder." | 9.08 | A multicenter study of nabumetone and diclofenac SR in patients with osteoarthritis. ( Ahmad, S; Beaulieu, A; Bell, MJ; Bellamy, N; Bensen, WG; Davis, P; Khanna, VN; Kraag, GR; Lussier, A; Siminovitch, KA, 1995) |
| "A multicentre randomised, double-blind, parallel group, general practice study was undertaken to investigate the efficacy and safety of aceclofenac (200 patients, 100 mg twice daily and placebo once daily) in comparison with diclofenac (197 patients, 50mg three times daily) in patients with osteoarthritis of the knee." | 9.08 | Comparison of aceclofenac with diclofenac in the treatment of osteoarthritis. ( Bowdler, JM; Roma, J; Veys, EM; Ward, DE, 1995) |
| "A multicentre, double-blind, randomized study was conducted in patients with osteoarthritis (OA) of the hip or knee in order to compare the efficacy and safety of the new cyclooxygenase-2 (COX-2) inhibitor, meloxicam, with diclofenac sodium, a conventional treatment for this condition." | 9.08 | Meloxicam in osteoarthritis: a 6-month, double-blind comparison with diclofenac sodium. ( Bluhmki, E; Distel, M; Hosie, J, 1996) |
| "To assess the clinical efficacy of chondroitin sulfate (CS) in comparison with the nonsteroidal antiinflammatory drug (NSAID) diclofenac sodium (DS) in a medium/longterm clinical study in patients with knee osteoarthritis (OA)." | 9.08 | Comparison of the antiinflammatory efficacy of chondroitin sulfate and diclofenac sodium in patients with knee osteoarthritis. ( Boccanera, L; Bocchi, L; Galati, M; Manopulo, R; Morreale, P; Saponati, G, 1996) |
| "Topical application, 4 times daily for 2 weeks, of the diclofenac-hyaluronan gel to 59 osteoarthritis patients induced a significantly greater (p = 0." | 9.08 | A controlled clinical investigation of 3% diclofenac/2.5% sodium hyaluronate topical gel in the treatment of uncontrolled pain in chronic oral NSAID users with osteoarthritis. ( Roth, SH, 1995) |
| "To compare the efficacy and tolerability of lornoxicam and diclofenac in the treatment of patients with osteoarthritis (OA) over 12 weeks and to assess the efficacy and tolerability of lornoxicam over a followup period of 40 weeks." | 9.08 | A multicenter, randomized, double blind study comparing lornoxicam with diclofenac in osteoarthritis. ( Frenzel, W; Kidd, B, 1996) |
| "The efficacy and tolerability of a new resinate formulation of diclofenac 75mg taken once or twice daily were compared with that of conventional enteric-coated diclofenac sodium 50mg tablets given two or three times daily in a double-blind, randomised, between-patient, 12-week trial in 216 adult patients suffering from painful osteoarthritis of the hip and/or knee." | 9.08 | Comparative efficacy and tolerability of two diclofenac formulations in the treatment of painful osteoarthritis. ( Bakshi, R, 1996) |
| "A comparative study was conducted to evaluate the therapeutic efficacy of diclofenac sodium and flurbiprofen both non-steroidal anti-inflammatory drugs (NSAIDS) in osteoarthritis." | 9.08 | Comparative study of diclofenac sodium and flurbiprofen in osteoarthritis. ( Ali, M; Shaikh, KA; Sharafatullah, T, 1996) |
| "A multicentre, double-blind, randomised, parallel group study was undertaken to investigate the efficacy and safety of aceclofenac (123 patients, 100 mg twice daily) in comparison to piroxicam (117 patients, 20 mg once daily and placebo once daily) in patients with osteoarthritis of the knee." | 9.08 | Comparison of aceclofenac with piroxicam in the treatment of osteoarthritis. ( Alepuz Pou, M; Bermudez, A; Calero, E; Caliz, R; Cano, M; Caracuel, MA; Castellon Arce, P; Ffernandez Crisostomos, C; Garcia Lopez, A; Garcia Perez, S; Garcia Villalba, F; Garcia, C; Gines Martinez, F; Gonzalez, A; Gonzalez, J; Guzman Ubeda, M; Linares, LF; Lopez, MA; Marenco de la Fuente, IL; Mesa, J; Peréz Busquier, M; Povedano, A; Rodríguez, M; Roldan, R; Valenzuela, A, 1997) |
| "The efficacy and safety of aceclofenac (100 mg bid), a new nonsteroidal anti-inflammatory/anti-rheumatic agent, were compared with those of naproxen (500 mg bid) in a multi-centre, twelve-week, randomized, double-blind, parallel-group clinical trial in outpatients with active osteoarthritis of the knee." | 9.08 | Aceclofenac is a well-tolerated alternative to naproxen in the treatment of osteoarthritis. ( Bowdler, J; Frerick, H; Kornasoff, D; Montull, E, 1997) |
| "The efficacy and safety of nabumetone are similar to those of aceclofenac in the treatment of knee osteoarthritis." | 9.08 | [Efficacy and safety of nabumetone in the treatment of knee osteoarthritis: a comparative clinical trial versus aceclofenac. Study Group of Nabumetone for Osteoarthritis of the Knee]. ( Gijón Baños, J, 1997) |
| "In a randomized, double blind, multicentre study with 4 weeks follow-up of 290 patients with osteoarthritis of the knee joint, a topical NSAID (eltenac) was compared with oral diclofenac and placebo." | 9.08 | Local NSAID gel (eltenac) in the treatment of osteoarthritis of the knee. A double blind study comparing eltenac with oral diclofenac and placebo gel. ( Crone, H; Forsskåhl, B; Hamberg, P; Harilainen, A; Sandelin, J; Tamelander, G, 1997) |
| " The aim of this study was to investigate the efficacy and tolerability of 15 mg meloxicam in comparison with 100 mg slow-release diclofenac in patients with osteoarthritis of the knee." | 9.08 | A double-blind, randomized trial to compare meloxicam 15 mg with diclofenac 100 mg in the treatment of osteoarthritis of the knee. ( Bluhmki, E; Distel, MR; Goei Thè, HS; Lund, B, 1997) |
| "Diclofenac/misoprostol at twice daily dosing is associated with significantly fewer gastroduodenal ulcers than either piroxicam or naproxen." | 9.07 | Double-blind comparison of efficacy and gastroduodenal safety of diclofenac/misoprostol, piroxicam, and naproxen in the treatment of osteoarthritis. ( Bruyn, GA; Geis, GS; Melo Gomes, JA; Roth, SH; Woods, EM; Zeeh, J, 1993) |
| "To conduct the first Canadian study of the comparative efficacy and safety of tenoxicam and diclofenac in patients with primary osteoarthritis (OA) of the knee." | 9.07 | A multicenter study of tenoxicam and diclofenac in patients with osteoarthritis of the knee. ( Bellamy, N; Buchanan, WW; Campbell, J; Chalmers, A; Ford, PM; Gerecz-Simon, E; Kean, WF; Kraag, GR, 1993) |
| "The efficacy of nabumetone was compared with that of diclofenac, naproxen, ibuprofen, and piroxicam in patients with osteoarthritis (OA) or rheumatoid arthritis (RA) in a randomized, controlled, open-label, multicenter trial." | 9.07 | Efficacy of nabumetone versus diclofenac, naproxen, ibuprofen, and piroxicam in osteoarthritis and rheumatoid arthritis. ( DeLapp, RE; Lister, BJ; Poland, M, 1993) |
| "A double-blind, randomized, parallel group study was conducted to compare the gastroduodenal safety and antiarthritic efficacy of a fixed combination of diclofenac 50 mg and misoprostol 200 micrograms with that of a combination of diclofenac 50 mg and placebo in patients with osteoarthritis." | 9.07 | The gastroduodenal safety and efficacy of the fixed combination of diclofenac and misoprostol in the treatment of osteoarthritis. ( Bolten, W; Geis, GS; Gomes, JA; Stead, H, 1992) |
| "A six week, double-blind, randomized, parallel group, multicentre study was conducted in 85 patients with osteoarthritis of the knee and hip to compare the efficacy, tolerability, and safety of Flurbiprofen-SR 200 mg with Diclofenac Sodium-SR 100 mg." | 9.07 | Double-blind randomized controlled trial of flurbiprofen-SR (ANSAID-SR) and diclofenac sodium-SR (Voltaren-SR) in the treatment of osteoarthritis. ( Bellamy, N; Bensen, WG; Ford, PM; Huang, SH; Lang, JY, 1992) |
| "The efficacy and tolerability of a new dispersible formulation of diclofenac were evaluated in a randomized, double-blind, placebo-controlled, multi-centre study in patients aged 60 to 80 years suffering from osteoarthritis." | 9.07 | Efficacy and tolerability of diclofenac dispersible in elderly patients with osteoarthritis. ( Bakshi, R; Darekar, B; Langdon, CG; Rotman, H, 1991) |
| "20 UK general-practice centres entered 243 patients into a 6-week double-blind, double-dummy, randomised, parallel-group trial designed to compare nabumetone 1 g at night with slow release diclofenac 100mg at night in the treatment of osteoarthritis." | 9.06 | A microcomputer-assisted study of nabumetone and slow release diclofenac in osteoarthritis. ( Fehilly, B; Laws, D; Saul, S, 1990) |
| "Eighty patients with osteoarthritis were randomly assigned to either piroxicam (20 mg daily) or diclofenac (75-150 mg daily) in a 12-week double-blind, parallel groups study." | 9.06 | A controlled comparison of piroxicam and diclofenac in patients with osteoarthritis. ( Buchanan, WW; Gerecz-Simon, E; Kean, WF; Rooney, PJ; Soper, WY; Tugwell, P, 1990) |
| "Seventy-four patients were enrolled in this double-blind, randomized single-center study to evaluate the therapeutic effectiveness of 50 mg tid regimens of flurbiprofen or diclofenac sodium in patients with osteoarthritis of the knee." | 9.06 | Flurbiprofen versus diclofenac for the treatment of osteoarthritis of the knee. ( Atra, E; Brown, BL; Metz, CA; Teoh, K, 1990) |
| "A double-blind, crossover study was undertaken in general practice to compare the efficacy and tolerability of a new controlled-release indomethacin with sustained-release diclofenac sodium in patients with osteoarthritis." | 9.06 | Controlled-release indomethacin and sustained-release diclofenac sodium in the treatment of osteoarthritis: a comparative controlled clinical trial in general practice. ( Gostick, N; James, IG; Khong, TK; Miller, AJ; Roy, P; Shepherd, PR, 1990) |
| "Interim results are reported for three double-blind clinical trials comparing etodolac, a new nonsteroidal anti-inflammatory drug (NSAID), with piroxicam, diclofenac, or naproxen in patients with osteoarthritis (OA) of the knee." | 9.06 | Recent clinical experience with etodolac in the treatment of osteoarthritis of the knee. ( Platt, PN, 1989) |
| "In a randomized, double-blind comparative study involving a total of 1630 outpatients, tenoxicam, a new nonsteroidal anti-inflammatory drug belonging to the oxicam group, piroxicam and diclofenac retard were tested for their efficacy und tolerability in the treatment of osteoarthritis and extra-articular rheumatism." | 9.06 | [Double-blind randomized multicenter study with tenoxicam, piroxicam and diclofenac sodium retard in the treatment of ambulatory patients with arthroses and soft tissue rheumatism]. ( Gobelet, CA; Moser, U; Schwarz, HA; Waldburger, M, 1989) |
| "In a randomised, double-blind comparative study involving a total of 1,630 out-patients, tenoxicam (a new non-steroidal anti-inflammatory drug belonging to the oxicam group), piroxicam and diclofenac retard were tested for their efficacy and tolerability in the treatment of osteoarthritis (OA) and extra-articular rheumatism (EAR)." | 9.06 | A double-blind randomised multicentre study with tenoxicam, piroxicam and diclofenac sodium retard in the treatment of ambulant patients with osteoarthritis and extra-articular rheumatism. ( Gobelet, CA; Moser, U; Schwarz, HA; Waldburger, H, 1989) |
| "Despite a wide range of study designs, a multiplicity of international trials of diclofenac in osteoarthritis have disclosed similar results." | 9.06 | International experiences with diclofenac in osteoarthritis. ( Altman, R, 1986) |
| "The role of diclofenac sodium in patients with symptomatic osteoarthritis of the hip or knee has been evaluated in five prospective, randomized, double-blind, controlled trials with placebo, aspirin, and naproxen conducted in the United States." | 9.06 | Efficacy of diclofenac in osteoarthritis. Experience in the United States. ( Ward, JR, 1986) |
| "150 mg/day sodic diclofenac was found particularly active in subjects with diathetic rheumatism and arthrosis." | 9.04 | [Experiences with the use of sodium diclofenac (Voltaren) in rheumatic diseases]. ( Durante, F, 1978) |
| "A five-centre double-blind crossover trial of two two-week periods using diclofenac and indomethacin showed that both drug groups (51 patients) with rheumatoid arthritis responded similarly in relation to pain scores and morning stiffness." | 9.04 | Diclofenac sodium (Voltarol) and indomethacin: a multicentre comparative study in rheumatoid arthritis and osteoarthritis. ( Barnes, CG; Berry, H; Carter, ME; Downie, WW; Fowler, PD; Moll, JM; Perry, JD; Sawaf, MS; Wright, V, 1979) |
| " In a two-week double-blind study, diclofenac was compared with indomethacin in 43 outpatients with osteoarthritis or rheumatoid arthritis." | 9.04 | An open assessment of the efficacy and tolerability of diclofenac sodium (Voltarol) in patients with rheumatic disease and a comparative study of diclofenac sodium (Voltarol) with indomethacin in patients with osteoarthritis and rheumatoid arthritis. ( Cash, HC; McMahon, MF, 1979) |
| "Oxaceprol, a derivative of l-proline, is an established drug for managing osteoarthritis (OA) with better safety profile than non-steroidal anti-inflammatory drugs (NSAIDs)." | 9.01 | A systematic review and meta-analysis of oxaceprol in the management of osteoarthritis: An evidence from randomized parallel-group controlled trials. ( Bhate, J; Durg, S; Lobo, M; Rao, G; Venkatachalam, L, 2019) |
| "Osteoarthritis (OA) is one of the most common causes of joint pain in the United States and non-steroidal anti-inflammatories (NSAIDs), such as Diclofenac sodium, which is currently available in two main routes of administration; oral and topical distribution have been established as one of the standard treatments for OA." | 8.95 | Oral Versus Topical Diclofenac Sodium in the Treatment of Osteoarthritis. ( Brown, TL; Davani, S; Tieppo Francio, V; Towery, C, 2017) |
| "The objective of this study was to evaluate the efficacy and safety of topical diclofenac therapy for osteoarthritis (OA)." | 8.93 | Topical diclofenac therapy for osteoarthritis: a meta-analysis of randomized controlled trials. ( Deng, ZH; Lei, GH; Li, H; Li, YS; Wei, J; Yang, T; Yang, Y; Zeng, C, 2016) |
| " This study compared the efficacy, safety, and tolerability of diclofenac, ibuprofen, naproxen, celecoxib, and etoricoxib for patients with pain caused by osteoarthritis (OA) or rheumatoid arthritis (RA)." | 8.91 | Relative benefit-risk comparing diclofenac to other traditional non-steroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors in patients with osteoarthritis or rheumatoid arthritis: a network meta-analysis. ( Guyot, P; Karabis, A; Moore, RA; Nixon, RM; Pandhi, S; van Walsem, A, 2015) |
| "The efficacy and safety of low-dose SoluMatrix diclofenac was evaluated in two randomized, placebo-controlled Phase III studies: a study in patients with acute pain following bunionectomy surgery and a study in patients with osteoarthritis pain of the hip or knee." | 8.91 | Low-dose SoluMatrix diclofenac : a review of safety across two Phase III studies in patients with acute and osteoarthritis pain. ( Altman, R; Daniels, S; Gibofsky, A; Imasogie, O; Young, C, 2015) |
| "Diclofenac is a nonsteroidal anti-inflammatory drug (NSAID) commonly prescribed for pain relief in osteoarthritis (OA)." | 8.88 | A comparison of the therapeutic efficacy of diclofenac in osteoarthritis: a systematic review of randomised controlled trials. ( Pavelka, K, 2012) |
| "A prespecified pooled intent-to-treat analysis of three double-blind randomised comparisons of etoricoxib (60 or 90 mg daily) and diclofenac (150 mg daily) in 34 701 patients with osteoarthritis or rheumatoid arthritis was done for upper gastrointestinal clinical events (bleeding, perforation, obstruction, or ulcer) and the subset of complicated events (perforation, obstruction, witnessed ulcer bleeding, or significant bleeding)." | 8.84 | Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. ( Cannon, CP; Cryer, B; Curtis, SP; Kaur, A; Laine, L, 2007) |
| " It has proved as effective as diclofenac, naproxen and piroxicam in patients with osteoarthritis, diclofenac, ketorolac, tenoxicam and indomethacin in patients with rheumatoid arthritis and tenoxicam, naproxen and indomethacin in patients with ankylosing spondylitis." | 8.82 | Aceclofenac in the management of inflammatory pain. ( Legrand, E, 2004) |
| "The aim of this meta-analysis based on the literature was to gather all evidence of randomized clinical trials to assess the efficacy of adenosylmethionine (SAM) and oxaceprol in the treatment of osteoarthritis." | 8.81 | [Meta-analysis of the efficacy of adenosylmethionine and oxaceprol in the treatment of osteoarthritis]. ( Lasek, R; Victor, N; Witte, S, 2002) |
| "World-wide experience with nimesulide confirms that it is an effective anti-inflammatory drug in the treatment of osteoarthritis." | 8.81 | Nimesulide, a balanced drug for the treatment of osteoarthritis. ( Huskisson, EC, 2001) |
| "The aim of this article is to critically review the potential role of aceclofenac in the treatment of inflammatory pain and chronic osteoarticular disorder, based on its activity on the mediators of inflammation, its effect on cartilage remodeling and on the results of clinical studies comparing aceclofenac with other NSAIDs in these disorders." | 8.81 | [What is the role of aceclofenac in the therapeutic arsenal against chronic osteoarthritis pathologies?]. ( Henrotin, Y; Paul, I; Reginster, JY, 2001) |
| "To obtain a better quantitative and qualitative estimate of the effect of tenoxicam (Tx) compared to piroxicam (Px), diclofenac (Dcl) and indomethacin (Ind) in the treatment of osteoarthritis (OA)." | 8.78 | A study to determine the efficacy and safety of tenoxicam versus piroxicam, diclofenac and indomethacin in patients with osteoarthritis: a meta-analysis. ( Bersinic, S; Cuddy, LJ; Riedemann, PJ; Torrance, GW; Tugwell, PX, 1993) |
| "A meta-analysis was done with the final data from three trials that provided the first results relating to efficacy and safety of the new sustained-release (SR) formulation of etodolac versus established nonsteroidal anti-inflammatory drugs (NSAIDs) in the treatment of osteoarthritis (OA) of the knee." | 8.78 | Meta-analysis of three double-blind comparative trials with sustained-release etodolac in the treatment of osteoarthritis of the knee. ( Porzio, F, 1993) |
| " Published data indicate that diclofenac 75 to 150mg daily (25 to 50mg 3 times daily) is comparable in efficacy with ordinary aspirin 3 to 5g daily and indomethacin 75 to 150mg daily in rheumatoid arthritis and with indomethacin in osteoarthritis." | 8.76 | Diclofenac sodium: a review of its pharmacological properties and therapeutic use in rheumatic diseases and pain of varying origin. ( Avery, GS; Brogden, RN; Heel, RC; Pakes, GE; Speight, TM, 1980) |
| "OA patients initiating tramadol have an increased risk of mortality, VTE, and hip fractures within 1 year compared with commonly prescribed NSAIDs, but not with codeine." | 8.12 | Association of tramadol with all-cause mortality, cardiovascular diseases, venous thromboembolism, and hip fractures among patients with osteoarthritis: a population-based study. ( Aviña-Zubieta, JA; Cibere, J; Esdaile, JM; Kopec, JA; Li, L; Lu, N; Marozoff, S; Xie, H, 2022) |
| "Joint pain decreased after 2 weeks of therapy in all patients during treatment with Voltaren Emulgel 2% (diclofenac diethylamine 2%) in both groups." | 8.02 | [Evaluation of topical therapy of patients with osteoarthritis of small joints of the hands with Voltaren® Emulgel® 2% (diclofenac diethylamine 2%)]. ( Gromova, MA; Tsurko, VV, 2021) |
| "Tramadol has been widely used among patients with osteoarthritis (OA); however, there is paucity of information on its cardiovascular risk." | 7.96 | Association of tramadol with risk of myocardial infarction among patients with osteoarthritis. ( Choi, HK; Dubreuil, M; LaRochelle, MR; Lei, G; Lin, J; Lu, N; Tomasson, G; Wei, J; Wood, MJ; Zeng, C; Zhang, Y, 2020) |
| "The anti-inflammatory and anti-catabolic actions of Diclofenac were compared with apigenin-C-glycosides rich Clinacanthus nutans (CN) leaf extract in osteoporotic-osteoarthritis rats." | 7.96 | Comparison of diclofenac with apigenin-glycosides rich Clinacanthus nutans extract for amending inflammation and catabolic protease regulations in osteoporotic-osteoarthritis rat model. ( Hussin, P; Lau, SF; Mohamed, S; Tantowi, NACA, 2020) |
| "We identified randomised controlled trials (RCTs) of diclofenac with planned study duration of at least 4 weeks for the treatment of osteoarthritis (OA) from 'legacy' studies conducted by Novartis but not published in a peer reviewed journal or included in any previous pooled analyses." | 7.85 | Efficacy and safety of diclofenac in osteoarthritis: Results of a network meta-analysis of unpublished legacy studies. ( Andrew Moore, R; Chaves, RL; Guyot, P; Iqbal, A; Nixon, RM; Pandhi, S, 2017) |
| "The aim of the present study was to investigate anti-inflammatory activity of Diclocor in the setting of collagen-induced osteoarthritis in rats in comparison with its active monocomponents-diclofenac sodium and quercetin." | 7.83 | Diclocor is superior to diclofenac sodium and quercetin in normalizing biochemical parameters in rats with collagen-induced osteoarthritis. ( Popov, OS; Shalamay, AS; Shebeko, SK; Zupanets, IA, 2016) |
| "Topical diclofenac, with and without dimethyl sulfoxide (DMSO), modestly improves pain and function scores (by 4%-8%) for as long as 12 weeks in patients with osteoarthritis (OA) of the knee." | 7.81 | Clinical inquiry: does topical diclofenac relieve osteoarthritis pain? ( Hodge, B; Skolnik, D, 2015) |
| "Celecoxib for the treatment of pain resulting from osteoarthritis (OA) was reviewed by the Tandvårds- och läkemedelsförmånsverket-Dental and Pharmaceutical Benefits Board (TLV) in Sweden in late 2010." | 7.80 | A cost-effectiveness analysis of celecoxib compared with diclofenac in the treatment of pain in osteoarthritis (OA) within the Swedish health system using an adaptation of the NICE OA model. ( Akehurst, R; Brereton, N; Ekelund, M; Pennington, B, 2014) |
| "The National Institute for Health and Clinical Excellence (NICE) health economic model for assessing the cost-effectiveness of celecoxib plus a proton pump inhibitor (PPI) compared to diclofenac plus PPI in the treatment of osteoarthritis has been updated using new adverse event (AE) risks from the CONDOR trial." | 7.78 | The cost-effectiveness of celecoxib vs diclofenac in the treatment of osteoarthritis in the UK; an update to the NICE model using data from the CONDOR trial. ( Akehurst, R; Brereton, N; Winn, B, 2012) |
| "To evaluate the safety of topical diclofenac sodium 1% gel (DSG) for knee and hand osteoarthritis (OA) in older and younger patients and in patients with versus without comorbid hypertension, type 2 diabetes, or cerebrovascular or cardiovascular disease." | 7.78 | Tolerability of topical diclofenac sodium 1% gel for osteoarthritis in seniors and patients with comorbidities. ( Baraf, HS; Gold, MS; Petruschke, RA; Wieman, MS, 2012) |
| "5% dimethyl sulfoxide (TDiclo) for the treatment of knee or hand osteoarthritis in persons aged 75 years or older." | 7.78 | Pooled safety analysis of diclofenac sodium topical solution 1.5% (w/w) in the treatment of osteoarthritis in patients aged 75 years or older. ( Fuller, P; Roth, SH, 2012) |
| " The MEDAL program is designed to provide a precise estimate of the relative cardiovascular event rates with the COX-2 selective inhibitor etoricoxib in comparison to the traditional NSAID diclofenac in patients with osteoarthritis and rheumatoid arthritis." | 7.73 | Clinical trial design and patient demographics of the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) study program: cardiovascular outcomes with etoricoxib versus diclofenac in patients with osteoarthritis and rheumatoid arthritis. ( Bolognese, JA; Cannon, CP; Curtis, SP; Laine, L, 2006) |
| "We designed a prespecified pooled analysis of data from three trials in which patients with osteoarthritis or rheumatoid arthritis were randomly assigned to etoricoxib (60 mg or 90 mg daily) or diclofenac (150 mg daily)." | 7.73 | Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. ( Bolognese, JA; Bombardier, C; Cannon, CP; Curtis, SP; Erdmann, E; FitzGerald, GA; Kaur, A; Krum, H; Laine, L; Reicin, AS; van der Heijde, D; Weinblatt, ME, 2006) |
| "To assess the economic efficiency of meloxicam, a cyclo-oxygenase (COX)-2 selective inhibitor, versus diclofenac and piroxicam in the UK for the treatment of patients with osteoarthritis and the impact on the NHS budget of substituting nonselective NSAIDs with meloxicam." | 7.72 | Modelling therapeutic strategies in the treatment of osteoarthritis: an economic evaluation of meloxicam versus diclofenac and piroxicam. ( Tavakoli, M, 2003) |
| " To compare the risk for thrombotic cardiovascular events among patients receiving rofecoxib, nonselective NSAIDs, and placebo, cardiovascular safety was assessed in 5,435 participants in 8 phase IIB/III osteoarthritis trials." | 7.71 | Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs (ibuprofen, diclofenac, and nabumetone). ( Barr, E; Reicin, AS; Shapiro, D; Sperling, RS; Yu, Q, 2002) |
| "This study combined existing data to test the hypothesis that GI comedications and GI diagnostic procedures occur less frequently in osteoarthritis (OA) patients treated with rofecoxib compared with nonselective NSAIDs." | 7.71 | Gastrointestinal medications and procedures in osteoarthritis patients treated with rofecoxib compared with nonselective NSAIDs. ( Bolognese, JA; Harper, SE; Simon, TJ; Watson, DJ; Zhao, PL, 2001) |
| "The incidence of lower extremity edema (LEE) AEs was generally similar between rofecoxib 12." | 7.71 | A comparison of adverse renovascular experiences among osteoarthritis patients treated with rofecoxib and comparator non-selective non-steroidal anti-inflammatory agents. ( Bolognese, JA; Gertz, BJ; Krupa, D; Reicin, A; Sperling, RS, 2002) |
| "To analyze results of treatment of osteoarthritis (OA) with acetaminophen and the nonsteroidal antiinflammatory drugs (NSAID) through a patient survey." | 7.70 | Preference for nonsteroidal antiinflammatory drugs versus acetaminophen and concomitant use of both types of drugs in patients with osteoarthritis. ( Callahan, LF; Cummins, P; Pincus, T; Swearingen, C, 2000) |
| "To examine the effects of tenidap and diclofenac on osteoarthritic lesions and metalloprotease activity in experimental osteoarthritis (OA)." | 7.69 | Effects of tenidap on canine experimental osteoarthritis. I. Morphologic and metalloprotease analysis. ( Fernandes, JC; Lopez-Anaya, A; Martel-Pelletier, J; Mineau, F; Otterness, IG; Pelletier, JP; Tardif, G, 1995) |
| "Severe immune haemolytic anaemia and thrombocytopenia developed in a 71-year-old female within 10 d of starting diclofenac (Voltarol) therapy." | 7.67 | Severe reversible autoimmune haemolytic anaemia and thrombocytopenia associated with diclofenac therapy. ( Hershko, C; Kramer, MR; Levene, C, 1986) |
| "The effect of diclofenac sodium (DS) on the metabolism of glycosaminoglycans (GAG) was studied in rabbits during the development of osteoarthritis of the knee induced by immobilization." | 7.67 | Effects of sodium diclofenac on glycosaminoglycan metabolism in experimental osteoarthritis in rabbits. ( Eronen, I; Videman, T, 1985) |
| " Evaluation of the profile of adverse events was the main aim of the trial, together with assessment of efficacy." | 6.69 | Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients. International MELISSA Study Group. Meloxicam Large-scale International Study Safety Assessment. ( Alegre, C; Baumelou, E; Bégaud, B; Dequeker, J; Hawkey, C; Isomäki, H; Kahan, A; Littlejohn, G; Mau, J; Papazoglou, S; Steinbrück, K, 1998) |
| "Conventional nonsteroidal anti-inflammatory drugs (NSAIDs) are associated with a spectrum of toxic effects, notably gastrointestinal (GI) effects, because of inhibition of cyclooxygenase (COX)-1." | 6.69 | Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. ( Agrawal, NM; Burr, AM; Eisen, G; Faich, G; Geis, GS; Goldstein, JL; Kent, JD; Lefkowith, JB; Makuch, R; Pincus, T; Silverstein, FE; Simon, LS; Stenson, WF; Verburg, KM; Whelton, A; Zhao, WW, 2000) |
| "Ibuprofen was also better tolerated than diclofenac sodium (100 mg/day), the latter being associated with gastrointestinal side effects in a significant proportion of patients." | 6.68 | Ibuprofen and diclofenac sodium in the treatment of osteoarthritis: a comparative trial of two once-daily sustained-release NSAID formulations. ( Baumgartner, H; Blum, W; Bruhin, A; Gallachi, G; Goldinger, G; Saxer, M; Schwarz, HA; Trost, H, 1996) |
| "Naproxen-treated patients experienced significantly (p < 0." | 6.67 | Safety experience with nabumetone versus diclofenac, naproxen, ibuprofen, and piroxicam in osteoarthritis and rheumatoid arthritis. ( DeLapp, RE; Eversmeyer, W; Jensen, CP; Poland, M, 1993) |
| " However, serious gastrointestinal and cardiovascular systemic adverse events (AEs) are associated with oral NSAIDs and can be treatment limiting." | 6.47 | Diclofenac sodium topical solution 1.5% w/w with dimethyl sulfoxide compared with placebo for the treatment of osteoarthritis: pooled safety results. ( Fuller, P; Roth, SH, 2011) |
| " We estimated 95% confidence interval, Q and 12 criteria, Mantel-Haenszel and DerSimonian-Laird statistics and relative risk of adverse reactions." | 6.46 | [Diclofenac sodium in osteoarthritis. Is there risk of hepatotoxicity? A systematic review]. ( Koniaeva, EI; Matveev, AV, 2010) |
| " The clinical trial in patients with periarthritis of shoulder showed statistical equivalence of pain reduction, whether they were treated with phlogenzym or diclofenac." | 6.19 | [Reducing pain by oral enzyme therapy in rheumatic diseases]. ( Klein, G; Kullich, W, 1999) |
| "The results of 4 pivotal multicentre double-blind trials demonstrating the clinical efficacy of diclofenac/misoprostol in the treatment of rheumatoid and osteoarthritis are reviewed." | 6.17 | Diclofenac/misoprostol. A review of the major clinical trials evaluating its clinical efficacy and upper gastrointestinal tolerability in rheumatoid arthritis and osteoarthritis. ( Downie, WW, 1993) |
| "To examine elevations in levels of serum glutamic oxaloacetic transaminase (SGOT) in patients with rheumatoid arthritis (RA) and osteoarthritis (OA) taking placebo, aspirin, or diclofenac, and to seek possible explanations for the occurrence of these elevations." | 6.17 | Differential effects of diclofenac and aspirin on serum glutamic oxaloacetic transaminase elevations in patients with rheumatoid arthritis and osteoarthritis. ( Anderson, W; Furst, DE, 1993) |
| "To evaluate the efficacy and safety of intra-articular injection of diclofenac etalhyaluronate (DF-HA) in patients with osteoarthritis (OA) of the hip, ankle, shoulder, or elbow." | 5.51 | Diclofenac-hyaluronate conjugate (diclofenac etalhyaluronate) intra-articular injection for hip, ankle, shoulder, and elbow osteoarthritis: a randomized controlled trial. ( Ikegami, H; Kano, K; Kubo, T; Kumai, T; Nishii, M; Seo, T, 2022) |
| " Both 27 and 48 demonstrated robust activity in the acute rat monoiodoacetate-induced osteoarthritis model of pain, and subchronic dosing of 48 showed a shift to a lower EC50 over 7 days." | 5.43 | Substituted Indazoles as Nav1.7 Blockers for the Treatment of Pain. ( Daanen, JF; DeGoey, DA; El-Kouhen, OF; Fricano, MM; Frost, JM; Ghoreishi-Haack, N; Gum, RJ; Hsieh, GC; Kort, ME; Lundgaard, GL; Matulenko, MA; Neelands, T; Pai, M; Shi, L; Zhan, C; Zhang, XF, 2016) |
| "To compare the efficacy and safety of ketoprofen plasters and diclofenac plasters after 3 weeks of administration in patients with osteoarthritis-related knee pain." | 5.41 | Comparison of the Efficacy and Safety of Ketoprofen Plaster and Diclofenac Plaster for Osteoarthritis-Related Knee Pain: A Multicenter, Randomized, Active-Controlled, Open-Label, Parallel-Group, Phase III Clinical Trial. ( Cha, JE; Ershova, O; Hyun, BJ; Kastanayan, A; Krechikova, D; Nikulenkova, N; Polyakova, S; Shvarts, Y; Vinogradova, I; Yakushin, S, 2021) |
| "Diclofenac was highly effective in both tests on day 3, while on day 20 it induced a less pronounced decrease in the Knee-Bend score and was ineffective in the CatWalk test." | 5.38 | Analgesic effects of lidocaine, morphine and diclofenac on movement-induced nociception, as assessed by the Knee-Bend and CatWalk tests in a rat model of osteoarthritis. ( Adães, S; Castro-Lopes, JM; Ferreira-Gomes, J; Mendonça, M, 2012) |
| "Diclofenac was the test NSAID and collagomers--novel vesicular-shaped microparticles based on collagen-lipid conjugates--were the carriers." | 5.35 | A novel Diclofenac-carrier for local treatment of osteoarthritis applying live-animal MRI. ( Biton, IE; Elron-Gross, I; Glucksam, Y; Margalit, R, 2009) |
| "98 per patient depending on the dosage of diclofenac used." | 5.30 | Economic evaluation of nimesulide versus diclofenac in the treatment of osteoarthritis in Greece. ( Diamantopoulos, E; Ifandi, G; Ignatiades, T; Katostaras, F; Liaropoulos, L; Spinthouri, M, 1998) |
| "Post-marketing study of combined therapy of OA of different localizations using diclofenac, aescin and original glucosamine sulfate in Russia and Ukraine demonstrated decrease of the pain severity, assessed by numeric rating scale, after 8 weeks of the treatment." | 5.17 | [Impact of combined therapy using glucosamine sulfate and anti-inflammatory agent on pain severity in patients with osteoarthritis: prospective, non-controlled postmarketing study]. ( Belen'kiĭ, DA; Borisenko, OV, 2013) |
| " Omeprazole and Diclofenac for At-Risk Osteoarthritis and Rheumatoid Arthritis Patients (CONDOR) trial showed that a haemoglobin drop ≥2 g/dL adjudicated as either of defined or presumed GI origin was the most frequent component/event for the composite GI primary end point." | 5.16 | Risk factors associated with a decrease ≥2 g/dL in haemoglobin and/or ≥10% haematocrit in osteoarthritis patients taking celecoxib or a nonselective NSAID plus a PPI in a large randomised controlled trial (CONDOR). ( Chan, FK; Goldstein, JL; Lanas, A; Li, C; Peura, DA; Sands, GH; Scheiman, JM; Wilcox, CM, 2012) |
| "Post-screening and on inclusion, patients were put on a 2-week washout period and then randomly assigned to either only lisinopril 10 mg or combination of lisinopril 10 mg and diclofenac sodium 100 mg treatments for 8-12 weeks in diseased states of hypertension and osteoarthritis with or without type 2 diabetes mellitus." | 5.15 | Potential pharmacodynamic drug-drug interaction between concomitantly administered lisinopril and diclofenac sodium: a call for appropriate management in hypertensive osteoarthritic patients. ( Chudasama, H; Goswami, SK; Jain, S; Santani, D, 2011) |
| "Patients > or = 50 years with rheumatoid arthritis or osteoarthritis were randomly assigned to diclofenac (150 mg daily) or etoricoxib (60 or 90 mg daily)." | 5.14 | How common is diclofenac-associated liver injury? Analysis of 17,289 arthritis patients in a long-term prospective clinical trial. ( Cannon, CP; Connors, LG; Curtis, SP; Goldkind, L; Laine, L; Yanqiong, Z, 2009) |
| "To assess the clinical, biochemical, and histologic effects of topically administered diclofenac liposomal cream (DLC) in the treatment of horses with experimentally induced osteoarthritis." | 5.14 | Evaluation of topically administered diclofenac liposomal cream for treatment of horses with experimentally induced osteoarthritis. ( Frisbie, DD; Kawcak, CE; McIlwraith, CW; Pearce, GL; Werpy, NM, 2009) |
| "To evaluate efficacy and safety of aceclofenac-paracetamol combination against aceclofenac alone in patients with osteoarthritis (OA) flare-up." | 5.14 | A randomized, multicentric, comparative evaluation of aceclofenac-paracetamol combination with aceclofenac alone in Indian patients with osteoarthritis flare-up. ( Bartakke, G; Chandurkar, N; Desai, M; Kini, S; Pareek, A; Sharma, VD, 2009) |
| "To evaluate the hypertensive effects of etoricoxib and diclofenac relative to baseline hypertension risk factors in arthritis patients." | 5.14 | Factors associated with blood pressure changes in patients receiving diclofenac or etoricoxib: results from the MEDAL study. ( Brater, DC; Cannon, CP; Curtis, SP; Kaur, A; Krum, H; Laine, L; Smugar, SS; Swergold, G; Wang, H; Weir, MR, 2009) |
| "To measure the efficacy and safety of diclofenac sodium gel in patients with primary hand osteoarthritis (OA)." | 5.14 | Diclofenac sodium gel in patients with primary hand osteoarthritis: a randomized, double-blind, placebo-controlled trial. ( Altman, RD; Chase, WF; Dreher, DS; Dreiser, RL; Fisher, CL; Zacher, J, 2009) |
| "A 4-week, multicentre, randomised, double-blind study has compared the effects of lumiracoxib 100 mg once daily (od) (n = 394) and ibuprofen 600 mg three times daily (tid) (n = 393) on ambulatory BP in osteoarthritis (OA) patients with controlled hypertension." | 5.14 | The effects of lumiracoxib 100 mg once daily vs. ibuprofen 600 mg three times daily on the blood pressure profiles of hypertensive osteoarthritis patients taking different classes of antihypertensive agents. ( Krammer, G; Lheritier, K; MacDonald, TM; Richard, D, 2010) |
| "To test whether treatment with celecoxib reduces the incidence of gastroduodenal ulcers compared to diclofenac in Asian patients with osteoarthritis (OA) or rheumatoid arthritis (RA) with minimal significant risk factors." | 5.14 | Incidence of gastroduodenal ulcers during treatment with celecoxib or diclofenac: pooled results from three 12-week trials in Chinese patients with osteoarthritis or rheumatoid arthritis. ( Cheng, TT; Cheung, R; Dong, Y; Feng, H; Lai, K; Lau, CS; Lin, HY; Parsons, B, 2010) |
| " To examine whether lumiracoxib 100 mg once daily would result in lower 24-h mean systolic ambulatory blood pressure than ibuprofen 600 mg three times daily in osteoarthritis patients with controlled hypertension, a 4-week, randomized, double-blind, parallel-group study was conducted in 79 centres in nine countries." | 5.13 | Effect on blood pressure of lumiracoxib versus ibuprofen in patients with osteoarthritis and controlled hypertension: a randomized trial. ( Krammer, G; Lheritier, K; Littlejohn, TW; MacDonald, TM; Rebuli, R; Reginster, JY; Richard, D, 2008) |
| " This safety study compared the GI tolerability, the blood pressure (BP) profile and the incidence of oedema with lumiracoxib and rofecoxib in the treatment of OA." | 5.13 | A 6-week, multicentre, randomised, double-blind, double-dummy, active-controlled, clinical safety study of lumiracoxib and rofecoxib in osteoarthritis patients. ( Krammer, G; Stricker, K; Yu, S, 2008) |
| "Patients >or=50 years old with osteoarthritis or rheumatoid arthritis were randomly assigned to etoricoxib (60 or 90 mg qd) or diclofenac (150 mg qd)." | 5.13 | Lower gastrointestinal events in a double-blind trial of the cyclo-oxygenase-2 selective inhibitor etoricoxib and the traditional nonsteroidal anti-inflammatory drug diclofenac. ( Cannon, CP; Cryer, B; Curtis, SP; Jensen, DM; Kaur, A; Laine, L; Langman, M, 2008) |
| "The aim of the study was to compare treatment with diclofenac sodium (Voltaren 3 x 50 mg) to occlusal splint therapy in a randomized, single-blind controlled trial of patients with a diagnosis of temporomandibular joint (TMJ) osteoarthritis (OA) in accordance with Research Diagnostic Criteria for temporomandibular disorders." | 5.13 | Diclofenac sodium and occlusal splint therapy in TMJ osteoarthritis: a randomized controlled trial. ( Mejersjö, C; Wenneberg, B, 2008) |
| "Randomized clinical trials evaluating ultramicronised diclofenac, diclofenac, celecoxib, etodolac and placebo in patients with osteoarthritis were identified." | 5.12 | Efficacy of ultramicronised diclofenac in patients with osteoarthritis - systematic review with network meta-analysis. ( Auletta, LL; de Almeida Macedo, E; de Campos, GC; Kummer, AM; Millan Fachi, M; Papaleo Rosim, M, 2021) |
| "To evaluate the efficacy and upper gastrointestinal (UGI) safety of celecoxib, compared with nonspecific nonsteroidal anti-inflammatory drugs (NSAIDs), among patients with osteoarthritis." | 5.12 | Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study. ( Agrawal, NM; Andrade-Ortega, L; Bello, AE; Eisen, GM; Fort, JG; Goldstein, JL; Hanrahan, PS; Levy, RA; Singh, G; Stenson, WF; Triadafilopoulos, G; Wallemark, C, 2006) |
| " As an application, we compared gastrointestinal tolerability in persons treated with diclofenac and celecoxib for osteoarthritis." | 5.12 | A randomized database study in general practice yielded quality data but patient recruitment in routine consultation was not practical. ( Dieleman, JP; Mosis, G; Stricker, BCh; Sturkenboom, MC; van der Lei, J, 2006) |
| "Aceclofenac is an effective and well-tolerated drug in osteoarthritis in the Indian setting." | 5.12 | Efficacy and safety of aceclofenac in the treatment of osteoarthritis: a randomized double-blind comparative clinical trial versus diclofenac - an Indian experience. ( Chandanwale, AS; Jain, UK; Kapoor, S; Oak, J; Pareek, A, 2006) |
| "The cardiorenal safety database from the Celecoxib Long-term Arthritis Safety Study (CLASS) was analyzed to examine whether supratherapeutic doses of celecoxib are associated with decreased renal function and blood pressure (BP) effects compared with standard doses of diclofenac and ibuprofen in osteoarthritis (OA) and rheumatoid arthritis (RA) patients." | 5.12 | Cardiorenal effects of celecoxib as compared with the nonsteroidal anti-inflammatory drugs diclofenac and ibuprofen. ( Lefkowith, JL; Verburg, KM; West, CR; Whelton, A, 2006) |
| " To compare the gastrointestinal (GI) tolerability, safety, and efficacy of etoricoxib and diclofenac in patients with osteoarthritis (OA)." | 5.12 | Gastrointestinal side effects of etoricoxib in patients with osteoarthritis: results of the Etoricoxib versus Diclofenac Sodium Gastrointestinal Tolerability and Effectiveness (EDGE) trial. ( Baraf, HS; Bird, S; Brzezicki, J; Curtis, SP; Fuentealba, C; Greenwald, M; Kaur, A; O'Brien, K; Polis, A; Soffer, B, 2007) |
| "To determine the cardiovascular outcomes in high risk patients with osteoarthritis treated with ibuprofen, naproxen or lumiracoxib." | 5.12 | Cardiovascular outcomes in high risk patients with osteoarthritis treated with ibuprofen, naproxen or lumiracoxib. ( Abramson, SB; Chesebro, JH; Farkouh, ME; Fuster, V; Greenberg, JD; Hochman, JS; Jeger, RV; Kirshner, H; Lay, CL; Matchaba, PT; Mellein, B; Ramanathan, K; Ruland, S; Verheugt, FW, 2007) |
| "Patients with osteoarthritis (age, >or=50 y) were randomized to receive lumiracoxib 400 mg once daily, naproxen 500 mg twice daily, or ibuprofen 800 mg 3 times daily for 12 months." | 5.12 | Effect of risk factors on complicated and uncomplicated ulcers in the TARGET lumiracoxib outcomes study. ( Gitton, X; Hawkey, CJ; Krammer, G; Matchaba, P; Mellein, B; Richard, D; Sallstig, P; Smalley, W; Stricker, K; Weinstein, WM, 2007) |
| "To compare the analgesic efficacy and tolerability of a sustained-release pellet formulation of diclofenac (Olfen-100 SR Depocaps, SR-CAP, Mepha Ltd, Aesch, Switzerland) with the standard reference formulation (Voltaren retard 100, SR-TAB, Novartis Pharma AG, Basel, Switzerland), both containing 100 mg diclofenac sodium, in patients with osteoarthritis (OA) of the knee and/or hip." | 5.12 | Comparative efficacy and tolerability of two sustained-release formulations of diclofenac: results of a double-blind, randomised study in patients with osteoarthritis and a reappraisal of diclofenac's use in this patient population. ( Cambon, N; Frentzel, A; Mueller, EA; Wagenitz, A, 2007) |
| "To determine whether or not N of 1 trials with diclofenac/misoprostol (Arthrotec) are superior and cost-effective compared with standard treatment in osteoarthritis (OA)." | 5.11 | The efficacy and cost effectiveness of N of 1 studies with diclofenac compared to standard treatment with nonsteroidal antiinflammatory drugs in osteoarthritis. ( Anderson, J; Pope, JE; Prashker, M, 2004) |
| "The Therapeutic Arthritis Research and Gastrointestinal Event Trial was a randomized, double-blind, 52-week study of lumiracoxib 400 mg once daily (two to four times the recommended dose for osteoarthritis) versus naproxen 500 mg twice daily or ibuprofen 800 mg three-times daily in patients with osteoarthritis." | 5.11 | Therapeutic arthritis research and gastrointestinal event trial of lumiracoxib - study design and patient demographics. ( Ehrsam, E; Farkouh, M; Gitton, X; Hawkey, CJ; Huels, J; Richardson, P, 2004) |
| "The efficacy and safety of SKI306X, an herbal anti-arthritic agent, was compared with that of diclofenac sodium for the treatment of osteoarthritis of the knee." | 5.11 | A four-week, randomized, double-blind trial of the efficacy and safety of SKI306X: a herbal anti-arthritic agent versus diclofenac in osteoarthritis of the knee. ( Ahn, JH; Chang, DY; Cho, YB; Han, CK; Jung, KO; Jung, YK; Kim, DH; Kim, JM; Kwak, WJ; Lee, CS; Lee, MC; Lung, YB; Park, BJ; Park, YS; Roh, KJ; Seo, JG; Seong, SC; Shin, YU, 2004) |
| "In patients with OA, lumiracoxib 200 mg or 400 mg qd was associated with a significantly lower risk of gastroduodenal ulceration than ibuprofen 800 mg tid, and was similar to celecoxib 200 mg qd." | 5.11 | Gastroduodenal safety and tolerability of lumiracoxib compared with Ibuprofen and celecoxib in patients with osteoarthritis. ( Cousin, M; Fiedorowicz-Fabrycy, IF; Gitton, X; Hawkey, CC; Hoexter, G; Nasonov, EL; Pikhlak, EG; Svoboda, P, 2004) |
| " In well designed clinical trials of 1-52 weeks' duration in patients with osteoarthritis (OA) or rheumatoid arthritis, the efficacy of oral lumiracoxib 100-400 mg/day in decreasing pain intensity and improving functional status was greater than that with placebo and similar to those with nonselective NSAIDs or celecoxib 200mg once daily." | 5.11 | Lumiracoxib. ( Curran, MP; Lyseng-Williamson, KA, 2004) |
| "STUDY OF HEALTHY VOLUNTEERS: This double blind study (bioadhesive plaster of diclofenac epolamine versus placebo), showed that the application of diclofenac epolamine for 24 hours induced a selective hypoanalgesic effect on the muscle, proportional to the degree of hypersensitivity to the pain observed in baseline conditions." | 5.11 | [Proof of the pharmacodynamic activity of Flector Plaster in healthy volunteers and patients suffering from osteo-arthritis of the knee]. ( Solignac, M, 2004) |
| " This study sought to evaluate dyspepsia-related health in osteoarthritis (OA) and rheumatoid arthritis (RA) patients taking valdecoxib compared with patients taking nonspecific NSAIDs." | 5.11 | Valdecoxib is associated with improved dyspepsia-related health compared with nonspecific NSAIDs in patients with osteoarthritis or rheumatoid arthritis. ( Goldstein, JL; Mayne, TJ; Rabeneck, L; Rublee, DA; Vu, A, 2005) |
| " Overall, the data indicate that administration of valdecoxib offers similar efficacy for the treatment of osteoarthritis but improved upper-gastrointestinal safety compared with the conventional NSAIDs, ibuprofen and diclofenac, based on the significantly lower incidence of gastroduodenal ulcers detected by endoscopy." | 5.10 | Incidence of gastroduodenal ulcers associated with valdecoxib compared with that of ibuprofen and diclofenac in patients with osteoarthritis. ( Agrawal, NM; Kent, JD; Recker, DP; Sikes, DH; Verburg, KM; Zhao, WW, 2002) |
| "A multi-centre, double-blind, randomised parallel-group study was conducted to compare the efficacy and safety between etodolac SR and diclofenac in treating patients with osteoarthritis of the knee." | 5.10 | Double-blind, randomised, comparative trial of etodolac SR versus diclofenac in the treatment of osteoarthritis of the knee. ( Hsu, PN; Liang, TH, 2003) |
| "To compare celecoxib (800 mg/day, n=1997) with diclofenac (150 mg/day, n=1996) on dyspepsia-related tolerability." | 5.10 | Dyspepsia tolerability from the patients' perspective: a comparison of celecoxib with diclofenac. ( Burke, TA; Eisen, GM; Geis, GS; Goldstein, JL; Lefkowith, J; Peña, BM, 2002) |
| ", Skokie, Illinois) administered twice daily with that of nabumetone 1500 mg administered once daily in 1203 patients with symptomatic osteoarthritis (OA) of the hip or knee." | 5.09 | Comparison of the upper gastrointestinal safety of Arthrotec 75 and nabumetone in osteoarthritis patients at high risk for developing nonsteroidal anti-inflammatory drug-induced gastrointestinal ulcers. ( Agrawal, NM; Ball, J; Bocanegra, TS; Caldwell, J; Dhadda, S; Hancock, L; Hurley, S; Kivitz, AJ; Weaver, AL, 1999) |
| "1), the rofecoxib group vs the Arthrotec group respectively reported diarrhea 6." | 5.09 | Tolerability profiles of rofecoxib (Vioxx) and Arthrotec. A comparison of six weeks treatment in patients with osteoarthritis. ( Acevedo, E; Beaulieu, AD; Caeiro, F; Casas, N; Castañeda, O; Garza-Elizondo, M; Gutierrez-Ureña, S; Hinojosa, W; Irazoque, F; Laurenzi, M; Pons-Estel, B; Rodgers, DB; Ugaz, M; Vandormael, K, 2001) |
| "To evaluate the efficacy and gastrointestinal safety of nabumetone and diclofenac in the treatment of elderly patients with osteoarthritis, participating in a 3-month efficacy trial." | 5.09 | Treatment of elderly patients with nabumetone or diclofenac: gastrointestinal safety profile. ( DeLapp, R; Kaine, J; Morgan , GJ; Palmer, R, 2001) |
| "The aim of this study was to evaluate the efficacy and tolerability of meloxicam compared with diclofenac in patients with osteoarthritis of the lumbar spine." | 5.09 | A comparison of the efficacy and tolerability of meloxicam and diclofenac in the treatment of patients with osteoarthritis of the lumbar spine. ( Accardo, S; Hettich, M; Lieu, PL; Reginster, JY; Valat, JP; Wouters, M, 2001) |
| "Fifteen women with arthritis and hypertension who were receiving lisinopril and HCT, and administered sequentially in random order ibuprofen, sulindac, and diclofenac for one month each, with an intervening two-week washout period between each treatment period." | 5.09 | Effects of non-steroidal anti-inflammatory drugs on hypertension control using angiotensin converting enzyme inhibitors and thiazide diuretics. ( Bhagat, K, 2001) |
| "The objective of this study was to determine the long-term efficacy of misoprostol in preventing diclofenac-induced gastroduodenal ulcers in rheumatoid arthritis and osteoarthritis patients." | 5.08 | Misoprostol coadministered with diclofenac for prevention of gastroduodenal ulcers. A one-year study. ( Agrawal, NM; Erhardt, LJ; Geis, GS; Van Kerckhove, HE, 1995) |
| "To conduct the first Canadian study of the comparative efficacy and safety of nabumetone and diclofenac SR in patients with primary osteoarthritis (OA) of the hip, knee and shoulder." | 5.08 | A multicenter study of nabumetone and diclofenac SR in patients with osteoarthritis. ( Ahmad, S; Beaulieu, A; Bell, MJ; Bellamy, N; Bensen, WG; Davis, P; Khanna, VN; Kraag, GR; Lussier, A; Siminovitch, KA, 1995) |
| "A multicentre randomised, double-blind, parallel group, general practice study was undertaken to investigate the efficacy and safety of aceclofenac (200 patients, 100 mg twice daily and placebo once daily) in comparison with diclofenac (197 patients, 50mg three times daily) in patients with osteoarthritis of the knee." | 5.08 | Comparison of aceclofenac with diclofenac in the treatment of osteoarthritis. ( Bowdler, JM; Roma, J; Veys, EM; Ward, DE, 1995) |
| "A multicentre, double-blind, randomized study was conducted in patients with osteoarthritis (OA) of the hip or knee in order to compare the efficacy and safety of the new cyclooxygenase-2 (COX-2) inhibitor, meloxicam, with diclofenac sodium, a conventional treatment for this condition." | 5.08 | Meloxicam in osteoarthritis: a 6-month, double-blind comparison with diclofenac sodium. ( Bluhmki, E; Distel, M; Hosie, J, 1996) |
| "To assess the clinical efficacy of chondroitin sulfate (CS) in comparison with the nonsteroidal antiinflammatory drug (NSAID) diclofenac sodium (DS) in a medium/longterm clinical study in patients with knee osteoarthritis (OA)." | 5.08 | Comparison of the antiinflammatory efficacy of chondroitin sulfate and diclofenac sodium in patients with knee osteoarthritis. ( Boccanera, L; Bocchi, L; Galati, M; Manopulo, R; Morreale, P; Saponati, G, 1996) |
| " Diclofenac-Na (2 x 50 mg capsules/day) on patients (n = 80) suffering from osteoarthritis of the knee in an acute phase was evaluated." | 5.08 | [Drug therapy of activated arthrosis. On the effectiveness of an enzyme mixture versus diclofenac]. ( Oberleitner, H; Singer, F, 1996) |
| "Topical application, 4 times daily for 2 weeks, of the diclofenac-hyaluronan gel to 59 osteoarthritis patients induced a significantly greater (p = 0." | 5.08 | A controlled clinical investigation of 3% diclofenac/2.5% sodium hyaluronate topical gel in the treatment of uncontrolled pain in chronic oral NSAID users with osteoarthritis. ( Roth, SH, 1995) |
| "To compare the efficacy and tolerability of lornoxicam and diclofenac in the treatment of patients with osteoarthritis (OA) over 12 weeks and to assess the efficacy and tolerability of lornoxicam over a followup period of 40 weeks." | 5.08 | A multicenter, randomized, double blind study comparing lornoxicam with diclofenac in osteoarthritis. ( Frenzel, W; Kidd, B, 1996) |
| "The efficacy and tolerability of a new resinate formulation of diclofenac 75mg taken once or twice daily were compared with that of conventional enteric-coated diclofenac sodium 50mg tablets given two or three times daily in a double-blind, randomised, between-patient, 12-week trial in 216 adult patients suffering from painful osteoarthritis of the hip and/or knee." | 5.08 | Comparative efficacy and tolerability of two diclofenac formulations in the treatment of painful osteoarthritis. ( Bakshi, R, 1996) |
| "A comparative study was conducted to evaluate the therapeutic efficacy of diclofenac sodium and flurbiprofen both non-steroidal anti-inflammatory drugs (NSAIDS) in osteoarthritis." | 5.08 | Comparative study of diclofenac sodium and flurbiprofen in osteoarthritis. ( Ali, M; Shaikh, KA; Sharafatullah, T, 1996) |
| "A multicentre, double-blind, randomised, parallel group study was undertaken to investigate the efficacy and safety of aceclofenac (123 patients, 100 mg twice daily) in comparison to piroxicam (117 patients, 20 mg once daily and placebo once daily) in patients with osteoarthritis of the knee." | 5.08 | Comparison of aceclofenac with piroxicam in the treatment of osteoarthritis. ( Alepuz Pou, M; Bermudez, A; Calero, E; Caliz, R; Cano, M; Caracuel, MA; Castellon Arce, P; Ffernandez Crisostomos, C; Garcia Lopez, A; Garcia Perez, S; Garcia Villalba, F; Garcia, C; Gines Martinez, F; Gonzalez, A; Gonzalez, J; Guzman Ubeda, M; Linares, LF; Lopez, MA; Marenco de la Fuente, IL; Mesa, J; Peréz Busquier, M; Povedano, A; Rodríguez, M; Roldan, R; Valenzuela, A, 1997) |
| "In this randomized double-blind, parallel-group study the efficacy of 300 mg oral dexibuprofen three times daily and 50 mg oral diclofenac sodium three times daily was tested for equivalence in 110 patients with painful osteoarthritis of the knee." | 5.08 | [Double-blind comparative study of the effectiveness and tolerance of 900 mg dexibuprofen and 150 mg diclofenac sodium in patients with painful gonarthrosis]. ( Brugger, A; Hawel, R; Klein, G; Mitterhuber, J, 1997) |
| "The efficacy and safety of aceclofenac (100 mg bid), a new nonsteroidal anti-inflammatory/anti-rheumatic agent, were compared with those of naproxen (500 mg bid) in a multi-centre, twelve-week, randomized, double-blind, parallel-group clinical trial in outpatients with active osteoarthritis of the knee." | 5.08 | Aceclofenac is a well-tolerated alternative to naproxen in the treatment of osteoarthritis. ( Bowdler, J; Frerick, H; Kornasoff, D; Montull, E, 1997) |
| "The efficacy and safety of nabumetone are similar to those of aceclofenac in the treatment of knee osteoarthritis." | 5.08 | [Efficacy and safety of nabumetone in the treatment of knee osteoarthritis: a comparative clinical trial versus aceclofenac. Study Group of Nabumetone for Osteoarthritis of the Knee]. ( Gijón Baños, J, 1997) |
| "In a randomized, double blind, multicentre study with 4 weeks follow-up of 290 patients with osteoarthritis of the knee joint, a topical NSAID (eltenac) was compared with oral diclofenac and placebo." | 5.08 | Local NSAID gel (eltenac) in the treatment of osteoarthritis of the knee. A double blind study comparing eltenac with oral diclofenac and placebo gel. ( Crone, H; Forsskåhl, B; Hamberg, P; Harilainen, A; Sandelin, J; Tamelander, G, 1997) |
| " The aim of this study was to investigate the efficacy and tolerability of 15 mg meloxicam in comparison with 100 mg slow-release diclofenac in patients with osteoarthritis of the knee." | 5.08 | A double-blind, randomized trial to compare meloxicam 15 mg with diclofenac 100 mg in the treatment of osteoarthritis of the knee. ( Bluhmki, E; Distel, MR; Goei Thè, HS; Lund, B, 1997) |
| "Three randomized, blinded, multicenter studies, including one in general practice, evaluated the efficacy of combination diclofenac/misoprostol versus diclofenac or ibuprofen in a total of 1824 patients with rheumatoid arthritis (RA) or osteoarthritis (OA)." | 5.08 | Diclofenac/misoprostol: the European clinical experience. ( McKenna, F, 1998) |
| "Twenty-three patients, mean age 69 years, with osteoarthritis requiring NSAID treatment, received treatment with diclofenac 100 mg/day, naproxen 750 mg/day and piroxicam 20 mg/day, representing a short, medium and long half-life NSAID respectively, in a double-blind, randomised, three way, cross-over block design." | 5.08 | NSAIDs and faecal blood loss in elderly patients with osteoarthritis: is plasma half-life relevant? ( Christophidis, N; Kwiatek, R; Scharf, S; Ugoni, A, 1998) |
| "The gastric tolerability of nimesulide, a new nonsteroidal anti-inflammatory drug (NSAID), was compared with diclofenac, an established NSAID for the treatment of osteoarthritis (OA)." | 5.07 | Double-blind study evaluating by endoscopy the tolerability of nimesulide and diclofenac on the gastric mucosa in osteoarthritic patients. ( Almeida, H; Cunha, MJ; Macciocchi, A; Porto, A, 1994) |
| " In this work we have evaluated the long-term effect of aceclofenac, a new NSAID, and diclofenac on the production of a series of inflammatory mediators by blood cells from 30 patients with severe knee osteoarthritis." | 5.07 | Long-term effect of nonsteroidal anti-inflammatory drugs on the production of cytokines and other inflammatory mediators by blood cells of patients with osteoarthritis. ( de la Cruz, C; de Nicoläs, R; Egido, J; González, E; Herrero-Beaumont, G, 1994) |
| " One hundred patients, free from endoscopically detectable lesions of the gastroduodenal mucosa, affected either by rheumatoid arthritis or osteoarthritis, and candidates for NSAID therapy, were randomly allocated either to 200 mg sulglycotide three times daily (n = 50) or to an indistinguishable placebo (n = 50) for 4 weeks, together with standard NSAID administration (50 mg diclofenac three times daily (n = 50); 50 mg indomethacin three times daily (n = 50))." | 5.07 | Sulglycotide in the prevention of nonsteroidal anti-inflammatory drug-induced gastroduodenal mucosal injury. A controlled double-blind, double-dummy, randomized endoscopic study versus placebo in rheumatic patients. ( Ardizzone, S; Bianchi Porro, G; Caruso, I; Montrone, F; Petrillo, M, 1993) |
| "Diclofenac/misoprostol at twice daily dosing is associated with significantly fewer gastroduodenal ulcers than either piroxicam or naproxen." | 5.07 | Double-blind comparison of efficacy and gastroduodenal safety of diclofenac/misoprostol, piroxicam, and naproxen in the treatment of osteoarthritis. ( Bruyn, GA; Geis, GS; Melo Gomes, JA; Roth, SH; Woods, EM; Zeeh, J, 1993) |
| "To conduct the first Canadian study of the comparative efficacy and safety of tenoxicam and diclofenac in patients with primary osteoarthritis (OA) of the knee." | 5.07 | A multicenter study of tenoxicam and diclofenac in patients with osteoarthritis of the knee. ( Bellamy, N; Buchanan, WW; Campbell, J; Chalmers, A; Ford, PM; Gerecz-Simon, E; Kean, WF; Kraag, GR, 1993) |
| "In a randomized, open-label, controlled, multicenter, 12-week study, the efficacy and safety of nabumetone (1,000-2,000 mg/day) versus diclofenac (100-200 mg/day), naproxen (500-1,500 mg/day), ibuprofen (1,200-3,200 mg/day), or piroxicam (10-20 mg/day) were evaluated in patients with osteoarthritis (OA) or rheumatoid arthritis (RA)." | 5.07 | Efficacy and safety of nabumetone versus diclofenac, naproxen, ibuprofen, and piroxicam in the elderly. ( DeLapp, RE; Morgan, GJ; Poland, M, 1993) |
| "The efficacy of nabumetone was compared with that of diclofenac, naproxen, ibuprofen, and piroxicam in patients with osteoarthritis (OA) or rheumatoid arthritis (RA) in a randomized, controlled, open-label, multicenter trial." | 5.07 | Efficacy of nabumetone versus diclofenac, naproxen, ibuprofen, and piroxicam in osteoarthritis and rheumatoid arthritis. ( DeLapp, RE; Lister, BJ; Poland, M, 1993) |
| "In a double-blind study, 455 patients with osteoarthritis were randomly assigned to receive a combination of Arthrotec, 50 mg of diclofenac and 200 micrograms of misoprostol, or 50 mg of diclofenac; the drugs were given two or three times daily for 4 weeks." | 5.07 | The efficacy of Arthrotec in the treatment of osteoarthritis. ( Doherty, M, 1992) |
| "A double-blind, randomized, parallel group study was conducted to compare the gastroduodenal safety and antiarthritic efficacy of a fixed combination of diclofenac 50 mg and misoprostol 200 micrograms with that of a combination of diclofenac 50 mg and placebo in patients with osteoarthritis." | 5.07 | The gastroduodenal safety and efficacy of the fixed combination of diclofenac and misoprostol in the treatment of osteoarthritis. ( Bolten, W; Geis, GS; Gomes, JA; Stead, H, 1992) |
| "A six week, double-blind, randomized, parallel group, multicentre study was conducted in 85 patients with osteoarthritis of the knee and hip to compare the efficacy, tolerability, and safety of Flurbiprofen-SR 200 mg with Diclofenac Sodium-SR 100 mg." | 5.07 | Double-blind randomized controlled trial of flurbiprofen-SR (ANSAID-SR) and diclofenac sodium-SR (Voltaren-SR) in the treatment of osteoarthritis. ( Bellamy, N; Bensen, WG; Ford, PM; Huang, SH; Lang, JY, 1992) |
| "An on-going multi-centre, double-blind, parallel-group study is being carried out to compare the efficacy and tolerability of sustained-release (SR) formulations of etodolac and diclofenac in patients with degenerative joint disease (osteoarthritis) of the knee." | 5.07 | Double-blind comparison of etodolac SR and diclofenac SR in the treatment of patients with degenerative joint disease of the knee. ( Khan, FM; Williams, PI, 1992) |
| "The efficacy and tolerability of a new dispersible formulation of diclofenac were evaluated in a randomized, double-blind, placebo-controlled, multi-centre study in patients aged 60 to 80 years suffering from osteoarthritis." | 5.07 | Efficacy and tolerability of diclofenac dispersible in elderly patients with osteoarthritis. ( Bakshi, R; Darekar, B; Langdon, CG; Rotman, H, 1991) |
| "Seventeen patients with primary osteoarthritis of the knee were evaluated with respect to the severity and clinical importance of pain, stiffness and physical function during the conduct of a double-blind randomized controlled trial of flurbiprofen SR versus diclofenac sodium SR using the WOMAC Osteoarthritis Index." | 5.07 | Relationship between severity and clinical importance of symptoms in osteoarthritis. ( Bellamy, N; Campbell, J; Wells, G, 1991) |
| "20 UK general-practice centres entered 243 patients into a 6-week double-blind, double-dummy, randomised, parallel-group trial designed to compare nabumetone 1 g at night with slow release diclofenac 100mg at night in the treatment of osteoarthritis." | 5.06 | A microcomputer-assisted study of nabumetone and slow release diclofenac in osteoarthritis. ( Fehilly, B; Laws, D; Saul, S, 1990) |
| "Eighty patients with osteoarthritis were randomly assigned to either piroxicam (20 mg daily) or diclofenac (75-150 mg daily) in a 12-week double-blind, parallel groups study." | 5.06 | A controlled comparison of piroxicam and diclofenac in patients with osteoarthritis. ( Buchanan, WW; Gerecz-Simon, E; Kean, WF; Rooney, PJ; Soper, WY; Tugwell, P, 1990) |
| "Seventy-four patients were enrolled in this double-blind, randomized single-center study to evaluate the therapeutic effectiveness of 50 mg tid regimens of flurbiprofen or diclofenac sodium in patients with osteoarthritis of the knee." | 5.06 | Flurbiprofen versus diclofenac for the treatment of osteoarthritis of the knee. ( Atra, E; Brown, BL; Metz, CA; Teoh, K, 1990) |
| "A double-blind, crossover study was undertaken in general practice to compare the efficacy and tolerability of a new controlled-release indomethacin with sustained-release diclofenac sodium in patients with osteoarthritis." | 5.06 | Controlled-release indomethacin and sustained-release diclofenac sodium in the treatment of osteoarthritis: a comparative controlled clinical trial in general practice. ( Gostick, N; James, IG; Khong, TK; Miller, AJ; Roy, P; Shepherd, PR, 1990) |
| "Interim results are reported for three double-blind clinical trials comparing etodolac, a new nonsteroidal anti-inflammatory drug (NSAID), with piroxicam, diclofenac, or naproxen in patients with osteoarthritis (OA) of the knee." | 5.06 | Recent clinical experience with etodolac in the treatment of osteoarthritis of the knee. ( Platt, PN, 1989) |
| "In a randomized, double-blind comparative study involving a total of 1630 outpatients, tenoxicam, a new nonsteroidal anti-inflammatory drug belonging to the oxicam group, piroxicam and diclofenac retard were tested for their efficacy und tolerability in the treatment of osteoarthritis and extra-articular rheumatism." | 5.06 | [Double-blind randomized multicenter study with tenoxicam, piroxicam and diclofenac sodium retard in the treatment of ambulatory patients with arthroses and soft tissue rheumatism]. ( Gobelet, CA; Moser, U; Schwarz, HA; Waldburger, M, 1989) |
| "In a randomised, double-blind comparative study involving a total of 1,630 out-patients, tenoxicam (a new non-steroidal anti-inflammatory drug belonging to the oxicam group), piroxicam and diclofenac retard were tested for their efficacy and tolerability in the treatment of osteoarthritis (OA) and extra-articular rheumatism (EAR)." | 5.06 | A double-blind randomised multicentre study with tenoxicam, piroxicam and diclofenac sodium retard in the treatment of ambulant patients with osteoarthritis and extra-articular rheumatism. ( Gobelet, CA; Moser, U; Schwarz, HA; Waldburger, H, 1989) |
| "Despite a wide range of study designs, a multiplicity of international trials of diclofenac in osteoarthritis have disclosed similar results." | 5.06 | International experiences with diclofenac in osteoarthritis. ( Altman, R, 1986) |
| "The role of diclofenac sodium in patients with symptomatic osteoarthritis of the hip or knee has been evaluated in five prospective, randomized, double-blind, controlled trials with placebo, aspirin, and naproxen conducted in the United States." | 5.06 | Efficacy of diclofenac in osteoarthritis. Experience in the United States. ( Ward, JR, 1986) |
| "150 mg/day sodic diclofenac was found particularly active in subjects with diathetic rheumatism and arthrosis." | 5.04 | [Experiences with the use of sodium diclofenac (Voltaren) in rheumatic diseases]. ( Durante, F, 1978) |
| "A five-centre double-blind crossover trial of two two-week periods using diclofenac and indomethacin showed that both drug groups (51 patients) with rheumatoid arthritis responded similarly in relation to pain scores and morning stiffness." | 5.04 | Diclofenac sodium (Voltarol) and indomethacin: a multicentre comparative study in rheumatoid arthritis and osteoarthritis. ( Barnes, CG; Berry, H; Carter, ME; Downie, WW; Fowler, PD; Moll, JM; Perry, JD; Sawaf, MS; Wright, V, 1979) |
| " In a two-week double-blind study, diclofenac was compared with indomethacin in 43 outpatients with osteoarthritis or rheumatoid arthritis." | 5.04 | An open assessment of the efficacy and tolerability of diclofenac sodium (Voltarol) in patients with rheumatic disease and a comparative study of diclofenac sodium (Voltarol) with indomethacin in patients with osteoarthritis and rheumatoid arthritis. ( Cash, HC; McMahon, MF, 1979) |
| "Oxaceprol, a derivative of l-proline, is an established drug for managing osteoarthritis (OA) with better safety profile than non-steroidal anti-inflammatory drugs (NSAIDs)." | 5.01 | A systematic review and meta-analysis of oxaceprol in the management of osteoarthritis: An evidence from randomized parallel-group controlled trials. ( Bhate, J; Durg, S; Lobo, M; Rao, G; Venkatachalam, L, 2019) |
| " An increased risk of acute myocardial infarction and heart failure is observed with all NSAIDs, while an elevated risk of hemorrhagic stroke appears to be restricted to the use of diclofenac and meloxicam." | 5.01 | Safety of Oral Non-Selective Non-Steroidal Anti-Inflammatory Drugs in Osteoarthritis: What Does the Literature Say? ( Al-Daghri, N; Bruyère, O; Chapurlat, R; Cooper, C; Herrero-Beaumont, G; Rannou, F; Reginster, JY; Roth, R; Uebelhart, D, 2019) |
| "To ascertain if etoricoxib increases the risk of gastrointestinal adverse events (GAEs) compared with placebo, diclofenac, and naproxen in the treatment of patients with osteoarthritis (OA) or rheumatoid arthritis (RA)." | 4.98 | Gastrointestinal safety of etoricoxib in osteoarthritis and rheumatoid arthritis: A meta-analysis. ( Feng, X; Mei, H; Tian, M; Zhang, W, 2018) |
| "Osteoarthritis (OA) is one of the most common causes of joint pain in the United States and non-steroidal anti-inflammatories (NSAIDs), such as Diclofenac sodium, which is currently available in two main routes of administration; oral and topical distribution have been established as one of the standard treatments for OA." | 4.95 | Oral Versus Topical Diclofenac Sodium in the Treatment of Osteoarthritis. ( Brown, TL; Davani, S; Tieppo Francio, V; Towery, C, 2017) |
| "In acute musculoskeletal pain (strains and sprains) with assessment at about seven days, therapies were diclofenac Emulgel (78% Emulgel, 20% placebo; 2 studies, 314 participants, NNT 1." | 4.95 | Topical analgesics for acute and chronic pain in adults - an overview of Cochrane Reviews. ( Aldington, D; Bell, RF; Derry, S; Gaskell, H; Kalso, EA; Moore, RA; Phillips, T; Wiffen, PJ, 2017) |
| " This review addresses these issues, with reference to topically administered diclofenac in osteoarthritis." | 4.95 | Skin penetration and tissue permeation after topical administration of diclofenac. ( Baker, M; Hagen, M, 2017) |
| "The objective of this study was to evaluate the efficacy and safety of topical diclofenac therapy for osteoarthritis (OA)." | 4.93 | Topical diclofenac therapy for osteoarthritis: a meta-analysis of randomized controlled trials. ( Deng, ZH; Lei, GH; Li, H; Li, YS; Wei, J; Yang, T; Yang, Y; Zeng, C, 2016) |
| " This study compared the efficacy, safety, and tolerability of diclofenac, ibuprofen, naproxen, celecoxib, and etoricoxib for patients with pain caused by osteoarthritis (OA) or rheumatoid arthritis (RA)." | 4.91 | Relative benefit-risk comparing diclofenac to other traditional non-steroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors in patients with osteoarthritis or rheumatoid arthritis: a network meta-analysis. ( Guyot, P; Karabis, A; Moore, RA; Nixon, RM; Pandhi, S; van Walsem, A, 2015) |
| "The efficacy and safety of low-dose SoluMatrix diclofenac was evaluated in two randomized, placebo-controlled Phase III studies: a study in patients with acute pain following bunionectomy surgery and a study in patients with osteoarthritis pain of the hip or knee." | 4.91 | Low-dose SoluMatrix diclofenac : a review of safety across two Phase III studies in patients with acute and osteoarthritis pain. ( Altman, R; Daniels, S; Gibofsky, A; Imasogie, O; Young, C, 2015) |
| "Diclofenac is a nonsteroidal anti-inflammatory drug (NSAID) commonly prescribed for pain relief in osteoarthritis (OA)." | 4.88 | A comparison of the therapeutic efficacy of diclofenac in osteoarthritis: a systematic review of randomised controlled trials. ( Pavelka, K, 2012) |
| "A prespecified pooled intent-to-treat analysis of three double-blind randomised comparisons of etoricoxib (60 or 90 mg daily) and diclofenac (150 mg daily) in 34 701 patients with osteoarthritis or rheumatoid arthritis was done for upper gastrointestinal clinical events (bleeding, perforation, obstruction, or ulcer) and the subset of complicated events (perforation, obstruction, witnessed ulcer bleeding, or significant bleeding)." | 4.84 | Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. ( Cannon, CP; Cryer, B; Curtis, SP; Kaur, A; Laine, L, 2007) |
| " It has proved as effective as diclofenac, naproxen and piroxicam in patients with osteoarthritis, diclofenac, ketorolac, tenoxicam and indomethacin in patients with rheumatoid arthritis and tenoxicam, naproxen and indomethacin in patients with ankylosing spondylitis." | 4.82 | Aceclofenac in the management of inflammatory pain. ( Legrand, E, 2004) |
| " In randomised, controlled clinical trials, lumiracoxib 100 - 200 mg/day has been shown to be superior to placebo in patients with symptomatic osteoarthritis, with clinical efficacy similar to diclofenac 150 mg/day, celecoxib 200 mg/day or rofecoxib 25 mg/day." | 4.82 | Clinical pharmacology of lumiracoxib, a second-generation cyclooxygenase 2 selective inhibitor. ( Bannwarth, B; Berenbaum, F, 2005) |
| "The aim of this meta-analysis based on the literature was to gather all evidence of randomized clinical trials to assess the efficacy of adenosylmethionine (SAM) and oxaceprol in the treatment of osteoarthritis." | 4.81 | [Meta-analysis of the efficacy of adenosylmethionine and oxaceprol in the treatment of osteoarthritis]. ( Lasek, R; Victor, N; Witte, S, 2002) |
| "World-wide experience with nimesulide confirms that it is an effective anti-inflammatory drug in the treatment of osteoarthritis." | 4.81 | Nimesulide, a balanced drug for the treatment of osteoarthritis. ( Huskisson, EC, 2001) |
| "The aim of this article is to critically review the potential role of aceclofenac in the treatment of inflammatory pain and chronic osteoarticular disorder, based on its activity on the mediators of inflammation, its effect on cartilage remodeling and on the results of clinical studies comparing aceclofenac with other NSAIDs in these disorders." | 4.81 | [What is the role of aceclofenac in the therapeutic arsenal against chronic osteoarthritis pathologies?]. ( Henrotin, Y; Paul, I; Reginster, JY, 2001) |
| "Prespecified analysis of all 8 double-blind, randomized phase 2b/3 rofecoxib osteoarthritis trials conducted from December 1996 through March 1998, including one 6-week dose-ranging study, two 6-week efficacy studies vs ibuprofen and placebo, two 1-year efficacy studies vs diclofenac, two 6-month endoscopy studies vs ibuprofen and placebo, and one 6-week efficacy study vs nabumetone and placebo." | 4.80 | Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. ( Bolognese, JA; Harper, SE; Jensen, DM; Langman, MJ; Quan, H; Simon, TJ; Watson, DJ; Zhao, PL, 1999) |
| "Celecoxib is the first COX-2-specific inhibitor approved for relief of the signs and symptoms of osteoarthritis (OA) and rheumatoid arthritis (RA), as well as for treatment of familial adenomatous polyposis." | 4.80 | Celecoxib clinical profile. ( Tive, L, 2000) |
| "Hyaluronan (HA) in combination with diclofenac is currently undergoing clinical trials as a topical preparation in the management of osteoarthritic pain, basal-cell carcinoma and actinic keratosis." | 4.79 | Hyaluronan as a drug delivery system for diclofenac: a hypothesis for mode of action. ( Moore, AR; Willoughby, DA, 1995) |
| "To obtain a better quantitative and qualitative estimate of the effect of tenoxicam (Tx) compared to piroxicam (Px), diclofenac (Dcl) and indomethacin (Ind) in the treatment of osteoarthritis (OA)." | 4.78 | A study to determine the efficacy and safety of tenoxicam versus piroxicam, diclofenac and indomethacin in patients with osteoarthritis: a meta-analysis. ( Bersinic, S; Cuddy, LJ; Riedemann, PJ; Torrance, GW; Tugwell, PX, 1993) |
| "A meta-analysis was done with the final data from three trials that provided the first results relating to efficacy and safety of the new sustained-release (SR) formulation of etodolac versus established nonsteroidal anti-inflammatory drugs (NSAIDs) in the treatment of osteoarthritis (OA) of the knee." | 4.78 | Meta-analysis of three double-blind comparative trials with sustained-release etodolac in the treatment of osteoarthritis of the knee. ( Porzio, F, 1993) |
| " Published data indicate that diclofenac 75 to 150mg daily (25 to 50mg 3 times daily) is comparable in efficacy with ordinary aspirin 3 to 5g daily and indomethacin 75 to 150mg daily in rheumatoid arthritis and with indomethacin in osteoarthritis." | 4.76 | Diclofenac sodium: a review of its pharmacological properties and therapeutic use in rheumatic diseases and pain of varying origin. ( Avery, GS; Brogden, RN; Heel, RC; Pakes, GE; Speight, TM, 1980) |
| "Findings will provide timely information on the safety, efficacy, and optimal dosing of t-PA to treat moderate/severe COVID-19-induced ARDS, which can be rapidly adapted to a phase III trial (NCT04357730; FDA IND 149634)." | 4.21 | ( Abbasi, S; Abd El-Wahab, A; Abdallah, M; Abebe, G; Aca-Aca, G; Adama, S; Adefegha, SA; Adidigue-Ndiome, R; Adiseshaiah, P; Adrario, E; Aghajanian, C; Agnese, W; Ahmad, A; Ahmad, I; Ahmed, MFE; Akcay, OF; Akinmoladun, AC; Akutagawa, T; Alakavuklar, MA; Álava-Rabasa, S; Albaladejo-Florín, MJ; Alexandra, AJE; Alfawares, R; Alferiev, IS; Alghamdi, HS; Ali, I; Allard, B; Allen, JD; Almada, E; Alobaid, A; Alonso, GL; Alqahtani, YS; Alqarawi, W; Alsaleh, H; Alyami, BA; Amaral, BPD; Amaro, JT; Amin, SAW; Amodio, E; Amoo, ZA; Andia Biraro, I; Angiolella, L; Anheyer, D; Anlay, DZ; Annex, BH; Antonio-Aguirre, B; Apple, S; Arbuznikov, AV; Arinsoy, T; Armstrong, DK; Ash, S; Aslam, M; Asrie, F; Astur, DC; Atzrodt, J; Au, DW; Aucoin, M; Auerbach, EJ; Azarian, S; Ba, D; Bai, Z; Baisch, PRM; Balkissou, AD; Baltzopoulos, V; Banaszewski, M; Banerjee, S; Bao, Y; Baradwan, A; Barandika, JF; Barger, PM; Barion, MRL; Barrett, CD; Basudan, AM; Baur, LE; Baz-Rodríguez, SA; Beamer, P; Beaulant, A; Becker, DF; Beckers, C; Bedel, J; Bedlack, R; Bermúdez de Castro, JM; Berry, JD; Berthier, C; Bhattacharya, D; Biadgo, B; Bianco, G; Bianco, M; Bibi, S; Bigliardi, AP; Billheimer, D; Birnie, DH; Biswas, K; Blair, HC; Bognetti, P; Bolan, PJ; Bolla, JR; Bolze, A; Bonnaillie, P; Borlimi, R; Bórquez, J; Bottari, NB; Boulleys-Nana, JR; Brighetti, G; Brodeur, GM; Budnyak, T; Budnyk, S; Bukirwa, VD; Bulman, DM; Burm, R; Busman-Sahay, K; Butcher, TW; Cai, C; Cai, H; Cai, L; Cairati, M; Calvano, CD; Camacho-Ordóñez, A; Camela, E; Cameron, T; Campbell, BS; Cansian, RL; Cao, Y; Caporale, AS; Carciofi, AC; Cardozo, V; Carè, J; Carlos, AF; Carozza, R; Carroll, CJW; Carsetti, A; Carubelli, V; Casarotta, E; Casas, M; Caselli, G; Castillo-Lora, J; Cataldi, TRI; Cavalcante, ELB; Cavaleiro, A; Cayci, Z; Cebrián-Tarancón, C; Cedrone, E; Cella, D; Cereda, C; Ceretti, A; Ceroni, M; Cha, YH; Chai, X; Chang, EF; Chang, TS; Chanteux, H; Chao, M; Chaplin, BP; Chaturvedi, S; Chaturvedi, V; Chaudhary, DK; Chen, A; Chen, C; Chen, HY; Chen, J; Chen, JJ; Chen, K; Chen, L; Chen, Q; Chen, R; Chen, SY; Chen, TY; Chen, WM; Chen, X; Chen, Y; Cheng, G; Cheng, GJ; Cheng, J; Cheng, YH; Cheon, HG; Chew, KW; Chhoker, S; Chiu, WN; Choi, ES; Choi, MJ; Choi, SD; Chokshi, S; Chorny, M; Chu, KI; Chu, WJ; Church, AL; Cirrincione, A; Clamp, AR; Cleff, MB; Cohen, M; Coleman, RL; Collins, SL; Colombo, N; Conduit, N; Cong, WL; Connelly, MA; Connor, J; Cooley, K; Correa Ramos Leal, I; Cose, S; Costantino, C; Cottrell, M; Cui, L; Cundall, J; Cutaia, C; Cutler, CW; Cuypers, ML; da Silva Júnior, FMR; Dahal, RH; Damiani, E; Damtie, D; Dan-Li, W; Dang, Z; Dasa, SSK; Davin, A; Davis, DR; de Andrade, CM; de Jong, PL; de Oliveira, D; de Paula Dorigam, JC; Dean, A; Deepa, M; Delatour, C; Dell'Aiera, S; Delley, MF; den Boer, RB; Deng, L; Deng, Q; Depner, RM; Derdau, V; Derici, U; DeSantis, AJ; Desmarini, D; Diffo-Sonkoue, L; Divizia, M; Djenabou, A; Djordjevic, JT; Dobrovolskaia, MA; Domizi, R; Donati, A; Dong, Y; Dos Santos, M; Dos Santos, MP; Douglas, RG; Duarte, PF; Dullaart, RPF; Duscha, BD; Edwards, LA; Edwards, TE; Eichenwald, EC; El-Baba, TJ; Elashiry, M; Elashiry, MM; Elashry, SH; Elliott, A; Elsayed, R; Emerson, MS; Emmanuel, YO; Emory, TH; Endale-Mangamba, LM; Enten, GA; Estefanía-Fernández, K; Estes, JD; Estrada-Mena, FJ; Evans, S; Ezra, L; Faria de, RO; Farraj, AK; Favre, C; Feng, B; Feng, J; Feng, L; Feng, W; Feng, X; Feng, Z; Fernandes, CLF; Fernández-Cuadros, ME; Fernie, AR; Ferrari, D; Florindo, PR; Fong, PC; Fontes, EPB; Fontinha, D; Fornari, VJ; Fox, NP; Fu, Q; Fujitaka, Y; Fukuhara, K; Fumeaux, T; Fuqua, C; Fustinoni, S; Gabbanelli, V; Gaikwad, S; Gall, ET; Galli, A; Gancedo, MA; Gandhi, MM; Gao, D; Gao, K; Gao, M; Gao, Q; Gao, X; Gao, Y; Gaponenko, V; Garber, A; Garcia, EM; García-Campos, C; García-Donas, J; García-Pérez, AL; Gasparri, F; Ge, C; Ge, D; Ge, JB; Ge, X; George, I; George, LA; Germani, G; Ghassemi Tabrizi, S; Gibon, Y; Gillent, E; Gillies, RS; Gilmour, MI; Goble, S; Goh, JC; Goiri, F; Goldfinger, LE; Golian, M; Gómez, MA; Gonçalves, J; Góngora-García, OR; Gonul, I; González, MA; Govers, TM; Grant, PC; Gray, EH; Gray, JE; Green, MS; Greenwald, I; Gregory, MJ; Gretzke, D; Griffin-Nolan, RJ; Griffith, DC; Gruppen, EG; Guaita, A; Guan, P; Guan, X; Guerci, P; Guerrero, DT; Guo, M; Guo, P; Guo, R; Guo, X; Gupta, J; Guz, G; Hajizadeh, N; Hamada, H; Haman-Wabi, AB; Han, TT; Hannan, N; Hao, S; Harjola, VP; Harmon, M; Hartmann, MSM; Hartwig, JF; Hasani, M; Hawthorne, WJ; Haykal-Coates, N; Hazari, MS; He, DL; He, P; He, SG; Héau, C; Hebbar Kannur, K; Helvaci, O; Heuberger, DM; Hidalgo, F; Hilty, MP; Hirata, K; Hirsch, A; Hoffman, AM; Hoffmann, JF; Holloway, RW; Holmes, RK; Hong, S; Hongisto, M; Hopf, NB; Hörlein, R; Hoshino, N; Hou, Y; Hoven, NF; Hsieh, YY; Hsu, CT; Hu, CW; Hu, JH; Hu, MY; Hu, Y; Hu, Z; Huang, C; Huang, D; Huang, DQ; Huang, L; Huang, Q; Huang, R; Huang, S; Huang, SC; Huang, W; Huang, Y; Huffman, KM; Hung, CH; Hung, CT; Huurman, R; Hwang, SM; Hyun, S; Ibrahim, AM; Iddi-Faical, A; Immordino, P; Isla, MI; Jacquemond, V; Jacques, T; Jankowska, E; Jansen, JA; Jäntti, T; Jaque-Fernandez, F; Jarvis, GA; Jatt, LP; Jeon, JW; Jeong, SH; Jhunjhunwala, R; Ji, F; Jia, X; Jia, Y; Jian-Bo, Z; Jiang, GD; Jiang, L; Jiang, W; Jiang, WD; Jiang, Z; Jiménez-Hoyos, CA; Jin, S; Jobling, MG; John, CM; John, T; Johnson, CB; Jones, KI; Jones, WS; Joseph, OO; Ju, C; Judeinstein, P; Junges, A; Junnarkar, M; Jurkko, R; Kaleka, CC; Kamath, AV; Kang, X; Kantsadi, AL; Kapoor, M; Karim, Z; Kashuba, ADM; Kassa, E; Kasztura, M; Kataja, A; Katoh, T; Kaufman, JS; Kaupp, M; Kehinde, O; Kehrenberg, C; Kemper, N; Kerr, CW; Khan, AU; Khan, MF; Khan, ZUH; Khojasteh, SC; Kilburn, S; Kim, CG; Kim, DU; Kim, DY; Kim, HJ; Kim, J; Kim, OH; Kim, YH; King, C; Klein, A; Klingler, L; Knapp, AK; Ko, TK; Kodavanti, UP; Kolla, V; Kong, L; Kong, RY; Kong, X; Kore, S; Kortz, U; Korucu, B; Kovacs, A; Krahnert, I; Kraus, WE; Kuang, SY; Kuehn-Hajder, JE; Kurz, M; Kuśtrowski, P; Kwak, YD; Kyttaris, VC; Laga, SM; Laguerre, A; Laloo, A; Langaro, MC; Langham, MC; Lao, X; Larocca, MC; Lassus, J; Lattimer, TA; Lazar, S; Le, MH; Leal, DB; Leal, M; Leary, A; Ledermann, JA; Lee, JF; Lee, MV; Lee, NH; Leeds, CM; Leeds, JS; Lefrandt, JD; Leicht, AS; Leonard, M; Lev, S; Levy, K; Li, B; Li, C; Li, CM; Li, DH; Li, H; Li, J; Li, L; Li, LJ; Li, N; Li, P; Li, T; Li, X; Li, XH; Li, XQ; Li, XX; Li, Y; Li, Z; Li, ZY; Liao, YF; Lin, CC; Lin, MH; Lin, Y; Ling, Y; Links, TP; Lira-Romero, E; Liu, C; Liu, D; Liu, H; Liu, J; Liu, L; Liu, LP; Liu, M; Liu, T; Liu, W; Liu, X; Liu, XH; Liu, Y; Liuwantara, D; Ljumanovic, N; Lobo, L; Lokhande, K; Lopes, A; Lopes, RMRM; López-Gutiérrez, JC; López-Muñoz, MJ; López-Santamaría, M; Lorenzo, C; Lorusso, D; Losito, I; Lu, C; Lu, H; Lu, HZ; Lu, SH; Lu, SN; Lu, Y; Lu, ZY; Luboga, F; Luo, JJ; Luo, KL; Luo, Y; Lutomski, CA; Lv, W; M Piedade, MF; Ma, J; Ma, JQ; Ma, JX; Ma, N; Ma, P; Ma, S; Maciel, M; Madureira, M; Maganaris, C; Maginn, EJ; Mahnashi, MH; Maierhofer, M; Majetschak, M; Malla, TR; Maloney, L; Mann, DL; Mansuri, A; Marelli, E; Margulis, CJ; Marrella, A; Martin, BL; Martín-Francés, L; Martínez de Pinillos, M; Martínez-Navarro, EM; Martinez-Quintanilla Jimenez, D; Martínez-Velasco, A; Martínez-Villaseñor, L; Martinón-Torres, M; Martins, BA; Massongo, M; Mathew, AP; Mathews, D; Matsui, J; Matsumoto, KI; Mau, T; Maves, RC; Mayclin, SJ; Mayer, JM; Maynard, ND; Mayr, T; Mboowa, MG; McEvoy, MP; McIntyre, RC; McKay, JA; McPhail, MJW; McVeigh, AL; Mebazaa, A; Medici, V; Medina, DN; Mehmood, T; Mei-Li, C; Melku, M; Meloncelli, S; Mendes, GC; Mendoza-Velásquez, C; Mercadante, R; Mercado, MI; Merenda, MEZ; Meunier, J; Mi, SL; Michels, M; Mijatovic, V; Mikhailov, V; Milheiro, SA; Miller, DC; Ming, F; Mitsuishi, M; Miyashita, T; Mo, J; Mo, S; Modesto-Mata, M; Moeller, S; Monte, A; Monteiro, L; Montomoli, J; Moore, EE; Moore, HB; Moore, PK; Mor, MK; Moratalla-López, N; Moratilla Lapeña, L; Moreira, R; Moreno, MA; Mörk, AC; Morton, M; Mosier, JM; Mou, LH; Mougharbel, AS; Muccillo-Baisch, AL; Muñoz-Serrano, AJ; Mustafa, B; Nair, GM; Nakanishi, I; Nakanjako, D; Naraparaju, K; Nawani, N; Neffati, R; Neil, EC; Neilipovitz, D; Neira-Borrajo, I; Nelson, MT; Nery, PB; Nese, M; Nguyen, F; Nguyen, MH; Niazy, AA; Nicolaï, J; Nogueira, F; Norbäck, D; Novaretti, JV; O'Donnell, T; O'Dowd, A; O'Malley, DM; Oaknin, A; Ogata, K; Ohkubo, K; Ojha, M; Olaleye, MT; Olawande, B; Olomo, EJ; Ong, EWY; Ono, A; Onwumere, J; Ortiz Bibriesca, DM; Ou, X; Oza, AM; Ozturk, K; Özütemiz, C; Palacio-Pastrana, C; Palaparthi, A; Palevsky, PM; Pan, K; Pantanetti, S; Papachristou, DJ; Pariani, A; Parikh, CR; Parissis, J; Paroul, N; Parry, S; Patel, N; Patel, SM; Patel, VC; Pawar, S; Pefura-Yone, EW; Peixoto Andrade, BCO; Pelepenko, LE; Peña-Lora, D; Peng, S; Pérez-Moro, OS; Perez-Ortiz, AC; Perry, LM; Peter, CM; Phillips, NJ; Phillips, P; Pia Tek, J; Piner, LW; Pinto, EA; Pinto, SN; Piyachaturawat, P; Poka-Mayap, V; Polledri, E; Poloni, TE; Ponessa, G; Poole, ST; Post, AK; Potter, TM; Pressly, BB; Prouty, MG; Prudêncio, M; Pulkki, K; Pupier, C; Qian, H; Qian, ZP; Qiu, Y; Qu, G; Rahimi, S; Rahman, AU; Ramadan, H; Ramanna, S; Ramirez, I; Randolph, GJ; Rasheed, A; Rault, J; Raviprakash, V; Reale, E; Redpath, C; Rema, V; Remucal, CK; Remy, D; Ren, T; Ribeiro, LB; Riboli, G; Richards, J; Rieger, V; Rieusset, J; Riva, A; Rivabella Maknis, T; Robbins, JL; Robinson, CV; Roche-Campo, F; Rodriguez, R; Rodríguez-de-Cía, J; Rollenhagen, JE; Rosen, EP; Rub, D; Rubin, N; Rubin, NT; Ruurda, JP; Saad, O; Sabell, T; Saber, SE; Sabet, M; Sadek, MM; Saejio, A; Salinas, RM; Saliu, IO; Sande, D; Sang, D; Sangenito, LS; Santos, ALSD; Sarmiento Caldas, MC; Sassaroli, S; Sassi, V; Sato, J; Sauaia, A; Saunders, K; Saunders, PR; Savarino, SJ; Scambia, G; Scanlon, N; Schetinger, MR; Schinkel, AFL; Schladweiler, MC; Schofield, CJ; Schuepbach, RA; Schulz, J; Schwartz, N; Scorcella, C; Seeley, J; Seemann, F; Seinige, D; Sengoku, T; Seravalli, J; Sgromo, B; Shaheen, MY; Shan, L; Shanmugam, S; Shao, H; Sharma, S; Shaw, KJ; Shen, BQ; Shen, CH; Shen, P; Shen, S; Shen, Y; Shen, Z; Shi, J; Shi-Li, L; Shimoda, K; Shoji, Y; Shun, C; Silva, MA; Silva-Cardoso, J; Simas, NK; Simirgiotis, MJ; Sincock, SA; Singh, MP; Sionis, A; Siu, J; Sivieri, EM; Sjerps, MJ; Skoczen, SL; Slabon, A; Slette, IJ; Smith, MD; Smith, S; Smith, TG; Snapp, KS; Snow, SJ; Soares, MCF; Soberman, D; Solares, MD; Soliman, I; Song, J; Sorooshian, A; Sorrell, TC; Spinar, J; Staudt, A; Steinhart, C; Stern, ST; Stevens, DM; Stiers, KM; Stimming, U; Su, YG; Subbian, V; Suga, H; Sukhija-Cohen, A; Suksamrarn, A; Suksen, K; Sun, J; Sun, M; Sun, P; Sun, W; Sun, XF; Sun, Y; Sundell, J; Susan, LF; Sutjarit, N; Swamy, KV; Swisher, EM; Sykes, C; Takahashi, JA; Talmor, DS; Tan, B; Tan, ZK; Tang, L; Tang, S; Tanner, JJ; Tanwar, M; Tarazi, Z; Tarvasmäki, T; Tay, FR; Teketel, A; Temitayo, GI; Thersleff, T; Thiessen Philbrook, H; Thompson, LC; Thongon, N; Tian, B; Tian, F; Tian, Q; Timothy, AT; Tingle, MD; Titze, IR; Tolppanen, H; Tong, W; Toyoda, H; Tronconi, L; Tseng, CH; Tu, H; Tu, YJ; Tung, SY; Turpault, S; Tuynman, JB; Uemoto, AT; Ugurlu, M; Ullah, S; Underwood, RS; Ungell, AL; Usandizaga-Elio, I; Vakonakis, I; van Boxel, GI; van den Beucken, JJJP; van der Boom, T; van Slegtenhorst, MA; Vanni, JR; Vaquera, A; Vasconcellos, RS; Velayos, M; Vena, R; Ventura, G; Verso, MG; Vincent, RP; Vitale, F; Vitali, S; Vlek, SL; Vleugels, MPH; Volkmann, N; Vukelic, M; Wagner Mackenzie, B; Wairagala, P; Waller, SB; Wan, J; Wan, MT; Wan, Y; Wang, CC; Wang, H; Wang, J; Wang, JF; Wang, K; Wang, L; Wang, M; Wang, S; Wang, WM; Wang, X; Wang, Y; Wang, YD; Wang, YF; Wang, Z; Wang, ZG; Warriner, K; Weberpals, JI; Weerachayaphorn, J; Wehrli, FW; Wei, J; Wei, KL; Weinheimer, CJ; Weisbord, SD; Wen, S; Wendel Garcia, PD; Williams, JW; Williams, R; Winkler, C; Wirman, AP; Wong, S; Woods, CM; Wu, B; Wu, C; Wu, F; Wu, P; Wu, S; Wu, Y; Wu, YN; Wu, ZH; Wurtzel, JGT; Xia, L; Xia, Z; Xia, ZZ; Xiao, H; Xie, C; Xin, ZM; Xing, Y; Xing, Z; Xu, S; Xu, SB; Xu, T; Xu, X; Xu, Y; Xue, L; Xun, J; Yaffe, MB; Yalew, A; Yamamoto, S; Yan, D; Yan, H; Yan, S; Yan, X; Yang, AD; Yang, E; Yang, H; Yang, J; Yang, JL; Yang, K; Yang, M; Yang, P; Yang, Q; Yang, S; Yang, W; Yang, X; Yang, Y; Yao, JC; Yao, WL; Yao, Y; Yaqub, TB; Ye, J; Ye, W; Yen, CW; Yeter, HH; Yin, C; Yip, V; Yong-Yi, J; Yu, HJ; Yu, MF; Yu, S; Yu, W; Yu, WW; Yu, X; Yuan, P; Yuan, Q; Yue, XY; Zaia, AA; Zakhary, SY; Zalwango, F; Zamalloa, A; Zamparo, P; Zampini, IC; Zani, JL; Zeitoun, R; Zeng, N; Zenteno, JC; Zepeda-Palacio, C; Zhai, C; Zhang, B; Zhang, G; Zhang, J; Zhang, K; Zhang, Q; Zhang, R; Zhang, T; Zhang, X; Zhang, Y; Zhang, YY; Zhao, B; Zhao, D; Zhao, G; Zhao, H; Zhao, Q; Zhao, R; Zhao, S; Zhao, T; Zhao, X; Zhao, XA; Zhao, Y; Zhao, Z; Zheng, Z; Zhi-Min, G; Zhou, CL; Zhou, HD; Zhou, J; Zhou, W; Zhou, XQ; Zhou, Z; Zhu, C; Zhu, H; Zhu, L; Zhu, Y; Zitzmann, N; Zou, L; Zou, Y, 2022) |
| "OA patients initiating tramadol have an increased risk of mortality, VTE, and hip fractures within 1 year compared with commonly prescribed NSAIDs, but not with codeine." | 4.12 | Association of tramadol with all-cause mortality, cardiovascular diseases, venous thromboembolism, and hip fractures among patients with osteoarthritis: a population-based study. ( Aviña-Zubieta, JA; Cibere, J; Esdaile, JM; Kopec, JA; Li, L; Lu, N; Marozoff, S; Xie, H, 2022) |
| "Joint pain decreased after 2 weeks of therapy in all patients during treatment with Voltaren Emulgel 2% (diclofenac diethylamine 2%) in both groups." | 4.02 | [Evaluation of topical therapy of patients with osteoarthritis of small joints of the hands with Voltaren® Emulgel® 2% (diclofenac diethylamine 2%)]. ( Gromova, MA; Tsurko, VV, 2021) |
| "Tramadol has been widely used among patients with osteoarthritis (OA); however, there is paucity of information on its cardiovascular risk." | 3.96 | Association of tramadol with risk of myocardial infarction among patients with osteoarthritis. ( Choi, HK; Dubreuil, M; LaRochelle, MR; Lei, G; Lin, J; Lu, N; Tomasson, G; Wei, J; Wood, MJ; Zeng, C; Zhang, Y, 2020) |
| "The anti-inflammatory and anti-catabolic actions of Diclofenac were compared with apigenin-C-glycosides rich Clinacanthus nutans (CN) leaf extract in osteoporotic-osteoarthritis rats." | 3.96 | Comparison of diclofenac with apigenin-glycosides rich Clinacanthus nutans extract for amending inflammation and catabolic protease regulations in osteoporotic-osteoarthritis rat model. ( Hussin, P; Lau, SF; Mohamed, S; Tantowi, NACA, 2020) |
| "We identified randomised controlled trials (RCTs) of diclofenac with planned study duration of at least 4 weeks for the treatment of osteoarthritis (OA) from 'legacy' studies conducted by Novartis but not published in a peer reviewed journal or included in any previous pooled analyses." | 3.85 | Efficacy and safety of diclofenac in osteoarthritis: Results of a network meta-analysis of unpublished legacy studies. ( Andrew Moore, R; Chaves, RL; Guyot, P; Iqbal, A; Nixon, RM; Pandhi, S, 2017) |
| "The aim of the present study was to investigate anti-inflammatory activity of Diclocor in the setting of collagen-induced osteoarthritis in rats in comparison with its active monocomponents-diclofenac sodium and quercetin." | 3.83 | Diclocor is superior to diclofenac sodium and quercetin in normalizing biochemical parameters in rats with collagen-induced osteoarthritis. ( Popov, OS; Shalamay, AS; Shebeko, SK; Zupanets, IA, 2016) |
| "Results of the CONDOR study suggest that in osteoarthritis and rheumatoid arthritis patients at elevated risk of gastrointestinal (GI) events, treatment with celecoxib, a cyclooxygenase (COX)-2 selective non-steroidal anti-inflammatory drug (NSAID), demonstrated significantly lower toxicity in the upper and lower (GI) tract when compared to the non-selective NSAID diclofenac plus a proton-pump-inhibitor (PPI), omeprazole." | 3.81 | How to mechanistically explain the CONDOR study data. ( Buttgereit, F; Spies, CM; Stemmler, E, 2015) |
| "Topical diclofenac, with and without dimethyl sulfoxide (DMSO), modestly improves pain and function scores (by 4%-8%) for as long as 12 weeks in patients with osteoarthritis (OA) of the knee." | 3.81 | Clinical inquiry: does topical diclofenac relieve osteoarthritis pain? ( Hodge, B; Skolnik, D, 2015) |
| "Celecoxib for the treatment of pain resulting from osteoarthritis (OA) was reviewed by the Tandvårds- och läkemedelsförmånsverket-Dental and Pharmaceutical Benefits Board (TLV) in Sweden in late 2010." | 3.80 | A cost-effectiveness analysis of celecoxib compared with diclofenac in the treatment of pain in osteoarthritis (OA) within the Swedish health system using an adaptation of the NICE OA model. ( Akehurst, R; Brereton, N; Ekelund, M; Pennington, B, 2014) |
| "The National Institute for Health and Clinical Excellence (NICE) health economic model for assessing the cost-effectiveness of celecoxib plus a proton pump inhibitor (PPI) compared to diclofenac plus PPI in the treatment of osteoarthritis has been updated using new adverse event (AE) risks from the CONDOR trial." | 3.78 | The cost-effectiveness of celecoxib vs diclofenac in the treatment of osteoarthritis in the UK; an update to the NICE model using data from the CONDOR trial. ( Akehurst, R; Brereton, N; Winn, B, 2012) |
| "To evaluate the safety of topical diclofenac sodium 1% gel (DSG) for knee and hand osteoarthritis (OA) in older and younger patients and in patients with versus without comorbid hypertension, type 2 diabetes, or cerebrovascular or cardiovascular disease." | 3.78 | Tolerability of topical diclofenac sodium 1% gel for osteoarthritis in seniors and patients with comorbidities. ( Baraf, HS; Gold, MS; Petruschke, RA; Wieman, MS, 2012) |
| "5% dimethyl sulfoxide (TDiclo) for the treatment of knee or hand osteoarthritis in persons aged 75 years or older." | 3.78 | Pooled safety analysis of diclofenac sodium topical solution 1.5% (w/w) in the treatment of osteoarthritis in patients aged 75 years or older. ( Fuller, P; Roth, SH, 2012) |
| "We evaluated 2-year CV outcomes in a prospective, nested biomarker study among patients (N = 6273) with rheumatoid arthritis and osteoarthritis treated with NSAID in the MEDAL (Multinational Etoricoxib and Diclofenac Arthritis Long-term) trial." | 3.77 | Evaluation of NT-proBNP and high sensitivity C-reactive protein for predicting cardiovascular risk in patients with arthritis taking longterm nonsteroidal antiinflammatory drugs. ( Brune, K; Cannon, CP; Contant, CF; Curtis, SP; Jarolim, P; Kaur, A; Laine, L; Morrow, DA; Ren, F; Ruff, CT, 2011) |
| " In both groups, the most frequently reported adverse events were gastrointestinal in nature, with abdominal pain reported most frequently (in 22." | 3.77 | Review of the safety of diclofenac/misoprostol. ( Gagnier, P, 1993) |
| " The five most commonly reported adverse events were abdominal pain by 23." | 3.77 | Overall safety of Arthrotec. ( Geis, GS, 1992) |
| "Etodolac has previously been reported to have an excellent safety profile." | 3.76 | A global safety evaluation of etodolac. ( Karbowski, A, 1989) |
| " The MEDAL program is designed to provide a precise estimate of the relative cardiovascular event rates with the COX-2 selective inhibitor etoricoxib in comparison to the traditional NSAID diclofenac in patients with osteoarthritis and rheumatoid arthritis." | 3.73 | Clinical trial design and patient demographics of the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) study program: cardiovascular outcomes with etoricoxib versus diclofenac in patients with osteoarthritis and rheumatoid arthritis. ( Bolognese, JA; Cannon, CP; Curtis, SP; Laine, L, 2006) |
| "We designed a prespecified pooled analysis of data from three trials in which patients with osteoarthritis or rheumatoid arthritis were randomly assigned to etoricoxib (60 mg or 90 mg daily) or diclofenac (150 mg daily)." | 3.73 | Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. ( Bolognese, JA; Bombardier, C; Cannon, CP; Curtis, SP; Erdmann, E; FitzGerald, GA; Kaur, A; Krum, H; Laine, L; Reicin, AS; van der Heijde, D; Weinblatt, ME, 2006) |
| "To assess the economic efficiency of meloxicam, a cyclo-oxygenase (COX)-2 selective inhibitor, versus diclofenac and piroxicam in the UK for the treatment of patients with osteoarthritis and the impact on the NHS budget of substituting nonselective NSAIDs with meloxicam." | 3.72 | Modelling therapeutic strategies in the treatment of osteoarthritis: an economic evaluation of meloxicam versus diclofenac and piroxicam. ( Tavakoli, M, 2003) |
| " Sex, body height, hypertrophic osteoarthritis of higher degree, size of the femoral component of the prosthesis, previous ipsi- or contralateral HO, and short course of nonsteroidal anti-inflammatory drug (diclofenac) therapy significantly influenced the HO rate in univariate analysis." | 3.72 | Preoperative irradiation for prevention of heterotopic ossification following prosthetic total hip replacement results of a prospective study in 462 hips. ( Flentje, M; Koelbl, O; Lehmann, H; Pohl, F; Seufert, J; Springorum, HW; Tauscher, A, 2003) |
| "To assess the effects of celecoxib, a cyclooxygenase (COX-2) selective inhibitor, on the metabolism of hyaluronan (HA) and proteoglycans (PG) in human cartilage explants with midrange severity of osteoarthritis (OA)." | 3.72 | Celecoxib has a positive effect on the overall metabolism of hyaluronan and proteoglycans in human osteoarthritic cartilage. ( Devogelaer, JP; El Hajjaji, H; Manicourt, DH; Marcelis, A, 2003) |
| " Rhein inhibited the IL-1beta induced NO degrees production, and may be a suitable treatment for osteoarthritis." | 3.71 | Inhibition of the nitrosothiol production of cultured osteoarthritic chondrocytes by rhein, cortisol and diclofenac. ( Borderie, D; Ekindjian, O; Hernvann, A; Lemarechal, H; Menkes, CJ, 2001) |
| "To perform a modelled economic analysis of the efficacy and tolerability of aceclofenac in comparison with those of other nonsteroidal antiinflammatory drugs (NSAIDs) used in the treatment of common arthritic disorders including osteoarthritis, rheumatoid arthritis and ankylosing spondylitis." | 3.71 | Iatrogenic cost factors incorporating mild and moderate adverse events in the economic comparison of aceclofenac and other NSAIDs. ( Badia, X; Brosa, M; Martínez, E; Peris, F, 2001) |
| " To compare the risk for thrombotic cardiovascular events among patients receiving rofecoxib, nonselective NSAIDs, and placebo, cardiovascular safety was assessed in 5,435 participants in 8 phase IIB/III osteoarthritis trials." | 3.71 | Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs (ibuprofen, diclofenac, and nabumetone). ( Barr, E; Reicin, AS; Shapiro, D; Sperling, RS; Yu, Q, 2002) |
| "This study combined existing data to test the hypothesis that GI comedications and GI diagnostic procedures occur less frequently in osteoarthritis (OA) patients treated with rofecoxib compared with nonselective NSAIDs." | 3.71 | Gastrointestinal medications and procedures in osteoarthritis patients treated with rofecoxib compared with nonselective NSAIDs. ( Bolognese, JA; Harper, SE; Simon, TJ; Watson, DJ; Zhao, PL, 2001) |
| "The incidence of lower extremity edema (LEE) AEs was generally similar between rofecoxib 12." | 3.71 | A comparison of adverse renovascular experiences among osteoarthritis patients treated with rofecoxib and comparator non-selective non-steroidal anti-inflammatory agents. ( Bolognese, JA; Gertz, BJ; Krupa, D; Reicin, A; Sperling, RS, 2002) |
| "Diclofenac had no significant effect on GAG or hydroxyproline content of implanted cartilage or on granuloma cytokine concentrations." | 3.70 | Effects of diacerhein on granuloma induced cartilage breakdown in the mouse. ( Alam, CA; Greenslade, KJ; Moore, AR; Willoughby, DA, 1998) |
| "This study investigated the efficacy and safety of a diclofenac/orphenadrin infusion in 21 female and 1 male patients with clinically and radiologically diagnosed inflammatory osteoarthritis of the big joints, especially the knee and hip joints." | 3.70 | [Diclofenac/orphenadrine infusion therapy in patients with active arthrosis]. ( Aglas, F; Rainer, F; Uitz, E; Wurm, A, 1998) |
| "This patient, who had a history of osteoarthritis, had severe hepatitis 5 weeks after being started on diclofenac for increasing pain in the joints." | 3.70 | Diclofenac-associated hepatitis. ( Al-Baghdadi, Y; Bhogaraju, A; Nazeer, S; Patel, N; Rahman, M; Wrestler, F, 1999) |
| "To analyze results of treatment of osteoarthritis (OA) with acetaminophen and the nonsteroidal antiinflammatory drugs (NSAID) through a patient survey." | 3.70 | Preference for nonsteroidal antiinflammatory drugs versus acetaminophen and concomitant use of both types of drugs in patients with osteoarthritis. ( Callahan, LF; Cummins, P; Pincus, T; Swearingen, C, 2000) |
| "To carry out a economic evaluation of diclofenac/misoprostol in the treatment of rheumatoid arthritis and osteoartritis when comparing with diclofenac alone, diclofenac + omeprazol, and diclofenac + ranitidine." | 3.70 | [Economic evaluation of the use of diclofenac/misoprostol in the treatment of osteoarticular diseases]. ( Soto Alvarez, J, 2000) |
| "To examine the effects of tenidap and diclofenac on osteoarthritic lesions and metalloprotease activity in experimental osteoarthritis (OA)." | 3.69 | Effects of tenidap on canine experimental osteoarthritis. I. Morphologic and metalloprotease analysis. ( Fernandes, JC; Lopez-Anaya, A; Martel-Pelletier, J; Mineau, F; Otterness, IG; Pelletier, JP; Tardif, G, 1995) |
| " Data from patients 65 years and older with osteoarthritis or rheumatoid arthritis show that etodolac is as well tolerated in elderly as in younger patients." | 3.69 | Safety profile of etodolac in the elderly population. ( Bacon, PA, 1994) |
| "To investigate the effects of tenidap, a new antirheumatic drug, sodium diclofenac, a non-steroidal antiinflammatory drug, and a disease modifying antirheumatic drug, hydroxychloroquine, on the level and expression of interleukin 1 receptors (IL-1R) on synovial fibroblasts from patients with osteoarthritis (OA) and rheumatoid arthritis (RA)." | 3.69 | Tenidap reduces the level of interleukin 1 receptors and collagenase expression in human arthritic synovial fibroblasts. ( Fernandes, JC; Loose, L; Martel-Pelletier, J; Mineau, F; Pelletier, JP; Ranger, P; Tardif, G, 1996) |
| "Severe immune haemolytic anaemia and thrombocytopenia developed in a 71-year-old female within 10 d of starting diclofenac (Voltarol) therapy." | 3.67 | Severe reversible autoimmune haemolytic anaemia and thrombocytopenia associated with diclofenac therapy. ( Hershko, C; Kramer, MR; Levene, C, 1986) |
| "The effect of diclofenac sodium (DS) on the metabolism of glycosaminoglycans (GAG) was studied in rabbits during the development of osteoarthritis of the knee induced by immobilization." | 3.67 | Effects of sodium diclofenac on glycosaminoglycan metabolism in experimental osteoarthritis in rabbits. ( Eronen, I; Videman, T, 1985) |
| "An open, multi-centre study was carried out in 239 elderly out-patients referred with symptomatic osteoarthritis of the hip and/or knee to assess the effectiveness of 200 mg sulindac twice daily compared with either 400 mg ibuprofen 3-times daily, 250 mg naproxen twice daily or 25 mg diclofenac 3-times daily." | 3.66 | Osteoarthritis and non-steroidal and anti-inflammatory drugs: a multi-centre comparative study. ( Pathy, MS, 1982) |
| "Non-steroidal anti-inflammatory drugs (NSAIDs) are an effective and common treatment for chronic pain disorders, but long-term use is associated with risk of potentially life-threatening gastrointestinal adverse events (AEs)." | 2.78 | Safety and efficacy of long-term esomeprazole 20 mg in Japanese patients with a history of peptic ulcer receiving daily non-steroidal anti-inflammatory drugs. ( Kinoshita, Y; Miwa, H; Sugano, K; Takeuchi, T, 2013) |
| " The cumulative gastrointestinal (GI)/liver adverse events (AEs) discontinuation rate was significantly lower for etoricoxib than diclofenac in each patient cohort; HR (95% CI) of 0." | 2.74 | Cardiovascular safety and gastrointestinal tolerability of etoricoxib vs diclofenac in a randomized controlled clinical trial (The MEDAL study). ( Cannon, CP; Combe, B; Connors, L; Curtis, S; Emery, P; Kaur, A; Laine, L; McCarthy, T; McLay, J; Swergold, G; Zerbini, C, 2009) |
| "Aceclofenac is a phenylacetic acid derivative with analgesic and anti-inflammatory properties and an improved gastrointestinal tolerance compared with other NSAIDs, such as diclofenac." | 2.73 | Bioequivalence and pharmacokinetic evaluation of two branded formulations of aceclofenac 100 mg: a single-dose, randomized, open-label, two-period crossover comparison in healthy Korean adult volunteers. ( Kang, JS; Lee, MH; Park, JH; Park, YS; Rhim, SY; Shaw, LM, 2008) |
| " Differences observed in blood pressure response between COX inhibitors may not be related in their sensitivity but rather their dosing frequency." | 2.71 | Effects of COX inhibition on blood pressure and kidney function in ACE inhibitor-treated blacks and hispanics. ( Alausa, T; Bakris, GL; Folker, A; Hung, E; Izhar, M, 2004) |
| "To investigate the effects of diclofenac alone or when combined with alpha-tocopherol on the oxidative activity of polymorphonuclear leukocytes (PMNs) in healthy and osteoarthritic (OA) patients." | 2.71 | Effect of diclofenac alone or in combination with alpha-tocopherol on the oxidative activity of polymorphonuclear leukocytes in healthy and osteoarthritic individuals. ( Al-Arfaj, AS; Al-Dalaan, AN; Al-Humayyd, MS; Al-Tuwaijri, AS; Alballa, SR; Mustafa, AA, 2004) |
| "80 outpatients with active primary osteoarthrosis with a radiological grade of II or III in the hip or knee joint (mean duration 4 years) were distributed randomly and equally to each treatment group." | 2.69 | [Oxaprozin versus diclofenac retard in treated of activated arthrosis]. ( Eckardt, A; Karbowski, A; Schwitalle, M, 1998) |
| " Evaluation of the profile of adverse events was the main aim of the trial, together with assessment of efficacy." | 2.69 | Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients. International MELISSA Study Group. Meloxicam Large-scale International Study Safety Assessment. ( Alegre, C; Baumelou, E; Bégaud, B; Dequeker, J; Hawkey, C; Isomäki, H; Kahan, A; Littlejohn, G; Mau, J; Papazoglou, S; Steinbrück, K, 1998) |
| "Conventional nonsteroidal anti-inflammatory drugs (NSAIDs) are associated with a spectrum of toxic effects, notably gastrointestinal (GI) effects, because of inhibition of cyclooxygenase (COX)-1." | 2.69 | Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. ( Agrawal, NM; Burr, AM; Eisen, G; Faich, G; Geis, GS; Goldstein, JL; Kent, JD; Lefkowith, JB; Makuch, R; Pincus, T; Silverstein, FE; Simon, LS; Stenson, WF; Verburg, KM; Whelton, A; Zhao, WW, 2000) |
| " In previous studies, meloxicam has been found to be safe and effective in the treatment of osteoarthritis (OA) at doses of 7." | 2.69 | Safety and efficacy of meloxicam in the treatment of osteoarthritis: a 12-week, double-blind, multiple-dose, placebo-controlled trial. The Meloxicam Osteoarthritis Investigators. ( Caldwell, J; Dalgin, P; Fleischmann, R; Hall, D; Roszko, P; Yocum, D, 2000) |
| "Ibuprofen was also better tolerated than diclofenac sodium (100 mg/day), the latter being associated with gastrointestinal side effects in a significant proportion of patients." | 2.68 | Ibuprofen and diclofenac sodium in the treatment of osteoarthritis: a comparative trial of two once-daily sustained-release NSAID formulations. ( Baumgartner, H; Blum, W; Bruhin, A; Gallachi, G; Goldinger, G; Saxer, M; Schwarz, HA; Trost, H, 1996) |
| "Naproxen-treated patients experienced significantly (p < 0." | 2.67 | Safety experience with nabumetone versus diclofenac, naproxen, ibuprofen, and piroxicam in osteoarthritis and rheumatoid arthritis. ( DeLapp, RE; Eversmeyer, W; Jensen, CP; Poland, M, 1993) |
| "Diclofenac was preferred to naproxen, aspirin and indomethacin, while piroxicam and placebo were preferred only to aspirin." | 2.66 | Double-blind preference and compliance multicentre study in osteoarthritis: once-a-day treatment. ( Bassi, GP; Borghi, C; Camarri, E; Cocco, F; Francucci, BM; Giannini, R; Giordano, N; Marcolongo, R; Mordini, M; Neri, D, 1985) |
| " Adverse experiences were infrequent and generally mild or transient." | 2.66 | Worldwide clinical safety experience with diclofenac. ( Willkens, RF, 1985) |
| " Randomized, double-blind, placebo-controlled, parallel-group trials that assessed adverse events (AEs) with topical NSAIDs in patients with OA were eligible for inclusion." | 2.61 | Safety of Topical Non-steroidal Anti-Inflammatory Drugs in Osteoarthritis: Outcomes of a Systematic Review and Meta-Analysis. ( Beaudart, C; Bruyère, O; Charles, A; Cooper, C; Geerinck, A; Honvo, G; Leclercq, V; Rabenda, V; Reginster, JY; Thomas, T; Veronese, N, 2019) |
| "Comfrey root extract has been used for the topical treatment of painful muscle and joint complaints." | 2.49 | Comfrey root: from tradition to modern clinical trials. ( Staiger, C, 2013) |
| " However, serious gastrointestinal and cardiovascular systemic adverse events (AEs) are associated with oral NSAIDs and can be treatment limiting." | 2.47 | Diclofenac sodium topical solution 1.5% w/w with dimethyl sulfoxide compared with placebo for the treatment of osteoarthritis: pooled safety results. ( Fuller, P; Roth, SH, 2011) |
| " We estimated 95% confidence interval, Q and 12 criteria, Mantel-Haenszel and DerSimonian-Laird statistics and relative risk of adverse reactions." | 2.46 | [Diclofenac sodium in osteoarthritis. Is there risk of hepatotoxicity? A systematic review]. ( Koniaeva, EI; Matveev, AV, 2010) |
| " Traditional NSAIDs are associated with an increased risk of serious gastrointestinal (GI) adverse events versus COX-2 selective inhibitors, and chronic use frequently necessitates adjunctive therapy with gastroprotective agents." | 2.44 | Efficacy of the newest COX-2 selective inhibitors in rheumatic disease. ( Baraf, HS, 2007) |
| "Pain is a common symptom experienced by people with osteoarthritis and rheumatoid arthritis and impacts upon mobility and quality of life." | 2.44 | Pain relief in osteoarthritis and rheumatoid arthritis: TENS. ( While, A; Ying, KN, 2007) |
| " Following oral administration, the less lipophilic celecoxib has a lower bioavailability (20-40%) than the other two coxibs (74-100%)." | 2.44 | Clinical use and pharmacological properties of selective COX-2 inhibitors. ( Klotz, U; Shi, S, 2008) |
| " Lumiracoxib has good oral bioavailability (74%)." | 2.43 | Clinical pharmacology of lumiracoxib: a selective cyclo-oxygenase-2 inhibitor. ( Choi, L; Mangold, JB; Marshall, P; Rordorf, CM, 2005) |
| "Diclofenac was as effective as indomethacin or sulindac in treating ankylosing spondylitis." | 2.38 | Diclofenac sodium. ( Small, RE, 1989) |
| "Osteoarthritis is the most common joint disorder worldwide and one of the leading causes of disability in the elderly." | 1.56 | [Residual Property of SI-613, a Novel Drug for Osteoarthritis, in Knee Joint]. ( Ishii, S; Morita, D; Yoshioka, K, 2020) |
| "Naproxen was not associated with any increase (adjusted OR 1." | 1.48 | Risk of myocardial infarction with use of selected non-steroidal anti-inflammatory drugs in patients with spondyloarthritis and osteoarthritis. ( Choi, HK; Dubreuil, M; Louie-Gao, Q; Neogi, T; Peloquin, CE; Zhang, Y, 2018) |
| "Diclofenac was used for comparison." | 1.46 | Mistletoe fig (Ficus deltoidea Jack) leaf extract prevented postmenopausal osteoarthritis by attenuating inflammation and cartilage degradation in rat model. ( Che Ahmad Tantowi, NA; Hussin, P; Lau, SF; Mohamed, S, 2017) |
| " Both 27 and 48 demonstrated robust activity in the acute rat monoiodoacetate-induced osteoarthritis model of pain, and subchronic dosing of 48 showed a shift to a lower EC50 over 7 days." | 1.43 | Substituted Indazoles as Nav1.7 Blockers for the Treatment of Pain. ( Daanen, JF; DeGoey, DA; El-Kouhen, OF; Fricano, MM; Frost, JM; Ghoreishi-Haack, N; Gum, RJ; Hsieh, GC; Kort, ME; Lundgaard, GL; Matulenko, MA; Neelands, T; Pai, M; Shi, L; Zhan, C; Zhang, XF, 2016) |
| " Their adverse effects on the upper gastrointestinal (GI) tract are well documented and well known among clinicians and often mitigated against by coprescribing proton pump inhibitors." | 1.39 | Lower gastrointestinal adverse effects of NSAIDS: an extreme example of a common problem. ( Conway, C; Elton, C; Mandegaran, R, 2013) |
| " Despite the many available forms of NSAIDs, including injectable as well as topical, oral dosing is the most common route, usually the one route consistently associated with chronic use and thus the one that carries the most risk." | 1.39 | Nonsteroidal anti-inflammatory drugs and their risk: a story still in development. ( Simon, LS, 2013) |
| " The results obtained in this study suggest that 84 days of continuous oral treatment of three different dosages of Polycan led to lesser degrees of articular stiffness and histological cartilage damage compared with OA controls 91 days after OA inducement, suggesting that the optimal Polycan dosage to treat OA is 42." | 1.38 | Efficacy test of Polycan, a beta-glucan originated from Aureobasidium pullulans SM-2001, on anterior cruciate ligament transection and partial medial meniscectomy-induced-osteoarthritis rats. ( Cho, HR; Kim, JW; Ku, SK, 2012) |
| "Diclofenac was highly effective in both tests on day 3, while on day 20 it induced a less pronounced decrease in the Knee-Bend score and was ineffective in the CatWalk test." | 1.38 | Analgesic effects of lidocaine, morphine and diclofenac on movement-induced nociception, as assessed by the Knee-Bend and CatWalk tests in a rat model of osteoarthritis. ( Adães, S; Castro-Lopes, JM; Ferreira-Gomes, J; Mendonça, M, 2012) |
| "Diclofenac was the test NSAID and collagomers--novel vesicular-shaped microparticles based on collagen-lipid conjugates--were the carriers." | 1.35 | A novel Diclofenac-carrier for local treatment of osteoarthritis applying live-animal MRI. ( Biton, IE; Elron-Gross, I; Glucksam, Y; Margalit, R, 2009) |
| "Osteoarthritis is a chronic and progressive joint disease." | 1.34 | [Articular cartilage in osteoarthritic patients: effects of diclofenac, celecoxib and glucosamine sulfate on inflammatory markers]. ( Brizuela, NY; Demurtas, SL; Meirovich, CI; Montrull, HL, 2007) |
| "Overview of three dose-response studies demonstrating the efficacy of lumiracoxib, a novel COX-2 selective inhibitor, for chronic pain associated with osteoarthritis (0A), or rheumatoid arthritis (RA) and acute pain following dental extraction." | 1.33 | Lumiracoxib in the treatment of osteoarthritis, rheumatoid arthritis and acute postoperative dental pain: results of three dose-response studies. ( Gitton, X; Jayawardene, S; Schnitzer, TJ; Sloan, VS, 2005) |
| "98 per patient depending on the dosage of diclofenac used." | 1.30 | Economic evaluation of nimesulide versus diclofenac in the treatment of osteoarthritis in Greece. ( Diamantopoulos, E; Ifandi, G; Ignatiades, T; Katostaras, F; Liaropoulos, L; Spinthouri, M, 1998) |
| "Chronic gastritis was seen in 76% of the patients taking NSAID and in 58% of the control cases; active inflammation was detected in 10% of the NSAID treated patients and in 24% of the control cases, and it appeared closely related with Helicobacter pylori infection." | 1.29 | Histological findings in gastric mucosa in patients treated with non-steroidal anti-inflammatory drugs. ( Aleotti, A; Alvisi, V; Caselli, M; DeCarlo, L; LaCorte, R; Ruina, M; Trevisani, L; Trotta, F, 1995) |
| "The aim of this study was the assessment of blood and synovial levels of diclofenac after repeated epicutaneous dosing with DHEP plasters in patients with joint effusion." | 1.29 | Pharmacokinetics of diclofenac hydroxyethylpyrrolidine (DHEP) plasters in patients with monolateral knee joint effusion. ( Gallacchi, G; Marcolongo, R, 1993) |
| "Treatment with diclofenac sodium tended to normalize this activity but there was no significant histological improvement." | 1.29 | Modulation of murine osteoarthritis. ( Bitensky, L; Chambers, MG; Chayen, J, 1996) |
| "Based upon a biochemically induced osteoarthrosis (OA) in the knee joints of rats we investigated the histomorphological alterations under therapy with diclofenac sodium by histological-histochemical grading." | 1.28 | Histomorphological and lectin-histochemical confirmation of the antidegenerative effect of diclofenac in experimental osteoarthrosis. ( Hoedt-Schmidt, S; Kalbhen, DA; Scheid, A, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 64 (18.34) | 18.7374 |
| 1990's | 95 (27.22) | 18.2507 |
| 2000's | 108 (30.95) | 29.6817 |
| 2010's | 68 (19.48) | 24.3611 |
| 2020's | 14 (4.01) | 2.80 |
| Authors | Studies |
|---|---|
| Hollinshead, SP | 1 |
| Tidwell, MW | 1 |
| Palmer, J | 1 |
| Guidetti, R | 1 |
| Sanderson, A | 1 |
| Johnson, MP | 2 |
| Chambers, MG | 5 |
| Oskins, J | 1 |
| Stratford, R | 1 |
| Astles, PC | 1 |
| Ruminski, PG | 1 |
| Massa, M | 1 |
| Strohbach, J | 1 |
| Hanau, CE | 1 |
| Schmidt, M | 1 |
| Scholten, JA | 1 |
| Fletcher, TR | 1 |
| Hamper, BC | 1 |
| Carroll, JN | 1 |
| Shieh, HS | 1 |
| Caspers, N | 1 |
| Collins, B | 1 |
| Grapperhaus, M | 1 |
| Palmquist, KE | 1 |
| Collins, J | 1 |
| Baldus, JE | 1 |
| Hitchcock, J | 1 |
| Kleine, HP | 1 |
| Rogers, MD | 1 |
| McDonald, J | 1 |
| Munie, GE | 1 |
| Messing, DM | 1 |
| Portolan, S | 1 |
| Whiteley, LO | 1 |
| Sunyer, T | 1 |
| Schnute, ME | 1 |
| Frost, JM | 1 |
| DeGoey, DA | 1 |
| Shi, L | 1 |
| Gum, RJ | 1 |
| Fricano, MM | 1 |
| Lundgaard, GL | 1 |
| El-Kouhen, OF | 1 |
| Hsieh, GC | 1 |
| Neelands, T | 1 |
| Matulenko, MA | 1 |
| Daanen, JF | 1 |
| Pai, M | 1 |
| Ghoreishi-Haack, N | 1 |
| Zhan, C | 1 |
| Zhang, XF | 1 |
| Kort, ME | 1 |
| Yakushin, S | 1 |
| Polyakova, S | 1 |
| Shvarts, Y | 1 |
| Kastanayan, A | 1 |
| Krechikova, D | 1 |
| Ershova, O | 1 |
| Nikulenkova, N | 1 |
| Vinogradova, I | 1 |
| Hyun, BJ | 1 |
| Cha, JE | 1 |
| Kamboj, AK | 1 |
| Moreira, RK | 1 |
| Sweetser, S | 1 |
| Cen, X | 1 |
| Pan, X | 1 |
| Zhang, B | 3 |
| Liu, C | 4 |
| Huang, X | 1 |
| Zhao, Z | 2 |
| de Campos, GC | 1 |
| de Almeida Macedo, E | 1 |
| Kummer, AM | 1 |
| Papaleo Rosim, M | 1 |
| Millan Fachi, M | 1 |
| Auletta, LL | 1 |
| Li, L | 2 |
| Marozoff, S | 1 |
| Lu, N | 2 |
| Xie, H | 1 |
| Kopec, JA | 1 |
| Cibere, J | 1 |
| Esdaile, JM | 1 |
| Aviña-Zubieta, JA | 1 |
| Kubo, T | 1 |
| Kumai, T | 1 |
| Ikegami, H | 1 |
| Kano, K | 1 |
| Nishii, M | 1 |
| Seo, T | 1 |
| Tsurko, VV | 1 |
| Gromova, MA | 1 |
| Madzuki, IN | 1 |
| Lau, SF | 4 |
| Mohamad Shalan, NAA | 1 |
| Mohd Ishak, NI | 1 |
| Mohamed, S | 4 |
| Wei, J | 3 |
| Wood, MJ | 1 |
| Dubreuil, M | 2 |
| Tomasson, G | 1 |
| LaRochelle, MR | 1 |
| Zeng, C | 2 |
| Lin, J | 1 |
| Choi, HK | 2 |
| Lei, G | 1 |
| Zhang, Y | 6 |
| Hanafy, AS | 1 |
| El-Ganainy, SO | 1 |
| Materkowski, M | 1 |
| Tantowi, NACA | 2 |
| Hussin, P | 2 |
| Nese, M | 1 |
| Riboli, G | 1 |
| Brighetti, G | 1 |
| Sassi, V | 1 |
| Camela, E | 1 |
| Caselli, G | 1 |
| Sassaroli, S | 1 |
| Borlimi, R | 1 |
| Aucoin, M | 1 |
| Cooley, K | 1 |
| Saunders, PR | 1 |
| Carè, J | 1 |
| Anheyer, D | 1 |
| Medina, DN | 1 |
| Cardozo, V | 1 |
| Remy, D | 1 |
| Hannan, N | 1 |
| Garber, A | 1 |
| Velayos, M | 1 |
| Muñoz-Serrano, AJ | 1 |
| Estefanía-Fernández, K | 1 |
| Sarmiento Caldas, MC | 1 |
| Moratilla Lapeña, L | 1 |
| López-Santamaría, M | 1 |
| López-Gutiérrez, JC | 1 |
| Li, J | 1 |
| Zhang, J | 1 |
| Shen, S | 1 |
| Yu, WW | 1 |
| Toyoda, H | 1 |
| Huang, DQ | 1 |
| Le, MH | 1 |
| Nguyen, MH | 1 |
| Huang, R | 1 |
| Zhu, L | 1 |
| Wang, J | 6 |
| Xue, L | 1 |
| Liu, L | 2 |
| Yan, X | 2 |
| Huang, S | 1 |
| Li, Y | 6 |
| Xu, T | 1 |
| Li, C | 3 |
| Ji, F | 1 |
| Ming, F | 1 |
| Zhao, Y | 2 |
| Cheng, J | 1 |
| Wang, Y | 3 |
| Zhao, H | 1 |
| Hong, S | 1 |
| Chen, K | 2 |
| Zhao, XA | 1 |
| Zou, L | 1 |
| Sang, D | 1 |
| Shao, H | 1 |
| Guan, X | 1 |
| Chen, X | 2 |
| Chen, Y | 4 |
| Zhu, C | 1 |
| Wu, C | 1 |
| Moore, HB | 1 |
| Barrett, CD | 1 |
| Moore, EE | 1 |
| Jhunjhunwala, R | 1 |
| McIntyre, RC | 1 |
| Moore, PK | 1 |
| Hajizadeh, N | 1 |
| Talmor, DS | 1 |
| Sauaia, A | 1 |
| Yaffe, MB | 1 |
| Lin, Y | 1 |
| Dong, Y | 2 |
| Wu, Y | 1 |
| Bao, Y | 1 |
| Yan, H | 2 |
| Ma, J | 1 |
| Fernández-Cuadros, ME | 1 |
| Albaladejo-Florín, MJ | 1 |
| Álava-Rabasa, S | 1 |
| Usandizaga-Elio, I | 1 |
| Martinez-Quintanilla Jimenez, D | 1 |
| Peña-Lora, D | 1 |
| Neira-Borrajo, I | 1 |
| López-Muñoz, MJ | 1 |
| Rodríguez-de-Cía, J | 1 |
| Pérez-Moro, OS | 1 |
| Abdallah, M | 1 |
| Alsaleh, H | 1 |
| Baradwan, A | 1 |
| Alfawares, R | 1 |
| Alobaid, A | 1 |
| Rasheed, A | 1 |
| Soliman, I | 1 |
| Wendel Garcia, PD | 1 |
| Fumeaux, T | 1 |
| Guerci, P | 1 |
| Heuberger, DM | 1 |
| Montomoli, J | 2 |
| Roche-Campo, F | 1 |
| Schuepbach, RA | 1 |
| Hilty, MP | 1 |
| Poloni, TE | 1 |
| Carlos, AF | 1 |
| Cairati, M | 1 |
| Cutaia, C | 1 |
| Medici, V | 1 |
| Marelli, E | 1 |
| Ferrari, D | 1 |
| Galli, A | 1 |
| Bognetti, P | 1 |
| Davin, A | 1 |
| Cirrincione, A | 1 |
| Ceretti, A | 1 |
| Cereda, C | 1 |
| Ceroni, M | 1 |
| Tronconi, L | 1 |
| Vitali, S | 1 |
| Guaita, A | 1 |
| Leeds, JS | 1 |
| Raviprakash, V | 1 |
| Jacques, T | 1 |
| Scanlon, N | 1 |
| Cundall, J | 1 |
| Leeds, CM | 1 |
| Riva, A | 1 |
| Gray, EH | 1 |
| Azarian, S | 1 |
| Zamalloa, A | 1 |
| McPhail, MJW | 1 |
| Vincent, RP | 1 |
| Williams, R | 1 |
| Chokshi, S | 1 |
| Patel, VC | 1 |
| Edwards, LA | 1 |
| Alqarawi, W | 1 |
| Birnie, DH | 1 |
| Golian, M | 1 |
| Nair, GM | 1 |
| Nery, PB | 1 |
| Klein, A | 1 |
| Davis, DR | 1 |
| Sadek, MM | 1 |
| Neilipovitz, D | 1 |
| Johnson, CB | 1 |
| Green, MS | 1 |
| Redpath, C | 1 |
| Miller, DC | 1 |
| Beamer, P | 1 |
| Billheimer, D | 1 |
| Subbian, V | 1 |
| Sorooshian, A | 1 |
| Campbell, BS | 1 |
| Mosier, JM | 1 |
| Novaretti, JV | 1 |
| Astur, DC | 1 |
| Cavalcante, ELB | 1 |
| Kaleka, CC | 1 |
| Amaro, JT | 1 |
| Cohen, M | 1 |
| Huang, W | 1 |
| Li, T | 1 |
| Ling, Y | 1 |
| Qian, ZP | 1 |
| Zhang, YY | 1 |
| Huang, D | 1 |
| Xu, SB | 1 |
| Liu, XH | 1 |
| Xia, L | 1 |
| Yang, Y | 4 |
| Lu, SH | 1 |
| Lu, HZ | 1 |
| Zhang, R | 2 |
| Ma, JX | 1 |
| Tang, S | 1 |
| Li, CM | 1 |
| Wan, J | 1 |
| Wang, JF | 1 |
| Ma, JQ | 1 |
| Luo, JJ | 1 |
| Chen, HY | 2 |
| Mi, SL | 1 |
| Chen, SY | 1 |
| Su, YG | 1 |
| Ge, JB | 1 |
| Milheiro, SA | 1 |
| Gonçalves, J | 1 |
| Lopes, RMRM | 1 |
| Madureira, M | 1 |
| Lobo, L | 1 |
| Lopes, A | 1 |
| Nogueira, F | 1 |
| Fontinha, D | 1 |
| Prudêncio, M | 1 |
| M Piedade, MF | 1 |
| Pinto, SN | 1 |
| Florindo, PR | 1 |
| Moreira, R | 1 |
| Castillo-Lora, J | 1 |
| Delley, MF | 1 |
| Laga, SM | 1 |
| Mayer, JM | 1 |
| Sutjarit, N | 1 |
| Thongon, N | 1 |
| Weerachayaphorn, J | 1 |
| Piyachaturawat, P | 1 |
| Suksamrarn, A | 1 |
| Suksen, K | 1 |
| Papachristou, DJ | 1 |
| Blair, HC | 1 |
| Hu, Y | 1 |
| Shen, P | 1 |
| Zeng, N | 1 |
| Wang, L | 3 |
| Yan, D | 1 |
| Cui, L | 1 |
| Yang, K | 2 |
| Zhai, C | 1 |
| Yang, M | 1 |
| Lao, X | 1 |
| Sun, J | 1 |
| Ma, N | 1 |
| Wang, S | 1 |
| Ye, W | 1 |
| Guo, P | 1 |
| Rahimi, S | 1 |
| Singh, MP | 1 |
| Gupta, J | 1 |
| Nakanishi, I | 1 |
| Ohkubo, K | 1 |
| Shoji, Y | 1 |
| Fujitaka, Y | 1 |
| Shimoda, K | 1 |
| Matsumoto, KI | 1 |
| Fukuhara, K | 1 |
| Hamada, H | 1 |
| van der Boom, T | 1 |
| Gruppen, EG | 1 |
| Lefrandt, JD | 1 |
| Connelly, MA | 1 |
| Links, TP | 1 |
| Dullaart, RPF | 1 |
| Berry, JD | 1 |
| Bedlack, R | 1 |
| Mathews, D | 1 |
| Agnese, W | 1 |
| Apple, S | 1 |
| Meloncelli, S | 1 |
| Divizia, M | 1 |
| Germani, G | 1 |
| Adefegha, SA | 1 |
| Bottari, NB | 1 |
| Leal, DB | 1 |
| de Andrade, CM | 1 |
| Schetinger, MR | 1 |
| Martínez-Velasco, A | 1 |
| Perez-Ortiz, AC | 1 |
| Antonio-Aguirre, B | 1 |
| Martínez-Villaseñor, L | 1 |
| Lira-Romero, E | 1 |
| Palacio-Pastrana, C | 1 |
| Zenteno, JC | 1 |
| Ramirez, I | 1 |
| Zepeda-Palacio, C | 1 |
| Mendoza-Velásquez, C | 1 |
| Camacho-Ordóñez, A | 1 |
| Ortiz Bibriesca, DM | 1 |
| Estrada-Mena, FJ | 1 |
| Martin, BL | 1 |
| Thompson, LC | 1 |
| Kim, YH | 2 |
| Snow, SJ | 1 |
| Schladweiler, MC | 1 |
| Phillips, P | 1 |
| Harmon, M | 1 |
| King, C | 1 |
| Richards, J | 1 |
| George, I | 1 |
| Haykal-Coates, N | 1 |
| Gilmour, MI | 1 |
| Kodavanti, UP | 1 |
| Hazari, MS | 1 |
| Farraj, AK | 1 |
| Shen, Z | 1 |
| Zou, Y | 1 |
| Gao, K | 1 |
| Lazar, S | 1 |
| Wurtzel, JGT | 1 |
| Ma, P | 1 |
| Goldfinger, LE | 1 |
| Vukelic, M | 1 |
| Laloo, A | 1 |
| Kyttaris, VC | 1 |
| Chen, R | 1 |
| Chen, J | 2 |
| Xun, J | 1 |
| Hu, Z | 1 |
| Huang, Q | 2 |
| Steinhart, C | 1 |
| Shen, Y | 1 |
| Lu, H | 1 |
| Mansuri, A | 1 |
| Lokhande, K | 1 |
| Kore, S | 1 |
| Gaikwad, S | 1 |
| Nawani, N | 1 |
| Swamy, KV | 1 |
| Junnarkar, M | 1 |
| Pawar, S | 1 |
| Shaheen, MY | 1 |
| Basudan, AM | 1 |
| Niazy, AA | 1 |
| van den Beucken, JJJP | 1 |
| Jansen, JA | 1 |
| Alghamdi, HS | 1 |
| Gao, Q | 2 |
| Guo, X | 1 |
| Cao, Y | 1 |
| Jia, X | 1 |
| Xu, S | 1 |
| Lu, C | 2 |
| Zhu, H | 2 |
| Melku, M | 1 |
| Abebe, G | 1 |
| Teketel, A | 1 |
| Asrie, F | 1 |
| Yalew, A | 1 |
| Biadgo, B | 1 |
| Kassa, E | 1 |
| Damtie, D | 1 |
| Anlay, DZ | 1 |
| Ahmed, MFE | 1 |
| Ramadan, H | 1 |
| Seinige, D | 1 |
| Kehrenberg, C | 1 |
| Abd El-Wahab, A | 1 |
| Volkmann, N | 1 |
| Kemper, N | 1 |
| Schulz, J | 1 |
| Hu, MY | 1 |
| Wu, YN | 1 |
| McEvoy, MP | 1 |
| Wang, YF | 1 |
| Cong, WL | 1 |
| Liu, LP | 1 |
| Li, XX | 1 |
| Zhou, CL | 1 |
| Chen, WM | 1 |
| Wei, KL | 1 |
| Tung, SY | 1 |
| Shen, CH | 1 |
| Chang, TS | 1 |
| Yen, CW | 1 |
| Hsieh, YY | 1 |
| Chiu, WN | 1 |
| Hu, JH | 1 |
| Lu, SN | 1 |
| Hung, CH | 1 |
| Alakavuklar, MA | 1 |
| Fuqua, C | 1 |
| Luo, KL | 1 |
| Underwood, RS | 1 |
| Greenwald, I | 1 |
| Elashiry, MM | 1 |
| Elashiry, M | 1 |
| Zeitoun, R | 1 |
| Elsayed, R | 1 |
| Tian, F | 1 |
| Saber, SE | 1 |
| Elashry, SH | 1 |
| Tay, FR | 1 |
| Cutler, CW | 1 |
| O'Dowd, A | 1 |
| Maciel, M | 1 |
| Poole, ST | 1 |
| Jobling, MG | 1 |
| Rollenhagen, JE | 1 |
| Woods, CM | 1 |
| Sincock, SA | 1 |
| McVeigh, AL | 1 |
| Gregory, MJ | 1 |
| Maves, RC | 1 |
| Prouty, MG | 1 |
| Holmes, RK | 1 |
| Savarino, SJ | 1 |
| Mor, MK | 1 |
| Palevsky, PM | 1 |
| Kaufman, JS | 1 |
| Thiessen Philbrook, H | 1 |
| Weisbord, SD | 1 |
| Parikh, CR | 1 |
| John, CM | 1 |
| Phillips, NJ | 1 |
| Jarvis, GA | 1 |
| Zhu, Y | 1 |
| Kilburn, S | 1 |
| Kapoor, M | 1 |
| Chaturvedi, S | 1 |
| Shaw, KJ | 1 |
| Chaturvedi, V | 1 |
| Kong, X | 1 |
| Zhang, T | 1 |
| Xiao, H | 1 |
| Feng, X | 2 |
| Tu, H | 1 |
| Feng, J | 1 |
| Sabet, M | 1 |
| Tarazi, Z | 1 |
| Griffith, DC | 1 |
| Nguyen, F | 1 |
| Guan, P | 1 |
| Guerrero, DT | 1 |
| Kolla, V | 1 |
| Naraparaju, K | 1 |
| Perry, LM | 1 |
| Soberman, D | 1 |
| Pressly, BB | 1 |
| Alferiev, IS | 1 |
| Chorny, M | 1 |
| Brodeur, GM | 1 |
| Gao, X | 2 |
| Cheng, YH | 1 |
| Enten, GA | 1 |
| DeSantis, AJ | 1 |
| Gaponenko, V | 1 |
| Majetschak, M | 1 |
| Kim, DY | 1 |
| Choi, MJ | 1 |
| Ko, TK | 1 |
| Lee, NH | 1 |
| Kim, OH | 1 |
| Cheon, HG | 1 |
| Cai, H | 1 |
| Yip, V | 1 |
| Lee, MV | 1 |
| Wong, S | 1 |
| Saad, O | 1 |
| Ma, S | 1 |
| Ljumanovic, N | 1 |
| Khojasteh, SC | 1 |
| Kamath, AV | 1 |
| Shen, BQ | 1 |
| Cuypers, ML | 1 |
| Chanteux, H | 1 |
| Gillent, E | 1 |
| Bonnaillie, P | 1 |
| Saunders, K | 1 |
| Beckers, C | 1 |
| Delatour, C | 1 |
| Dell'Aiera, S | 1 |
| Ungell, AL | 1 |
| Nicolaï, J | 1 |
| Knapp, AK | 1 |
| Chen, A | 1 |
| Griffin-Nolan, RJ | 1 |
| Baur, LE | 1 |
| Carroll, CJW | 1 |
| Gray, JE | 1 |
| Hoffman, AM | 1 |
| Li, X | 4 |
| Post, AK | 1 |
| Slette, IJ | 1 |
| Collins, SL | 1 |
| Luo, Y | 1 |
| Smith, MD | 1 |
| Temitayo, GI | 1 |
| Olawande, B | 1 |
| Emmanuel, YO | 1 |
| Timothy, AT | 1 |
| Kehinde, O | 1 |
| Susan, LF | 1 |
| Ezra, L | 1 |
| Joseph, OO | 1 |
| Lev, S | 1 |
| Desmarini, D | 1 |
| Liuwantara, D | 1 |
| Sorrell, TC | 1 |
| Hawthorne, WJ | 1 |
| Djordjevic, JT | 1 |
| Verso, MG | 1 |
| Costantino, C | 1 |
| Marrella, A | 1 |
| Immordino, P | 1 |
| Vitale, F | 1 |
| Amodio, E | 1 |
| Wang, YD | 1 |
| Yao, WL | 1 |
| Xin, ZM | 1 |
| Han, TT | 1 |
| Wang, ZG | 1 |
| Chen, L | 1 |
| Cai, C | 1 |
| Ba, D | 1 |
| Wen, S | 1 |
| Tian, Q | 1 |
| Lv, W | 1 |
| Cheng, G | 1 |
| Li, N | 1 |
| Yue, XY | 1 |
| Chu, WJ | 1 |
| Chen, Q | 1 |
| Choi, ES | 1 |
| Zhao, X | 3 |
| Zhou, HD | 1 |
| Sun, XF | 1 |
| Sharma, S | 2 |
| Chhoker, S | 1 |
| Xie, C | 1 |
| Ong, EWY | 1 |
| Tan, ZK | 1 |
| Evans, S | 1 |
| Weinheimer, CJ | 1 |
| Kovacs, A | 1 |
| Williams, JW | 1 |
| Randolph, GJ | 1 |
| Jiang, W | 1 |
| Barger, PM | 1 |
| Mann, DL | 1 |
| Liu, J | 2 |
| Huang, Y | 1 |
| Kong, L | 1 |
| Yu, X | 1 |
| Feng, B | 1 |
| Liu, D | 1 |
| Zhao, B | 1 |
| Mendes, GC | 1 |
| Yuan, P | 1 |
| Ge, D | 1 |
| Wang, WM | 1 |
| Fontes, EPB | 1 |
| Li, P | 1 |
| Shan, L | 1 |
| He, P | 1 |
| Katoh, T | 1 |
| Sengoku, T | 1 |
| Hirata, K | 1 |
| Ogata, K | 1 |
| Suga, H | 1 |
| Shun, C | 1 |
| Yong-Yi, J | 1 |
| Mei-Li, C | 1 |
| Shi-Li, L | 1 |
| Jian-Bo, Z | 1 |
| Dan-Li, W | 1 |
| Zhi-Min, G | 1 |
| Ibrahim, AM | 1 |
| Zakhary, SY | 1 |
| Amin, SAW | 1 |
| Ugurlu, M | 1 |
| Fornari, VJ | 1 |
| Hartmann, MSM | 1 |
| Vanni, JR | 1 |
| Rodriguez, R | 1 |
| Langaro, MC | 1 |
| Pelepenko, LE | 1 |
| Zaia, AA | 1 |
| Nakanjako, D | 1 |
| Zalwango, F | 1 |
| Wairagala, P | 1 |
| Luboga, F | 1 |
| Andia Biraro, I | 1 |
| Bukirwa, VD | 1 |
| Mboowa, MG | 1 |
| Cose, S | 1 |
| Seeley, J | 1 |
| Elliott, A | 1 |
| Zhao, G | 1 |
| Sun, P | 1 |
| Hao, S | 1 |
| Wang, X | 1 |
| Qu, G | 1 |
| Xing, Y | 1 |
| Xu, X | 1 |
| Maierhofer, M | 1 |
| Rieger, V | 1 |
| Mayr, T | 1 |
| Liu, Y | 2 |
| Zhang, Q | 1 |
| Bigliardi, AP | 1 |
| Fernandes, CLF | 1 |
| Pinto, EA | 1 |
| Dos Santos, M | 1 |
| Garcia, EM | 1 |
| Baisch, PRM | 1 |
| Soares, MCF | 1 |
| Muccillo-Baisch, AL | 1 |
| da Silva Júnior, FMR | 1 |
| Yu, W | 1 |
| Ju, C | 1 |
| Wang, K | 1 |
| Zheng, Z | 1 |
| Liu, H | 1 |
| Gao, Y | 1 |
| Martínez-Navarro, EM | 1 |
| Cebrián-Tarancón, C | 1 |
| Moratalla-López, N | 1 |
| Lorenzo, C | 1 |
| Alonso, GL | 1 |
| Salinas, RM | 1 |
| Bermúdez de Castro, JM | 1 |
| Modesto-Mata, M | 1 |
| Martín-Francés, L | 1 |
| García-Campos, C | 1 |
| Martínez de Pinillos, M | 1 |
| Martinón-Torres, M | 1 |
| Hasani, M | 1 |
| Wu, F | 2 |
| Warriner, K | 1 |
| Kurz, M | 1 |
| Gretzke, D | 1 |
| Hörlein, R | 1 |
| Turpault, S | 1 |
| Atzrodt, J | 1 |
| Derdau, V | 1 |
| Yao, Y | 1 |
| Ou, X | 1 |
| Zhao, S | 1 |
| Tian, B | 1 |
| Jin, S | 1 |
| Jiang, Z | 1 |
| Zhou, Z | 1 |
| Liu, M | 2 |
| Jiang, GD | 1 |
| Mou, LH | 1 |
| Chen, JJ | 1 |
| Li, ZY | 1 |
| He, SG | 1 |
| Reale, E | 1 |
| Fustinoni, S | 1 |
| Mercadante, R | 1 |
| Polledri, E | 1 |
| Hopf, NB | 1 |
| Grant, PC | 1 |
| Levy, K | 1 |
| Lattimer, TA | 1 |
| Depner, RM | 1 |
| Kerr, CW | 1 |
| Sato, J | 1 |
| Merenda, MEZ | 1 |
| Uemoto, AT | 1 |
| Dos Santos, MP | 1 |
| Barion, MRL | 1 |
| Carciofi, AC | 1 |
| de Paula Dorigam, JC | 1 |
| Ribeiro, LB | 1 |
| Vasconcellos, RS | 1 |
| Waller, SB | 1 |
| Peter, CM | 1 |
| Hoffmann, JF | 1 |
| Cleff, MB | 1 |
| Faria de, RO | 1 |
| Zani, JL | 1 |
| Martins, BA | 1 |
| Sande, D | 1 |
| Solares, MD | 1 |
| Takahashi, JA | 1 |
| Yang, S | 2 |
| Jia, Y | 1 |
| Yin, C | 1 |
| Zhao, R | 1 |
| Ojha, M | 1 |
| Wu, B | 1 |
| Deepa, M | 1 |
| Mo, J | 1 |
| Au, DW | 1 |
| Wan, MT | 1 |
| Shi, J | 1 |
| Zhang, G | 1 |
| Winkler, C | 1 |
| Kong, RY | 1 |
| Seemann, F | 1 |
| Bianco, M | 1 |
| Calvano, CD | 1 |
| Ventura, G | 1 |
| Bianco, G | 1 |
| Losito, I | 1 |
| Cataldi, TRI | 1 |
| Angiolella, L | 1 |
| Staudt, A | 1 |
| Duarte, PF | 1 |
| Amaral, BPD | 1 |
| Peixoto Andrade, BCO | 1 |
| Simas, NK | 1 |
| Correa Ramos Leal, I | 1 |
| Sangenito, LS | 1 |
| Santos, ALSD | 1 |
| de Oliveira, D | 1 |
| Junges, A | 1 |
| Cansian, RL | 1 |
| Paroul, N | 1 |
| Siu, J | 1 |
| Klingler, L | 1 |
| Hung, CT | 1 |
| Jeong, SH | 1 |
| Smith, S | 1 |
| Tingle, MD | 1 |
| Wagner Mackenzie, B | 1 |
| Biswas, K | 1 |
| Douglas, RG | 1 |
| Oza, AM | 1 |
| Lorusso, D | 1 |
| Aghajanian, C | 1 |
| Oaknin, A | 1 |
| Dean, A | 1 |
| Colombo, N | 1 |
| Weberpals, JI | 1 |
| Clamp, AR | 1 |
| Scambia, G | 1 |
| Leary, A | 1 |
| Holloway, RW | 1 |
| Gancedo, MA | 1 |
| Fong, PC | 1 |
| Goh, JC | 1 |
| O'Malley, DM | 1 |
| Armstrong, DK | 1 |
| Banerjee, S | 1 |
| García-Donas, J | 1 |
| Swisher, EM | 1 |
| Cella, D | 1 |
| Meunier, J | 1 |
| Goble, S | 1 |
| Cameron, T | 1 |
| Maloney, L | 1 |
| Mörk, AC | 1 |
| Bedel, J | 1 |
| Ledermann, JA | 1 |
| Coleman, RL | 1 |
| Vlek, SL | 1 |
| Burm, R | 1 |
| Govers, TM | 1 |
| Vleugels, MPH | 1 |
| Tuynman, JB | 1 |
| Mijatovic, V | 1 |
| Leicht, AS | 1 |
| Connor, J | 1 |
| Conduit, N | 1 |
| Vaquera, A | 1 |
| Gómez, MA | 1 |
| McKay, JA | 1 |
| Church, AL | 1 |
| Rubin, N | 1 |
| Emory, TH | 1 |
| Hoven, NF | 1 |
| Kuehn-Hajder, JE | 1 |
| Nelson, MT | 1 |
| Ramanna, S | 1 |
| Auerbach, EJ | 1 |
| Moeller, S | 1 |
| Bolan, PJ | 1 |
| Fox, NP | 1 |
| Leonard, M | 1 |
| Sjerps, MJ | 1 |
| Chang, EF | 1 |
| Hyun, S | 1 |
| Saejio, A | 1 |
| Shanmugam, S | 1 |
| Liu, X | 1 |
| Sun, M | 1 |
| Bai, Z | 1 |
| Jaque-Fernandez, F | 1 |
| Beaulant, A | 1 |
| Berthier, C | 1 |
| Monteiro, L | 1 |
| Allard, B | 1 |
| Casas, M | 1 |
| Rieusset, J | 1 |
| Jacquemond, V | 1 |
| Góngora-García, OR | 1 |
| Aca-Aca, G | 1 |
| Baz-Rodríguez, SA | 1 |
| Monte, A | 1 |
| Maganaris, C | 1 |
| Baltzopoulos, V | 1 |
| Zamparo, P | 1 |
| Wang, Z | 2 |
| Hou, Y | 1 |
| Cai, L | 1 |
| Tu, YJ | 1 |
| Tan, B | 1 |
| Jiang, L | 1 |
| Wu, ZH | 1 |
| Yu, HJ | 1 |
| Li, XQ | 1 |
| Yang, AD | 1 |
| Titze, IR | 1 |
| Palaparthi, A | 1 |
| Mau, T | 1 |
| González, MA | 1 |
| Goiri, F | 1 |
| Barandika, JF | 1 |
| García-Pérez, AL | 1 |
| Jatt, LP | 1 |
| Gandhi, MM | 1 |
| Guo, R | 1 |
| Sukhija-Cohen, A | 1 |
| Bhattacharya, D | 1 |
| Tseng, CH | 1 |
| Chew, KW | 1 |
| Onwumere, J | 1 |
| Pia Tek, J | 1 |
| Budnyak, T | 1 |
| Budnyk, S | 1 |
| Karim, Z | 1 |
| Thersleff, T | 1 |
| Kuśtrowski, P | 1 |
| Mathew, AP | 1 |
| Slabon, A | 1 |
| Guo, M | 1 |
| Zhao, T | 1 |
| Xing, Z | 1 |
| Qiu, Y | 1 |
| Pan, K | 1 |
| Li, Z | 2 |
| Zhou, W | 1 |
| Ghassemi Tabrizi, S | 1 |
| Arbuznikov, AV | 1 |
| Jiménez-Hoyos, CA | 1 |
| Kaupp, M | 1 |
| Lin, MH | 2 |
| Bulman, DM | 1 |
| Remucal, CK | 1 |
| Chaplin, BP | 1 |
| Laguerre, A | 1 |
| George, LA | 1 |
| Gall, ET | 1 |
| Emerson, MS | 1 |
| Wang, H | 4 |
| Maginn, EJ | 1 |
| Margulis, CJ | 1 |
| Li, H | 3 |
| Feng, W | 1 |
| Kang, X | 2 |
| Yan, S | 1 |
| Chao, M | 1 |
| Mo, S | 1 |
| Sun, W | 1 |
| Lu, Y | 1 |
| Chen, C | 1 |
| Stevens, DM | 1 |
| Adiseshaiah, P | 1 |
| Dasa, SSK | 1 |
| Potter, TM | 1 |
| Skoczen, SL | 1 |
| Snapp, KS | 1 |
| Cedrone, E | 1 |
| Patel, N | 2 |
| Busman-Sahay, K | 1 |
| Rosen, EP | 1 |
| Sykes, C | 1 |
| Cottrell, M | 1 |
| Dobrovolskaia, MA | 1 |
| Estes, JD | 1 |
| Kashuba, ADM | 1 |
| Stern, ST | 1 |
| Özütemiz, C | 1 |
| Neil, EC | 1 |
| Tanwar, M | 1 |
| Rubin, NT | 1 |
| Ozturk, K | 1 |
| Cayci, Z | 1 |
| Duscha, BD | 1 |
| Kraus, WE | 1 |
| Jones, WS | 1 |
| Robbins, JL | 1 |
| Piner, LW | 1 |
| Huffman, KM | 1 |
| Allen, JD | 1 |
| Annex, BH | 1 |
| Mehmood, T | 1 |
| Ahmad, I | 1 |
| Bibi, S | 1 |
| Mustafa, B | 1 |
| Ali, I | 1 |
| Dahal, RH | 1 |
| Chaudhary, DK | 1 |
| Kim, DU | 1 |
| Kim, J | 1 |
| Yeter, HH | 1 |
| Gonul, I | 1 |
| Guz, G | 1 |
| Helvaci, O | 1 |
| Korucu, B | 1 |
| Akcay, OF | 1 |
| Derici, U | 1 |
| Arinsoy, T | 1 |
| Neffati, R | 1 |
| Judeinstein, P | 1 |
| Rault, J | 1 |
| Xu, Y | 1 |
| Chai, X | 1 |
| Ren, T | 1 |
| Yu, S | 3 |
| Fu, Q | 2 |
| Ye, J | 1 |
| Ge, X | 1 |
| Song, J | 1 |
| Yang, H | 2 |
| El-Baba, TJ | 1 |
| Lutomski, CA | 1 |
| Kantsadi, AL | 1 |
| Malla, TR | 1 |
| John, T | 1 |
| Mikhailov, V | 1 |
| Bolla, JR | 1 |
| Schofield, CJ | 1 |
| Zitzmann, N | 1 |
| Vakonakis, I | 1 |
| Robinson, CV | 1 |
| Langham, MC | 1 |
| Caporale, AS | 1 |
| Wehrli, FW | 1 |
| Parry, S | 1 |
| Schwartz, N | 1 |
| den Boer, RB | 1 |
| Jones, KI | 1 |
| Ash, S | 1 |
| van Boxel, GI | 1 |
| Gillies, RS | 1 |
| O'Donnell, T | 1 |
| Ruurda, JP | 1 |
| Sgromo, B | 1 |
| Silva, MA | 1 |
| Maynard, ND | 1 |
| Sivieri, EM | 1 |
| Eichenwald, EC | 1 |
| Rub, D | 1 |
| Abbasi, S | 1 |
| Krahnert, I | 1 |
| Bolze, A | 1 |
| Gibon, Y | 1 |
| Fernie, AR | 1 |
| Huang, L | 1 |
| Wan, Y | 1 |
| Dang, Z | 1 |
| Yang, P | 1 |
| Yang, Q | 1 |
| Wu, S | 2 |
| Lin, CC | 1 |
| Hsu, CT | 1 |
| Liu, W | 2 |
| Huang, SC | 1 |
| Kortz, U | 1 |
| Mougharbel, AS | 1 |
| Chen, TY | 1 |
| Hu, CW | 1 |
| Lee, JF | 1 |
| Wang, CC | 1 |
| Liao, YF | 1 |
| Li, LJ | 1 |
| Peng, S | 1 |
| Stimming, U | 1 |
| Hebbar Kannur, K | 1 |
| Yaqub, TB | 1 |
| Pupier, C | 1 |
| Héau, C | 1 |
| Cavaleiro, A | 1 |
| Yamamoto, S | 1 |
| Ono, A | 1 |
| Matsui, J | 1 |
| Hoshino, N | 1 |
| Akutagawa, T | 1 |
| Miyashita, T | 1 |
| Mitsuishi, M | 1 |
| Patel, SM | 1 |
| Smith, TG | 1 |
| Morton, M | 1 |
| Stiers, KM | 1 |
| Seravalli, J | 1 |
| Mayclin, SJ | 1 |
| Edwards, TE | 1 |
| Tanner, JJ | 1 |
| Becker, DF | 1 |
| Butcher, TW | 1 |
| Yang, JL | 1 |
| Hartwig, JF | 1 |
| Yu, MF | 1 |
| Xia, ZZ | 1 |
| Yao, JC | 1 |
| Feng, Z | 1 |
| Li, DH | 1 |
| Liu, T | 1 |
| Cheng, GJ | 1 |
| He, DL | 1 |
| Li, XH | 1 |
| Huurman, R | 1 |
| Schinkel, AFL | 1 |
| de Jong, PL | 1 |
| van Slegtenhorst, MA | 1 |
| Hirsch, A | 1 |
| Michels, M | 1 |
| Kataja, A | 1 |
| Tarvasmäki, T | 1 |
| Lassus, J | 1 |
| Sionis, A | 1 |
| Mebazaa, A | 1 |
| Pulkki, K | 1 |
| Banaszewski, M | 1 |
| Carubelli, V | 1 |
| Hongisto, M | 1 |
| Jankowska, E | 1 |
| Jurkko, R | 1 |
| Jäntti, T | 1 |
| Kasztura, M | 1 |
| Parissis, J | 1 |
| Sabell, T | 1 |
| Silva-Cardoso, J | 1 |
| Spinar, J | 1 |
| Tolppanen, H | 1 |
| Harjola, VP | 1 |
| Carsetti, A | 1 |
| Damiani, E | 1 |
| Casarotta, E | 1 |
| Scorcella, C | 1 |
| Domizi, R | 1 |
| Gasparri, F | 1 |
| Gabbanelli, V | 1 |
| Pantanetti, S | 1 |
| Carozza, R | 1 |
| Adrario, E | 1 |
| Donati, A | 1 |
| Almada, E | 1 |
| Pariani, A | 1 |
| Rivabella Maknis, T | 1 |
| Hidalgo, F | 1 |
| Vena, R | 1 |
| Favre, C | 1 |
| Larocca, MC | 1 |
| Lu, ZY | 1 |
| Jiang, WD | 1 |
| Wu, P | 1 |
| Kuang, SY | 1 |
| Tang, L | 1 |
| Yang, J | 1 |
| Zhou, XQ | 1 |
| Feng, L | 1 |
| Leal, M | 1 |
| Zampini, IC | 1 |
| Mercado, MI | 1 |
| Moreno, MA | 1 |
| Simirgiotis, MJ | 1 |
| Bórquez, J | 1 |
| Ponessa, G | 1 |
| Isla, MI | 1 |
| Saliu, IO | 1 |
| Amoo, ZA | 1 |
| Khan, MF | 1 |
| Olaleye, MT | 1 |
| Rema, V | 1 |
| Akinmoladun, AC | 1 |
| Khan, AU | 1 |
| Rahman, AU | 1 |
| Yuan, Q | 1 |
| Ahmad, A | 1 |
| Khan, ZUH | 1 |
| Mahnashi, MH | 1 |
| Alyami, BA | 1 |
| Alqahtani, YS | 1 |
| Ullah, S | 1 |
| Wirman, AP | 1 |
| Gao, M | 1 |
| Deng, L | 1 |
| Zhang, K | 1 |
| Wang, M | 1 |
| Xia, Z | 1 |
| Gao, D | 1 |
| Balkissou, AD | 1 |
| Poka-Mayap, V | 1 |
| Massongo, M | 1 |
| Djenabou, A | 1 |
| Endale-Mangamba, LM | 1 |
| Olomo, EJ | 1 |
| Boulleys-Nana, JR | 1 |
| Diffo-Sonkoue, L | 1 |
| Adidigue-Ndiome, R | 1 |
| Alexandra, AJE | 1 |
| Haman-Wabi, AB | 1 |
| Adama, S | 1 |
| Iddi-Faical, A | 1 |
| Pefura-Yone, EW | 1 |
| Zhao, Q | 1 |
| Tong, W | 1 |
| Ge, C | 1 |
| Zhao, D | 1 |
| Norbäck, D | 1 |
| Li, B | 1 |
| Huang, C | 1 |
| Zhang, X | 1 |
| Qian, H | 1 |
| Yang, X | 1 |
| Sun, Y | 1 |
| Sundell, J | 1 |
| Deng, Q | 1 |
| Kim, HJ | 1 |
| Jeon, JW | 1 |
| Hwang, SM | 1 |
| Chu, KI | 1 |
| Cha, YH | 1 |
| Kwak, YD | 1 |
| Choi, SD | 1 |
| Aslam, M | 1 |
| Kim, CG | 1 |
| Zhou, J | 1 |
| Yang, E | 1 |
| Yang, W | 1 |
| Ishii, S | 1 |
| Yoshioka, K | 2 |
| Morita, D | 1 |
| Ha, W | 1 |
| Wang, ZH | 1 |
| Zhao, XB | 1 |
| Shi, YP | 1 |
| Deveza, LA | 1 |
| Robbins, SR | 1 |
| Duong, V | 1 |
| Fu, K | 1 |
| Wajon, A | 1 |
| Eyles, JP | 1 |
| Jongs, R | 1 |
| Riordan, EA | 1 |
| Oo, WM | 1 |
| Hunter, DJ | 1 |
| Tieppo Francio, V | 1 |
| Davani, S | 1 |
| Towery, C | 1 |
| Brown, TL | 1 |
| Derry, S | 1 |
| Wiffen, PJ | 1 |
| Kalso, EA | 1 |
| Bell, RF | 1 |
| Aldington, D | 1 |
| Phillips, T | 1 |
| Gaskell, H | 1 |
| Moore, RA | 2 |
| Che Ahmad Tantowi, NA | 1 |
| Hagen, M | 1 |
| Baker, M | 1 |
| Breivik, H | 1 |
| Guyot, P | 2 |
| Pandhi, S | 2 |
| Nixon, RM | 2 |
| Iqbal, A | 1 |
| Chaves, RL | 1 |
| Andrew Moore, R | 1 |
| Tian, M | 1 |
| Zhang, W | 1 |
| Mei, H | 1 |
| Bokhari, RA | 1 |
| Louie-Gao, Q | 1 |
| Peloquin, CE | 1 |
| Neogi, T | 1 |
| Xue, YH | 1 |
| Peng, YS | 1 |
| Ting, HF | 1 |
| Peijer Hsieh, J | 1 |
| Huang, YK | 1 |
| Wang, YH | 1 |
| Chiou, JY | 1 |
| Wei, JC | 1 |
| Durg, S | 1 |
| Lobo, M | 1 |
| Venkatachalam, L | 1 |
| Rao, G | 1 |
| Bhate, J | 1 |
| Cooper, C | 2 |
| Chapurlat, R | 1 |
| Al-Daghri, N | 1 |
| Herrero-Beaumont, G | 2 |
| Bruyère, O | 2 |
| Rannou, F | 1 |
| Roth, R | 1 |
| Uebelhart, D | 1 |
| Reginster, JY | 6 |
| Honvo, G | 1 |
| Leclercq, V | 1 |
| Geerinck, A | 1 |
| Thomas, T | 1 |
| Veronese, N | 1 |
| Charles, A | 1 |
| Rabenda, V | 1 |
| Beaudart, C | 1 |
| Kisukeda, T | 1 |
| Onaya, J | 1 |
| Mandegaran, R | 1 |
| Conway, C | 1 |
| Elton, C | 1 |
| Magaña-Villa, MC | 1 |
| Rocha-González, HI | 1 |
| Fernández del Valle-Laisequilla, C | 1 |
| Granados-Soto, V | 1 |
| Rodríguez-Silverio, J | 1 |
| Flores-Murrieta, FJ | 1 |
| Carrasco-Portugal, MC | 1 |
| Reyes-García, JG | 1 |
| Sugano, K | 1 |
| Kinoshita, Y | 1 |
| Miwa, H | 1 |
| Takeuchi, T | 1 |
| Borisenko, OV | 1 |
| Belen'kiĭ, DA | 1 |
| Simon, LS | 2 |
| Brereton, N | 2 |
| Pennington, B | 1 |
| Ekelund, M | 1 |
| Akehurst, R | 2 |
| Bishnoi, M | 1 |
| Jain, A | 1 |
| Hurkat, P | 1 |
| Jain, SK | 1 |
| Raza, K | 1 |
| Kumar, M | 1 |
| Kumar, P | 1 |
| Malik, R | 1 |
| Sharma, G | 1 |
| Kaur, M | 1 |
| Katare, OP | 1 |
| Spies, CM | 1 |
| Stemmler, E | 1 |
| Buttgereit, F | 1 |
| Hodge, B | 1 |
| Skolnik, D | 1 |
| van Walsem, A | 1 |
| Karabis, A | 1 |
| Gibofsky, A | 1 |
| Altman, R | 3 |
| Daniels, S | 1 |
| Imasogie, O | 1 |
| Young, C | 1 |
| Temperilli, F | 1 |
| Di Franco, M | 1 |
| Massimi, I | 1 |
| Guarino, ML | 1 |
| Guzzo, MP | 1 |
| Valesini, G | 1 |
| Frati, L | 1 |
| Pulcinelli, FM | 1 |
| Deng, ZH | 1 |
| Li, YS | 1 |
| Yang, T | 1 |
| Lei, GH | 1 |
| Zupanets, IA | 1 |
| Shebeko, SK | 1 |
| Popov, OS | 1 |
| Shalamay, AS | 1 |
| Kang, ML | 1 |
| Kim, JE | 1 |
| Im, GI | 1 |
| MacDonald, TM | 3 |
| Littlejohn, TW | 1 |
| Richard, D | 4 |
| Lheritier, K | 2 |
| Krammer, G | 5 |
| Rebuli, R | 1 |
| Brizuela, NY | 1 |
| Montrull, HL | 1 |
| Demurtas, SL | 1 |
| Meirovich, CI | 1 |
| Stricker, K | 2 |
| Laine, L | 8 |
| Curtis, SP | 10 |
| Langman, M | 1 |
| Jensen, DM | 2 |
| Cryer, B | 2 |
| Kaur, A | 7 |
| Cannon, CP | 8 |
| Elron-Gross, I | 1 |
| Glucksam, Y | 1 |
| Biton, IE | 1 |
| Margalit, R | 1 |
| Goldkind, L | 1 |
| Connors, LG | 1 |
| Yanqiong, Z | 1 |
| Woodson, SA | 1 |
| Combe, B | 1 |
| Swergold, G | 2 |
| McLay, J | 1 |
| McCarthy, T | 1 |
| Zerbini, C | 1 |
| Emery, P | 1 |
| Connors, L | 1 |
| Curtis, S | 1 |
| Frisbie, DD | 1 |
| McIlwraith, CW | 1 |
| Kawcak, CE | 1 |
| Werpy, NM | 1 |
| Pearce, GL | 1 |
| Barkin, RL | 2 |
| Pareek, A | 2 |
| Chandurkar, N | 1 |
| Sharma, VD | 1 |
| Desai, M | 1 |
| Kini, S | 1 |
| Bartakke, G | 1 |
| Maĭko, OIu | 1 |
| Bagirova, GG | 1 |
| Krum, H | 2 |
| Smugar, SS | 1 |
| Weir, MR | 1 |
| Brater, DC | 1 |
| Altman, RD | 2 |
| Dreiser, RL | 3 |
| Fisher, CL | 1 |
| Chase, WF | 1 |
| Dreher, DS | 1 |
| Zacher, J | 1 |
| Fernández-Jorge, B | 1 |
| Goday-Buján, JJ | 1 |
| Murga, M | 1 |
| Molina, FP | 1 |
| Pérez-Varela, L | 1 |
| Fonseca, E | 2 |
| Barthel, HR | 1 |
| Peniston, JH | 2 |
| Clark, MB | 1 |
| Gold, MS | 3 |
| Romero Vázquez, J | 1 |
| Herrerías Gutiérrez, JM | 1 |
| Caunedo-Alvarez, A | 1 |
| Gómez-Rodríguez, BJ | 1 |
| Romero-Vázquez, J | 1 |
| Argüelles-Arias, F | 1 |
| Romero-Castro, R | 1 |
| García-Montes, JM | 1 |
| Pellicer-Bautista, FJ | 1 |
| Herrerías-Gutiérrez, JM | 1 |
| Cheung, R | 1 |
| Cheng, TT | 1 |
| Lin, HY | 1 |
| Lai, K | 1 |
| Lau, CS | 1 |
| Feng, H | 1 |
| Parsons, B | 1 |
| Rosemann, T | 1 |
| Huber, CA | 1 |
| Rosemann, A | 1 |
| Rahme, E | 1 |
| Bernatsky, S | 1 |
| Chan, FK | 3 |
| Lanas, A | 3 |
| Scheiman, J | 1 |
| Berger, MF | 2 |
| Nguyen, H | 2 |
| Goldstein, JL | 8 |
| Alekseeva, LI | 1 |
| Schuelert, N | 1 |
| Oskins, JL | 1 |
| Jassal, K | 1 |
| McDougall, JJ | 1 |
| Gulmez, SE | 1 |
| Droz-Perroteau, C | 1 |
| Lassalle, R | 1 |
| Blin, P | 1 |
| Bégaud, B | 2 |
| Rossignol, M | 1 |
| Moore, N | 1 |
| Fourrier-Réglat, A | 1 |
| Matveev, AV | 1 |
| Koniaeva, EI | 1 |
| Ruff, CT | 1 |
| Morrow, DA | 1 |
| Jarolim, P | 1 |
| Ren, F | 1 |
| Contant, CF | 1 |
| Brune, K | 1 |
| Wilcox, CM | 2 |
| Peura, D | 1 |
| Sands, GH | 2 |
| Scheiman, JM | 2 |
| Grazio, S | 1 |
| Abdulganieva, DI | 1 |
| Belianskaia, NE | 1 |
| Goswami, SK | 1 |
| Jain, S | 1 |
| Chudasama, H | 1 |
| Santani, D | 1 |
| Roth, SH | 4 |
| Fuller, P | 2 |
| Pillans, PI | 1 |
| Ghiculescu, RA | 1 |
| Lampe, G | 1 |
| Wilson, R | 1 |
| Wong, R | 1 |
| Macdonald, GA | 1 |
| Pavelka, K | 1 |
| Winn, B | 1 |
| Baraf, HS | 3 |
| Petruschke, RA | 1 |
| Wieman, MS | 2 |
| Kim, JW | 1 |
| Cho, HR | 1 |
| Ku, SK | 1 |
| Ferreira-Gomes, J | 1 |
| Adães, S | 1 |
| Mendonça, M | 1 |
| Castro-Lopes, JM | 1 |
| Solmaz, D | 1 |
| Sari, I | 1 |
| Can, G | 1 |
| Akar, S | 1 |
| Ceylan, I | 1 |
| Secil, M | 1 |
| Akkoc, N | 1 |
| de Souza, RF | 1 |
| Lovato da Silva, CH | 1 |
| Nasser, M | 1 |
| Fedorowicz, Z | 1 |
| Al-Muharraqi, MA | 1 |
| Mackenzie, IS | 1 |
| Wei, L | 1 |
| Peura, DA | 1 |
| Alwine, LK | 1 |
| Staiger, C | 1 |
| Sikes, DH | 1 |
| Agrawal, NM | 5 |
| Zhao, WW | 2 |
| Kent, JD | 2 |
| Recker, DP | 1 |
| Verburg, KM | 3 |
| Suárez-Otero, R | 1 |
| Robles-San Román, M | 1 |
| Jaimes-Hernández, J | 1 |
| Oropeza-De La Madrid, E | 1 |
| Medina-Peñaloza, RM | 1 |
| Rosas-Ramos, R | 1 |
| Castañeda-Hernández, G | 1 |
| Witte, S | 1 |
| Lasek, R | 1 |
| Victor, N | 1 |
| Al-Ghamdi, MY | 1 |
| Malatjalian, DA | 1 |
| Veldhuyzen van Zanten, S | 1 |
| Tavakoli, M | 1 |
| Liang, TH | 1 |
| Hsu, PN | 1 |
| Oviedo, JA | 1 |
| Wolfe, MM | 1 |
| Koelbl, O | 1 |
| Seufert, J | 1 |
| Pohl, F | 1 |
| Tauscher, A | 1 |
| Lehmann, H | 1 |
| Springorum, HW | 1 |
| Flentje, M | 1 |
| Burian, M | 1 |
| Geisslinger, G | 1 |
| El Hajjaji, H | 1 |
| Marcelis, A | 2 |
| Devogelaer, JP | 2 |
| Manicourt, DH | 2 |
| Shi, W | 2 |
| Wang, YM | 2 |
| Cheng, NN | 2 |
| Chen, BY | 2 |
| Li, D | 2 |
| Pope, JE | 1 |
| Prashker, M | 1 |
| Anderson, J | 1 |
| Izhar, M | 1 |
| Alausa, T | 1 |
| Folker, A | 1 |
| Hung, E | 1 |
| Bakris, GL | 1 |
| Al-Arfaj, AS | 1 |
| Alballa, SR | 1 |
| Mustafa, AA | 1 |
| Al-Tuwaijri, AS | 1 |
| Al-Dalaan, AN | 1 |
| Al-Humayyd, MS | 1 |
| Li, SL | 1 |
| Yan, M | 1 |
| Legrand, E | 1 |
| Hawkey, CJ | 4 |
| Farkouh, M | 1 |
| Gitton, X | 7 |
| Ehrsam, E | 2 |
| Huels, J | 1 |
| Richardson, P | 1 |
| Lung, YB | 1 |
| Seong, SC | 1 |
| Lee, MC | 1 |
| Shin, YU | 1 |
| Kim, DH | 1 |
| Kim, JM | 1 |
| Jung, YK | 1 |
| Ahn, JH | 1 |
| Seo, JG | 1 |
| Park, YS | 2 |
| Lee, CS | 1 |
| Roh, KJ | 1 |
| Han, CK | 1 |
| Cho, YB | 1 |
| Chang, DY | 1 |
| Kwak, WJ | 1 |
| Jung, KO | 1 |
| Park, BJ | 1 |
| Aziz, KA | 1 |
| Hawkey, CC | 1 |
| Svoboda, P | 1 |
| Fiedorowicz-Fabrycy, IF | 1 |
| Nasonov, EL | 1 |
| Pikhlak, EG | 1 |
| Cousin, M | 1 |
| Hoexter, G | 3 |
| Lyseng-Williamson, KA | 1 |
| Curran, MP | 1 |
| Solignac, M | 2 |
| Biegert, C | 1 |
| Wagner, I | 1 |
| Lüdtke, R | 2 |
| Kötter, I | 1 |
| Lohmüller, C | 1 |
| Günaydin, I | 1 |
| Taxis, K | 1 |
| Heide, L | 1 |
| Summerton, N | 1 |
| Rabeneck, L | 1 |
| Vu, A | 1 |
| Mayne, TJ | 1 |
| Rublee, DA | 1 |
| Schnitzer, TJ | 1 |
| Jayawardene, S | 1 |
| Sloan, VS | 2 |
| Bannwarth, B | 2 |
| Berenbaum, F | 2 |
| Hochberg, MC | 1 |
| Matchaba, P | 2 |
| Olson, M | 1 |
| Mellein, B | 3 |
| Orloff, J | 1 |
| Garaud, JJ | 1 |
| Rosenberg, JA | 1 |
| Bockow, B | 1 |
| Fisher, C | 1 |
| Olaleye, J | 1 |
| Compton, A | 1 |
| Ko, AT | 2 |
| Reicin, AS | 4 |
| Rordorf, CM | 1 |
| Choi, L | 1 |
| Marshall, P | 1 |
| Mangold, JB | 1 |
| Weinstein, WM | 2 |
| Singh, G | 1 |
| Fort, JG | 1 |
| Levy, RA | 1 |
| Hanrahan, PS | 1 |
| Bello, AE | 1 |
| Andrade-Ortega, L | 1 |
| Wallemark, C | 1 |
| Eisen, GM | 2 |
| Stenson, WF | 2 |
| Triadafilopoulos, G | 1 |
| Wyplosz, B | 1 |
| Vautier, S | 1 |
| Lillo-Le Louët, A | 1 |
| Capron, L | 1 |
| Mosis, G | 1 |
| Dieleman, JP | 1 |
| Stricker, BCh | 1 |
| van der Lei, J | 1 |
| Sturkenboom, MC | 1 |
| Chandanwale, AS | 1 |
| Oak, J | 1 |
| Jain, UK | 1 |
| Kapoor, S | 1 |
| Bolognese, JA | 6 |
| Whelton, A | 2 |
| Lefkowith, JL | 1 |
| West, CR | 1 |
| FitzGerald, GA | 1 |
| Bombardier, C | 1 |
| Weinblatt, ME | 1 |
| van der Heijde, D | 1 |
| Erdmann, E | 1 |
| Cavanaugh, PF | 1 |
| Dougados, M | 1 |
| Moore, A | 1 |
| Fuentealba, C | 1 |
| Greenwald, M | 1 |
| Brzezicki, J | 1 |
| O'Brien, K | 1 |
| Soffer, B | 1 |
| Polis, A | 1 |
| Bird, S | 1 |
| Sun, BH | 1 |
| Wu, CW | 1 |
| Kalunian, KC | 1 |
| Einecke, D | 2 |
| Farkouh, ME | 1 |
| Greenberg, JD | 1 |
| Jeger, RV | 1 |
| Ramanathan, K | 1 |
| Verheugt, FW | 1 |
| Chesebro, JH | 1 |
| Kirshner, H | 1 |
| Hochman, JS | 1 |
| Lay, CL | 1 |
| Ruland, S | 1 |
| Matchaba, PT | 1 |
| Fuster, V | 1 |
| Abramson, SB | 1 |
| Loyd, M | 1 |
| Rublee, D | 1 |
| Jacobs, P | 1 |
| Krüger, K | 1 |
| Smalley, W | 1 |
| Sallstig, P | 2 |
| Wagenitz, A | 1 |
| Mueller, EA | 1 |
| Frentzel, A | 1 |
| Cambon, N | 1 |
| Singh, H | 1 |
| Burton, B | 1 |
| Ying, KN | 1 |
| While, A | 1 |
| Shi, S | 1 |
| Klotz, U | 1 |
| Fleischmann, R | 2 |
| Tannenbaum, H | 1 |
| Patel, NP | 1 |
| Notter, M | 1 |
| McMahon, K | 1 |
| Nelson, M | 1 |
| Jones, G | 1 |
| Michalsen, A | 1 |
| Cesur, Ö | 1 |
| Afra, D | 1 |
| Musial, F | 1 |
| Baecker, M | 1 |
| Fink, M | 1 |
| Dobos, GJ | 1 |
| Mejersjö, C | 1 |
| Wenneberg, B | 1 |
| Rhim, SY | 1 |
| Park, JH | 1 |
| Lee, MH | 1 |
| Shaw, LM | 1 |
| Kang, JS | 1 |
| Baroni, L | 1 |
| Borghi, C | 2 |
| Trombetta, N | 1 |
| Gross, W | 1 |
| Kroh, J | 1 |
| Krebs, A | 1 |
| Zöller, H | 1 |
| Famaey, JP | 1 |
| Ginsberg, F | 1 |
| Marcolongo, R | 6 |
| Giordano, N | 3 |
| Mattara, L | 3 |
| Leardini, G | 2 |
| Lavezzari, M | 1 |
| Gruni, G | 1 |
| Mandelli, V | 1 |
| Al-Sharkawi, MS | 1 |
| Dux, S | 1 |
| Groslop, I | 1 |
| Garty, M | 1 |
| Rosenfeld, JB | 1 |
| Guobis, G | 1 |
| Iushenaite, Ia | 1 |
| Schlumpf, U | 1 |
| Knüsel, O | 1 |
| Brogden, RN | 1 |
| Heel, RC | 1 |
| Pakes, GE | 1 |
| Speight, TM | 1 |
| Avery, GS | 1 |
| Brooks, PM | 1 |
| Hill, W | 1 |
| Geddes, R | 1 |
| Schubiger, BI | 2 |
| Ciccolunghi, SN | 2 |
| Tanner, K | 1 |
| Mele, C | 1 |
| Ehmann, L | 1 |
| Tyberghein, JM | 1 |
| Stambuk, B | 1 |
| Zenić, N | 2 |
| Crook, PR | 2 |
| Fowler, PD | 3 |
| Hothersall, TE | 2 |
| Chiswell, RJ | 3 |
| Scharf, Y | 1 |
| Nahir, M | 1 |
| Schapira, D | 1 |
| Lorber, M | 1 |
| Pathy, MS | 1 |
| Seldrup, J | 1 |
| Grieve, AP | 1 |
| MacDonald, IR | 1 |
| Mazzucco, A | 1 |
| Rossetto, G | 1 |
| Gargot, D | 1 |
| Chaussade, S | 1 |
| d'Alteroche, L | 1 |
| Desbazeille, F | 1 |
| Grandjouan, S | 1 |
| Louvel, A | 1 |
| Douvin, J | 1 |
| Causse, X | 1 |
| Festin, D | 1 |
| Chapuis, Y | 1 |
| Fernandes, JC | 2 |
| Martel-Pelletier, J | 3 |
| Otterness, IG | 1 |
| Lopez-Anaya, A | 1 |
| Mineau, F | 2 |
| Tardif, G | 2 |
| Pelletier, JP | 3 |
| Porto, A | 1 |
| Almeida, H | 1 |
| Cunha, MJ | 1 |
| Macciocchi, A | 1 |
| Caselli, M | 1 |
| LaCorte, R | 1 |
| DeCarlo, L | 1 |
| Aleotti, A | 1 |
| Trevisani, L | 1 |
| Ruina, M | 1 |
| Trotta, F | 1 |
| Alvisi, V | 1 |
| Bakshi, R | 3 |
| Ezzet, N | 1 |
| Frey, L | 1 |
| Lasry, D | 1 |
| Salliere, D | 1 |
| Downie, WW | 2 |
| Geis, GS | 8 |
| Gagnier, P | 1 |
| Van Kerckhove, HE | 1 |
| Erhardt, LJ | 1 |
| Bacon, PA | 1 |
| Ardia, A | 1 |
| Franchini, S | 1 |
| Baggio, A | 1 |
| Cornelli, U | 1 |
| Barr, S | 1 |
| Bellamy, N | 6 |
| Buchanan, WW | 4 |
| Chalmers, A | 2 |
| Ford, PM | 3 |
| Kean, WF | 4 |
| Kraag, GR | 3 |
| Gerecz-Simon, E | 4 |
| Campbell, J | 4 |
| González, E | 1 |
| de la Cruz, C | 1 |
| de Nicoläs, R | 1 |
| Egido, J | 1 |
| March, L | 1 |
| Irwig, L | 1 |
| Schwarz, J | 1 |
| Simpson, J | 1 |
| Chock, C | 1 |
| Brooks, P | 1 |
| Riedemann, PJ | 1 |
| Bersinic, S | 1 |
| Cuddy, LJ | 1 |
| Torrance, GW | 1 |
| Tugwell, PX | 1 |
| Galeazzi, M | 1 |
| Tisne-Camus, M | 1 |
| Gallacchi, G | 1 |
| Porzio, F | 1 |
| Bacon, P | 1 |
| Wittenberg, RH | 1 |
| Willburger, RE | 1 |
| Kleemeyer, KS | 1 |
| Peskar, BA | 1 |
| Bianchi Porro, G | 2 |
| Montrone, F | 3 |
| Petrillo, M | 2 |
| Caruso, I | 2 |
| Ardizzone, S | 2 |
| Cullen, D | 1 |
| Melo Gomes, JA | 1 |
| Zeeh, J | 1 |
| Bruyn, GA | 1 |
| Woods, EM | 1 |
| Dunham, J | 2 |
| Hoedt-Schmidt, S | 2 |
| Kalbhen, DA | 2 |
| Dieppe, P | 1 |
| Cushnaghan, J | 1 |
| Jasani, MK | 3 |
| McCrae, F | 1 |
| Watt, I | 1 |
| Eversmeyer, W | 1 |
| Poland, M | 3 |
| DeLapp, RE | 3 |
| Jensen, CP | 1 |
| Morgan, GJ | 1 |
| Lister, BJ | 1 |
| Furst, DE | 1 |
| Anderson, W | 1 |
| Bensen, WG | 2 |
| Beaulieu, A | 1 |
| Siminovitch, KA | 1 |
| Lussier, A | 1 |
| Ahmad, S | 1 |
| Khanna, VN | 1 |
| Davis, P | 1 |
| Bell, MJ | 1 |
| Ward, DE | 1 |
| Veys, EM | 1 |
| Bowdler, JM | 1 |
| Roma, J | 1 |
| Hosie, J | 1 |
| Distel, M | 1 |
| Bluhmki, E | 2 |
| Ranger, P | 1 |
| Loose, L | 1 |
| Morreale, P | 1 |
| Manopulo, R | 1 |
| Galati, M | 1 |
| Boccanera, L | 1 |
| Saponati, G | 1 |
| Bocchi, L | 1 |
| Singer, F | 1 |
| Oberleitner, H | 1 |
| Moore, AR | 2 |
| Willoughby, DA | 2 |
| Kidd, B | 1 |
| Frenzel, W | 1 |
| Chayen, J | 3 |
| Bitensky, L | 3 |
| Miglioli, M | 1 |
| Vaira, D | 1 |
| Menegatti, M | 1 |
| Brunetti, G | 1 |
| Frizziero, L | 1 |
| Grandinetti, G | 1 |
| Shaikh, KA | 1 |
| Ali, M | 1 |
| Sharafatullah, T | 1 |
| Baumgartner, H | 2 |
| Schwarz, HA | 3 |
| Blum, W | 1 |
| Bruhin, A | 1 |
| Gallachi, G | 1 |
| Goldinger, G | 1 |
| Saxer, M | 1 |
| Trost, H | 1 |
| Peréz Busquier, M | 1 |
| Calero, E | 1 |
| Rodríguez, M | 1 |
| Castellon Arce, P | 1 |
| Bermudez, A | 1 |
| Linares, LF | 1 |
| Mesa, J | 1 |
| Ffernandez Crisostomos, C | 1 |
| Garcia, C | 1 |
| Garcia Lopez, A | 1 |
| Valenzuela, A | 1 |
| Povedano, A | 1 |
| Garcia Perez, S | 1 |
| Lopez, MA | 1 |
| Caliz, R | 1 |
| Garcia Villalba, F | 1 |
| Cano, M | 1 |
| Gines Martinez, F | 1 |
| Gonzalez, J | 1 |
| Caracuel, MA | 1 |
| Roldan, R | 1 |
| Guzman Ubeda, M | 1 |
| Gonzalez, A | 1 |
| Marenco de la Fuente, IL | 1 |
| Alepuz Pou, M | 1 |
| Hawel, R | 1 |
| Klein, G | 2 |
| Mitterhuber, J | 1 |
| Brugger, A | 1 |
| Kornasoff, D | 1 |
| Frerick, H | 1 |
| Bowdler, J | 1 |
| Montull, E | 1 |
| Gijón Baños, J | 1 |
| Sandelin, J | 1 |
| Harilainen, A | 1 |
| Crone, H | 1 |
| Hamberg, P | 1 |
| Forsskåhl, B | 1 |
| Tamelander, G | 1 |
| Goei Thè, HS | 1 |
| Lund, B | 1 |
| Distel, MR | 1 |
| Le Loët, X | 1 |
| Le Gros, V | 1 |
| Febvre, N | 1 |
| Tavella, A | 1 |
| Ursini, G | 1 |
| McKenna, F | 1 |
| Greenslade, KJ | 1 |
| Alam, CA | 1 |
| Karbowski, A | 2 |
| Schwitalle, M | 1 |
| Eckardt, A | 1 |
| Uitz, E | 1 |
| Aglas, F | 1 |
| Wurm, A | 1 |
| Rainer, F | 1 |
| Scharf, S | 1 |
| Kwiatek, R | 1 |
| Ugoni, A | 1 |
| Christophidis, N | 1 |
| Rau, R | 2 |
| Hawkey, C | 1 |
| Kahan, A | 1 |
| Steinbrück, K | 1 |
| Alegre, C | 1 |
| Baumelou, E | 1 |
| Dequeker, J | 1 |
| Isomäki, H | 1 |
| Littlejohn, G | 1 |
| Mau, J | 1 |
| Papazoglou, S | 1 |
| Liaropoulos, L | 1 |
| Spinthouri, M | 1 |
| Ignatiades, T | 1 |
| Ifandi, G | 1 |
| Katostaras, F | 1 |
| Diamantopoulos, E | 1 |
| Caldwell, J | 2 |
| Kivitz, AJ | 1 |
| Weaver, AL | 1 |
| Bocanegra, TS | 1 |
| Ball, J | 1 |
| Dhadda, S | 1 |
| Hurley, S | 1 |
| Hancock, L | 1 |
| Bhogaraju, A | 1 |
| Nazeer, S | 1 |
| Al-Baghdadi, Y | 1 |
| Rahman, M | 1 |
| Wrestler, F | 1 |
| Edworthy, SM | 1 |
| Devins, GM | 1 |
| Llenas, J | 1 |
| Jones, AK | 1 |
| Langman, MJ | 1 |
| Watson, DJ | 2 |
| Harper, SE | 2 |
| Zhao, PL | 2 |
| Quan, H | 1 |
| Simon, TJ | 2 |
| Zgradie, I | 1 |
| Kullich, W | 1 |
| Pincus, T | 3 |
| Swearingen, C | 1 |
| Cummins, P | 1 |
| Callahan, LF | 1 |
| Mohammed, EP | 1 |
| Stevens, JM | 1 |
| Silverstein, FE | 1 |
| Faich, G | 1 |
| Makuch, R | 1 |
| Eisen, G | 1 |
| Burr, AM | 1 |
| Lefkowith, JB | 1 |
| Yocum, D | 1 |
| Dalgin, P | 1 |
| Hall, D | 1 |
| Roszko, P | 1 |
| Blot, L | 1 |
| Soto Alvarez, J | 1 |
| Borderie, D | 1 |
| Hernvann, A | 1 |
| Lemarechal, H | 1 |
| Menkes, CJ | 1 |
| Ekindjian, O | 1 |
| Acevedo, E | 1 |
| Castañeda, O | 1 |
| Ugaz, M | 1 |
| Beaulieu, AD | 1 |
| Pons-Estel, B | 1 |
| Caeiro, F | 1 |
| Casas, N | 1 |
| Garza-Elizondo, M | 1 |
| Irazoque, F | 1 |
| Hinojosa, W | 1 |
| Gutierrez-Ureña, S | 1 |
| Vandormael, K | 1 |
| Rodgers, DB | 1 |
| Laurenzi, M | 1 |
| Morgan , GJ | 1 |
| Kaine, J | 1 |
| DeLapp, R | 1 |
| Palmer, R | 1 |
| Tive, L | 1 |
| Huskisson, EC | 1 |
| Valat, JP | 1 |
| Accardo, S | 1 |
| Wouters, M | 1 |
| Hettich, M | 1 |
| Lieu, PL | 1 |
| du Souich, P | 1 |
| Vergés, J | 1 |
| Paul, I | 1 |
| Henrotin, Y | 1 |
| Peris, F | 1 |
| Martínez, E | 1 |
| Badia, X | 1 |
| Brosa, M | 1 |
| Goday Buján, JJ | 1 |
| García Alvarez-Eire, GM | 1 |
| Martinez, W | 1 |
| del Pozo, J | 1 |
| Schellenberg, RR | 1 |
| Isserow, SH | 1 |
| Shapiro, D | 1 |
| Sperling, RS | 2 |
| Barr, E | 1 |
| Yu, Q | 1 |
| Bhagat, K | 1 |
| Burke, TA | 1 |
| Peña, BM | 1 |
| Lefkowith, J | 1 |
| Ravaud, P | 1 |
| Wepner, U | 1 |
| Gertz, BJ | 1 |
| Krupa, D | 1 |
| Reicin, A | 1 |
| Pappalardo, A | 1 |
| Pulizzi, C | 1 |
| Mantia, S | 1 |
| Peltier, AP | 1 |
| Rivet, JP | 1 |
| Siraux, P | 1 |
| Durante, F | 1 |
| Abrams, GJ | 1 |
| Solomon, L | 1 |
| Meyers, OL | 1 |
| Car, A | 1 |
| Jajić, I | 1 |
| Krampac, I | 1 |
| Vitaus, M | 1 |
| Zivković, M | 1 |
| Fomina, AA | 1 |
| Mironova, KA | 1 |
| Klimovich, MD | 1 |
| Chaudri, HA | 1 |
| Barnes, CG | 1 |
| Berry, H | 1 |
| Carter, ME | 1 |
| Moll, JM | 1 |
| Perry, JD | 1 |
| Sawaf, MS | 1 |
| Wright, V | 1 |
| Bonomo, I | 1 |
| McMahon, MF | 1 |
| Cash, HC | 1 |
| Giancola, R | 1 |
| Nannei, A | 1 |
| Kendall, MJ | 1 |
| Thornhill, DP | 1 |
| Willis, JV | 1 |
| Corts Giner, JR | 1 |
| García Borrás, JJ | 1 |
| Doherty, M | 1 |
| de Melo Gomes, JA | 1 |
| Bach, GL | 1 |
| Bolten, W | 1 |
| Gomes, JA | 1 |
| Stead, H | 2 |
| Huang, SH | 1 |
| Lang, JY | 1 |
| Khan, FM | 1 |
| Williams, PI | 1 |
| Giacovazzo, M | 1 |
| Ghosh, P | 1 |
| Wells, C | 1 |
| Smith, M | 1 |
| Hutadilok, N | 1 |
| Darekar, B | 1 |
| Langdon, CG | 1 |
| Rotman, H | 1 |
| Fioravanti, A | 2 |
| Wallemark, CB | 1 |
| Nicholson, PA | 1 |
| Wells, G | 1 |
| Ouellette, GS | 1 |
| Slitzky, BE | 1 |
| Gates, JA | 1 |
| Lagarde, S | 1 |
| West, AB | 1 |
| Laws, D | 1 |
| Saul, S | 1 |
| Fehilly, B | 1 |
| Soper, WY | 1 |
| Rooney, PJ | 1 |
| Tugwell, P | 1 |
| Helfgott, SM | 1 |
| Sandberg-Cook, J | 1 |
| Zakim, D | 1 |
| Nestler, J | 1 |
| Atra, E | 1 |
| Metz, CA | 1 |
| Brown, BL | 1 |
| Teoh, K | 1 |
| Waterworth, RF | 1 |
| Waterworth, SM | 1 |
| Gostick, N | 1 |
| James, IG | 1 |
| Khong, TK | 1 |
| Roy, P | 1 |
| Shepherd, PR | 1 |
| Miller, AJ | 1 |
| Pataki, A | 1 |
| Graf, HP | 1 |
| Witzemann, E | 1 |
| Miller, LG | 1 |
| Bowman, RC | 1 |
| Platt, PN | 1 |
| Biasi, G | 1 |
| Vaccai, D | 1 |
| Cataldi, V | 1 |
| Scheid, A | 1 |
| Moser, U | 2 |
| Waldburger, M | 1 |
| Gobelet, CA | 2 |
| Small, RE | 1 |
| Höckel, S | 1 |
| Waldburger, H | 1 |
| Stewart, I | 1 |
| Thomas, A | 1 |
| Chahade, WH | 1 |
| Marques, GC | 1 |
| Liebergall, M | 1 |
| Floman, Y | 1 |
| Milgrom, C | 1 |
| Ward, JR | 1 |
| Aylward, M | 1 |
| Maddock, J | 1 |
| Lewis, PA | 1 |
| Dewland, PM | 1 |
| Vetter, G | 1 |
| Bassi, GP | 1 |
| Giannini, R | 1 |
| Francucci, BM | 1 |
| Camarri, E | 1 |
| Mordini, M | 1 |
| Cocco, F | 1 |
| Neri, D | 1 |
| Fumagalli, M | 1 |
| Santandrea, S | 1 |
| Boccassini, L | 1 |
| Greco, M | 1 |
| Willkens, RF | 1 |
| Pagano, M | 1 |
| Sapienza, M | 1 |
| Fuschi, C | 1 |
| Nardi, I | 1 |
| Liauw, HL | 1 |
| Ku, E | 1 |
| Brandt, KD | 2 |
| Benson, MD | 2 |
| Aldo-Benson, MA | 1 |
| Waiter, SL | 1 |
| Lee, W | 1 |
| Chan, K | 1 |
| Vyas, K | 1 |
| Kramer, MR | 1 |
| Levene, C | 1 |
| Hershko, C | 1 |
| Eronen, I | 1 |
| Videman, T | 1 |
| Fornasari, PA | 1 |
| Aldo-Benson, M | 1 |
| Macauley, D | 1 |
| Caldwell, JR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Effect of Electroacupuncture (EA) on the Success of Inferior Alveolar Nerve Block (IANB) and Post-operative Pain Relief in Mandibular Molar With Symptomatic Irreversible Pulpitis (SIP) Among Malaysians: A Study Protocol for Randomized Double-Blinded C[NCT04804761] | 20 participants (Anticipated) | Interventional | 2023-01-01 | Recruiting | |||
| A Long Term Study to Investigate the Efficacy and Safety Study of D961H (Esomeprazole) (20 mg Once Daily) for the Prevention of Gastric and/or Duodenal Ulcers Associated With Daily Nonsteroidal Anti-inflammatory Drug (NSAID) Use[NCT00595517] | Phase 3 | 395 participants (Actual) | Interventional | 2007-10-31 | Completed | ||
| The Effect of Chronic Pain Relief Over Knee Joint Area by Gua Sha Therapy[NCT03821194] | 40 participants (Anticipated) | Interventional | 2019-01-25 | Recruiting | |||
| A 4-week, Multicentre, Randomized, Double-blind, Double-dummy, Parallel Group Ambulatory Blood Pressure Monitoring Study to Investigate Whether Treatment With Lumiracoxib 100 mg Once Daily Results in an Improved 24-hour Blood Pressure Profile Compared to [NCT00267176] | Phase 4 | 1,020 participants | Interventional | 2005-11-30 | Completed | ||
| A 6-Week Multicenter, Randomized, Double-Blind, Double-Dummy, Active-Controlled Parallel Group Clinical Saftey Study to Evaluate Incidence of Predefined Gastrointestinal Adverse Events and Peripheral Edema in Subjects With Primary Osteoarthritis Treated W[NCT00637949] | Phase 3 | 309 participants (Actual) | Interventional | 2000-12-31 | Completed | ||
| A Randomized, Double-Blind, Multicenter Study to Evaluate the Tolerability and Effectiveness of Etoricoxib 90 mg q.d. vs. Diclofenac Sodium 50 mg t.i.d. in Patients With Osteoarthritis[NCT00092703] | Phase 3 | 6,000 participants | Interventional | 2002-06-27 | Completed | ||
| A Randomized, Double-Blind, Multicenter Study to Evaluate the Tolerability and Effectiveness of Etoricoxib 90 mg q.d. vs. Diclofenac Sodium 75 mg b.i.d. in Patients With Rheumatoid Arthritis[NCT00092742] | Phase 3 | 4,086 participants (Actual) | Interventional | 2003-02-28 | Completed | ||
| A Randomized, Double-Blind, Active-Comparator-Controlled, Parallel-Group Study to Evaluate the Safety of Etoricoxib in Patients With Osteoarthritis or Rheumatoid Arthritis[NCT00250445] | Phase 3 | 23,498 participants (Actual) | Interventional | 2003-01-31 | Completed | ||
| Efficacy and Safety of Diclofenac Sodium Gel in Hand Osteoarthritis[NCT00171665] | Phase 3 | 360 participants | Interventional | 2005-05-31 | Completed | ||
| Efficacy and Safety of Diclofenac Sodium Gel in Hand Osteoarthritis[NCT00171652] | Phase 3 | 360 participants | Interventional | 2005-05-31 | Completed | ||
| Double-Blind, Triple Dummy, Parallel-Group, Randomized, Six-Month Study To Compare Celecoxib (200 Mg BID) With Diclofenac Sr (75 Mg BID) Plus Omeprazole (20 Mg QD) For Gastrointestinal Events In Subjects With Osteoarthritis And Rheumatoid Arthritis At Hig[NCT00141102] | Phase 4 | 4,484 participants (Actual) | Interventional | 2005-10-31 | Completed | ||
| Osteoarthritis of the Knee Pain Study Using CBD and THC in Rapidly Dissolvable Sublingual Tablet[NCT04195269] | Phase 2 | 30 participants (Anticipated) | Interventional | 2020-04-20 | Recruiting | ||
| A Randomized, Placebo-controlled Trial of St.John's Wort(a Natural Health Product) in the Treatment on Raynaud's Phenomenon[NCT00351117] | Phase 3 | 20 participants (Actual) | Interventional | 2007-03-31 | Completed | ||
| External Validation of a Clinical Scoring System to Predict Microscopic Colitis in Patients With Chronic Watery Diarrhoea[NCT06031064] | 200 participants (Anticipated) | Observational | 2022-05-15 | Recruiting | |||
| A Placebo-Controlled, Parallel-Group, Double-Blind Study to Assess Safety and to Define the Clinically Effective Dose Range of MK0663 in Patients With Osteoarthritis of the Knee, Followed by a Double-Blind, Active-Comparator-Controlled Extension.[NCT00242489] | Phase 2 | 1,167 participants (Actual) | Interventional | 1998-06-30 | Completed | ||
| A Single Center, Randomized, Double-blind, Placebo-controlled 2-way Crossover Study to Investigate the Mechanism of Action of Etoricoxib in Subjects With Osteoarthritis Knee Pain.[NCT01619150] | Phase 2 | 39 participants (Actual) | Interventional | 2012-07-31 | Completed | ||
| A 13-week, Multicenter, Randomized, Double-blind, Double-dummy, Placebo-controlled, Parallel Trial of 2 Different Dose Regimens of Lumiracoxib (100 mg od and 200 mg od Initial Dose for Two Weeks Followed by 100 mg od) in Patients With Primary Knee Osteoar[NCT00366938] | Phase 3 | 1,464 participants | Interventional | 2003-09-30 | Completed | ||
| A 13-week, Multicenter, Randomized, Double-blind, Double-dummy, Placebo-controlled, Parallel Trial of 2 Different Dose Regimens of Lumiracoxib (100 mg od and 200 mg od Initial Dose for Two Weeks Followed by 100 mg od) in Patients With Primary Knee Osteoar[NCT00367315] | Phase 3 | 1,684 participants | Interventional | 2003-09-30 | Completed | ||
| A 12-Week, Randomized, Placebo- and Active-Comparator-Controlled, Parallel-Group, Double-Blind Study to Assess the Safety and Efficacy of Etoricoxib 30 mg Versus Ibuprofen 2400 mg in Patients With Osteoarthritis (Study 1)[NCT00269191] | Phase 3 | 528 participants (Actual) | Interventional | 2003-02-05 | Completed | ||
| A 52-week, International, Multi-center, Randomized, Double-blind, Double-dummy, Parallel-group Clinical Trial to Compare Retention on Treatment, Safety, Tolerability and Efficacy of Lumiracoxib 100 mg od, Lumiracoxib 100 mg Bid and Celecoxib 200 mg od in [NCT00145301] | Phase 3 | 3,036 participants | Interventional | 2004-09-30 | Completed | ||
| Efficacy of Intra-Articular Injection of Etanercept for Moderate and Severe Knee Osteoarthritis[NCT02722772] | 60 participants (Anticipated) | Interventional | 2016-02-29 | Recruiting | |||
| Efficacy of Subcutaneous Injection of Etanercept for Moderate and Severe Knee Osteoarthritis[NCT02722811] | 60 participants (Anticipated) | Interventional | 2016-02-29 | Recruiting | |||
| Arthroscopic Surgery Versus Non-surgical Treatment of Osteoarthritis of the Knee[NCT00158431] | Phase 3 | 186 participants (Actual) | Interventional | 1999-01-31 | Completed | ||
| Clinical Evaluation of Condrosulf 800 mg in the Treatment of Symptomatic OA of the Hand: a 6-month, Double-blind, Placebo Controlled Study[NCT00291499] | Phase 3 | 163 participants (Actual) | Interventional | 2005-06-30 | Completed | ||
| Study of the Effect of Chondroitin Sulphate on Synovial Inflammation in Patients With Osteoarthritis of the Knee[NCT00604539] | Phase 3 | 70 participants (Anticipated) | Interventional | 2008-02-29 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00595517)
Timeframe: up to 52 weeks
| Intervention | Participants (Number) |
|---|---|
| Esomeprazole 20mg | 125 |
(NCT00595517)
Timeframe: up to 12 weeks after treatment
| Intervention | participants (Number) |
|---|---|
| Esomeprazole 20mg | 127 |
(NCT00595517)
Timeframe: up to 24 weeks after treatment
| Intervention | participants (Number) |
|---|---|
| Esomeprazole 20mg | 126 |
(NCT00595517)
Timeframe: up to 4 weeks after treatment
| Intervention | Participants (Number) |
|---|---|
| Esomeprazole 20mg | 130 |
(NCT00141102)
Timeframe: Month 6/ET
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Celecoxib | 0.058 |
| Oral Diclofenac Plus Omeprazole | 0.073 |
(NCT00141102)
Timeframe: Month 6/ET
| Intervention | ug/dL (Least Squares Mean) |
|---|---|
| Celecoxib | -3.396 |
| Oral Diclofenac Plus Omeprazole | -1.990 |
(NCT00141102)
Timeframe: Month 6/ET
| Intervention | percent (Least Squares Mean) |
|---|---|
| Celecoxib | -0.306 |
| Oral Diclofenac Plus Omeprazole | -1.425 |
(NCT00141102)
Timeframe: Month 6/ET
| Intervention | grams (g)/deciliter (dL) (Least Squares Mean) |
|---|---|
| Celecoxib | -0.017 |
| Oral Diclofenac Plus Omeprazole | -0.423 |
(NCT00141102)
Timeframe: Month 6/ET
| Intervention | microgram (ug)/dL (Least Squares Mean) |
|---|---|
| Celecoxib | 2.517 |
| Oral Diclofenac Plus Omeprazole | 1.952 |
"Subjects rated response to question: Considering all the ways the osteoarthritis or rheumatoid arthritis affects you, how are you doing today? using a 1 to 5 grading scale where 1=very good and 5=very poor." (NCT00141102)
Timeframe: Month 6/Early Termination (ET)
| Intervention | scores on a scale (Least Squares Mean) |
|---|---|
| Celecoxib | 0.754 |
| Oral Diclofenac Plus Omeprazole | 0.773 |
Interview occurred via telephone to obtain follow-up mortality and hospitalization information. (NCT00141102)
Timeframe: 6 months following last dose
| Intervention | participants (Number) |
|---|---|
| Celecoxib | 2018 |
| Oral Diclofenac Plus Omeprazole | 2023 |
Interview occurred via telephone to obtain follow-up mortality and hospitalization information. (NCT00141102)
Timeframe: 6 months following last dose
| Intervention | participants (Number) |
|---|---|
| Celecoxib | 82 |
| Oral Diclofenac Plus Omeprazole | 79 |
A clinically significant decrease from baseline was defined as a fall in hematocrit > = 10 percentage points and/or hemoglobin > = 2 g/dL. (NCT00141102)
Timeframe: 6 month treatment duration
| Intervention | participants (Number) |
|---|---|
| Celecoxib | 45 |
| Oral Diclofenac Plus Omeprazole | 123 |
CSULGIE=any of the following: gastroduodenal (GD) hemorrhage; gastric outlet obstruction; GD, small or large bowel perforation; small or large bowel hemorrhage; clinically significant anemia of defined GI origin; acute GI hemorrhage of unknown origin, including presumed small bowel hemorrhage; clinically significant anemia of presumed occult GI origin including possible small bowel blood loss. Subjects were assessed by an independent GI Events Adjudication Committee, who were blinded to study treatment assignments. (NCT00141102)
Timeframe: 6 month treatment duration
| Intervention | participants (Number) |
|---|---|
| Celecoxib | 20 |
| Oral Diclofenac Plus Omeprazole | 81 |
CSULGIE=any of the following: GD hemorrhage; gastric outlet obstruction; GD, small or large bowel perforation; small or large bowel hemorrhage; clinically significant anemia of defined GI origin; acute GI hemorrhage of unknown origin, including presumed small bowel hemorrhage; clinically significant anemia of presumed occult GI origin including possible small bowel blood loss. Subjects with evaluation at an event visit and found to have an ulcer on endoscopy, but did not meet any criteria considered for the primary endpoint by the GI committee were designated as having an SU. (NCT00141102)
Timeframe: 6 month treatment duration
| Intervention | participants (Number) |
|---|---|
| Celecoxib | 25 |
| Oral Diclofenac Plus Omeprazole | 92 |
"Abdominal symptoms were defined by the Medical Dictionary for Regulatory Activities MedDRA System Organ Class (SOC) 'Gastrointestinal Disorders' and keeping high level group term (HLGT) equal to Gastrointestinal Signs and Symptoms." (NCT00141102)
Timeframe: 6 month treatment duration
| Intervention | participants (Number) |
|---|---|
| Celecoxib | 132 |
| Oral Diclofenac Plus Omeprazole | 162 |
Subjects with evaluation at an event visit and found to have an ulcer on endoscopy, but did not meet any criteria considered for the primary endpoint by the GI committee were designated as having an SU. (NCT00141102)
Timeframe: 6 month treatment duration
| Intervention | participants (Number) |
|---|---|
| Celecoxib | 5 |
| Oral Diclofenac Plus Omeprazole | 11 |
"GI AEs were defined using MedDRA SOC Gastrointestinal Disorders but excluding the following HLGTs: Benign Neoplasms Gastrointestinal; Dental and Gingival Conditions; Oral Soft Tissue Conditions; Salivary Gland Conditions; and Tongue Conditions." (NCT00141102)
Timeframe: 6 month treatment duration
| Intervention | participants (Number) |
|---|---|
| Celecoxib | 114 |
| Oral Diclofenac Plus Omeprazole | 167 |
(NCT00141102)
Timeframe: Month 6/ET
| Intervention | IU/L (Least Squares Mean) | ||
|---|---|---|---|
| GGT | AST | ALT | |
| Celecoxib | -2.689 | -0.901 | -1.151 |
| Oral Diclofenac Plus Omeprazole | 7.455 | 1.490 | 5.213 |
CSULGIE=any of the following: gastroduodenal (GD) hemorrhage; gastric outlet obstruction; GD, small or large bowel perforation; small or large bowel hemorrhage; clinically significant anemia of defined GI origin; acute GI hemorrhage of unknown origin, including presumed small bowel hemorrhage; clinically significant anemia of presumed occult GI origin including possible small bowel blood loss. Subjects were assessed by an independent GI Events Adjudication Committee, who were blinded to study treatment assignments. (NCT00141102)
Timeframe: 6 month treatment duration
| Intervention | participants (Number) | |
|---|---|---|
| History of GD Ulceration (n=395, 400) | No History of GD Ulceration (n=1843, 1846) | |
| Celecoxib | 7 | 13 |
| Oral Diclofenac Plus Omeprazole | 13 | 68 |
GGT ULN was 49 international units (IU)/liter (L) for females and 61 IU/L for males, AST ULN was 37 IU/L for females and 39 IU/L for males, and ALT ULN was 43 IU/L for females and 45 IU/L for males. (NCT00141102)
Timeframe: 6 month treatment duration
| Intervention | participants (Number) | ||
|---|---|---|---|
| GGT | AST | ALT | |
| Celecoxib | 26 | 8 | 13 |
| Oral Diclofenac Plus Omeprazole | 86 | 12 | 27 |
"Functional Index for Hand Osteoarthritis (Dreiser's Index). Range 0-30 Patients reported the severity of their symptoms by answering a set of 10 questions. Severity was rated on a numerical scale (0 = possible without difficulty, 1 = possible with slight difficulty, 2 =possible with great difficulty, and 3 = impossible), being 30 points the worst possible pain score.~Change calculated as difference between the month 6 value and baseline value~Target hand defined as the patient's most symptomatic hand or, when both hands were equally painful, the patient's dominant hand" (NCT00291499)
Timeframe: 6 month
| Intervention | score on a scale (Mean) |
|---|---|
| Chondroitin 4&6 Sulfate (Condrosulf) | -2.9 |
| Placebo | -0.7 |
Intensity of global spontaneous pain is evaluated by the patient himself on a Huskisson's visual analogue scale (VAS) of 100 mm. 0=no pain 100=max pain Change calculated as difference between Month 6 value and baseline value target hand is defined as the patient's most symptomatic hand or, when both hands were equally painful, the patient's dominant hand. (NCT00291499)
Timeframe: 6 months
| Intervention | mm (Mean) |
|---|---|
| Chondroitin 4&6 Sulfate (Condrosulf) | -20 |
| Placebo | -11.3 |
"Grip strength determined on both hands using a Jamar dynamometer.Patients were required to grip the dynamometer handle and squeeze as hard as possible according to their individual pain limits. The right hand grip was measured first, then the left; this procedure was performed 3 times. The mean value of these 3 measurements was recorded.~Change calculated as difference between the month 6 value and baseline value" (NCT00291499)
Timeframe: 6 months
| Intervention | Kg/cm^2 (Mean) |
|---|---|
| Chondroitin 4&6 Sulfate (Condrosulf) | 2.5 |
| Placebo | 0.6 |
Change in morning stiffness duration calculated as the difference between the month 6 value and the baseline value (NCT00291499)
Timeframe: 6 months
| Intervention | minutes (Mean) |
|---|---|
| Chondroitin 4&6 Sulfate (Condrosulf) | -4.8 |
| Placebo | 0.3 |
Total consumption (between ^baseline and month 6) of paracetamol (500 mg tablets) reported by the patients on a daily diary (NCT00291499)
Timeframe: 6 months
| Intervention | tablets/week (Mean) |
|---|---|
| Chondroitin 4&6 Sulfate (Condrosulf) | 1.9 |
| Placebo | 2.0 |
63 reviews available for diclofenac and Osteoarthritis
| Article | Year |
|---|---|
Efficacy of ultramicronised diclofenac in patients with osteoarthritis - systematic review with network meta-analysis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Diclofenac; Humans; Network Meta-Analysis; Osteo | 2021 |
[Kompleksowe spojrzenie na chorobę zwyrodnieniową stawów - zastosowanie aceklofenaku w leczeniu tej jednostki chorobowej].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Drug Administration Schedule; Humans; Low Back | 2019 |
Topics: 3T3-L1 Cells; A Kinase Anchor Proteins; Acetates; Achilles Tendon; Acute Kidney Injury; Acute Pain; | 2022 |
Oral Versus Topical Diclofenac Sodium in the Treatment of Osteoarthritis.
Topics: Administration, Cutaneous; Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac | 2017 |
Topical analgesics for acute and chronic pain in adults - an overview of Cochrane Reviews.
Topics: Acute Pain; Adult; Analgesics; Arthritis, Rheumatoid; Capsaicin; Chronic Pain; Diclofenac; Humans; K | 2017 |
Skin penetration and tissue permeation after topical administration of diclofenac.
Topics: Administration, Cutaneous; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Humans; Osteoarthrit | 2017 |
Gastrointestinal safety of etoricoxib in osteoarthritis and rheumatoid arthritis: A meta-analysis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cyclooxygenase 2 Inhibitors; Diclofe | 2018 |
A systematic review and meta-analysis of oxaceprol in the management of osteoarthritis: An evidence from randomized parallel-group controlled trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Diclofenac; Humans; Hydroxyproline; I | 2019 |
Safety of Oral Non-Selective Non-Steroidal Anti-Inflammatory Drugs in Osteoarthritis: What Does the Literature Say?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthralgia; Diclofenac; Gastrointestinal Diseases; Humans; | 2019 |
Safety of Topical Non-steroidal Anti-Inflammatory Drugs in Osteoarthritis: Outcomes of a Systematic Review and Meta-Analysis.
Topics: Administration, Cutaneous; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Drug-Related Side Ef | 2019 |
Topical delivery of aceclofenac: challenges and promises of novel drug delivery systems.
Topics: Administration, Topical; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Drug Delivery Systems; | 2014 |
Relative benefit-risk comparing diclofenac to other traditional non-steroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors in patients with osteoarthritis or rheumatoid arthritis: a network meta-analysis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cyclooxygenase 2 Inhibitors; Diclofe | 2015 |
Low-dose SoluMatrix diclofenac : a review of safety across two Phase III studies in patients with acute and osteoarthritis pain.
Topics: Acute Pain; Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials, Phase III as Topic; Diclofenac | 2015 |
Topical diclofenac therapy for osteoarthritis: a meta-analysis of randomized controlled trials.
Topics: Administration, Topical; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Humans; Osteoarthritis | 2016 |
Topical therapy for osteoarthritis: clinical and pharmacologic perspectives.
Topics: Administration, Cutaneous; Anti-Inflammatory Agents, Non-Steroidal; Capsaicin; Diclofenac; Drug-Rela | 2009 |
[Osteoarthritis - which approach is evidence based?].
Topics: Acetaminophen; Analgesics; Analgesics, Opioid; Anti-Ulcer Agents; Antirheumatic Agents; Cyclooxygena | 2010 |
[Comparative evaluation of the safety and efficacy of etoricoxib and diclofenac on the upper gastrointestinal tract in patients with osteoarthrosis and rheumatoid arthritis (the multinational etoricoxib and diclofenac arthritis long-term (MEDAL) study pro
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Diclofenac; Etoricoxib; Gastrointest | 2010 |
[Diclofenac sodium in osteoarthritis. Is there risk of hepatotoxicity? A systematic review].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Chemical and Drug Induced Liver Injury; Databases, Factual; | 2010 |
Diclofenac sodium topical solution 1.5% w/w with dimethyl sulfoxide compared with placebo for the treatment of osteoarthritis: pooled safety results.
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; | 2011 |
A comparison of the therapeutic efficacy of diclofenac in osteoarthritis: a systematic review of randomised controlled trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Humans; Meta-Analysis as Topic; Osteoarthritis; | 2012 |
Interventions for the management of temporomandibular joint osteoarthritis.
Topics: Anti-Inflammatory Agents; Betamethasone; Diclofenac; Glucosamine; Humans; Hyaluronic Acid; Ibuprofen | 2012 |
Cardiovascular safety of lumiracoxib: a meta-analysis of randomised controlled trials in patients with osteoarthritis.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Cardiovascular System; Cyclo | 2013 |
Comfrey root: from tradition to modern clinical trials.
Topics: Adult; Anti-Inflammatory Agents; Back Pain; Child; Child, Preschool; Comfrey; Diclofenac; Drug Combi | 2013 |
[Meta-analysis of the efficacy of adenosylmethionine and oxaceprol in the treatment of osteoarthritis].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Confidence Intervals; Data Interpretation, Statistical; Dic | 2002 |
Gastroprotection by coxibs: what do the Celecoxib Long-Term Arthritis Safety Study and the Vioxx Gastrointestinal Outcomes Research Trial tell us?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Celecoxib; Cyclooxygenase Inhibitors; Di | 2003 |
[Clinical pharmacology of the selective COX-2 inhibitors].
Topics: Acute Disease; Administration, Oral; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis | 2003 |
[Meta-analysis on the effect and adverse reaction on patients with osteoarthritis and rheumatoid arthritis treated with non-steroidal anti-inflammatory drugs].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Butanones; China; Diclofenac; Humans | 2003 |
Aceclofenac in the management of inflammatory pain.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Clinical Trials as Topic; Diclofenac | 2004 |
[Assessment of a topical NSAIDs in the treatment of pain and inflammation. The example of Flector Plaster, a local bioadhesive plaster containing diclofenac epolamine].
Topics: Administration, Topical; Animals; Ankle Injuries; Anti-Inflammatory Agents, Non-Steroidal; Athletic | 2004 |
Clinical pharmacology of lumiracoxib, a second-generation cyclooxygenase 2 selective inhibitor.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cyclooxygenase 2 Inhibitors | 2005 |
COX-2 selective inhibitors in the treatment of arthritis: a rheumatologist perspective.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cost-Benefit Analysis; Cy | 2005 |
Cardiovascular safety of lumiracoxib: a meta-analysis of all randomized controlled trials > or =1 week and up to 1 year in duration of patients with osteoarthritis and rheumatoid arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Cyclooxygen | 2005 |
Clinical pharmacology of lumiracoxib: a selective cyclo-oxygenase-2 inhibitor.
Topics: Arthritis, Rheumatoid; Clinical Trials as Topic; Cyclooxygenase 2 Inhibitors; Diclofenac; Humans; Ki | 2005 |
Gastrointestinal tolerability of lumiracoxib in patients with osteoarthritis and rheumatoid arthritis.
Topics: Aged; Arthritis, Rheumatoid; Cyclooxygenase 2 Inhibitors; Diclofenac; Female; Gastrointestinal Disea | 2006 |
Pooled analysis of thrombotic cardiovascular events in clinical trials of the COX-2 selective Inhibitor etoricoxib.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Clinical Trials, Phase II as Topic; | 2006 |
Evaluation of the patient acceptable symptom state in a pooled analysis of two multicentre, randomised, double-blind, placebo-controlled studies evaluating lumiracoxib and celecoxib in patients with osteoarthritis.
Topics: Aged; Celecoxib; Diclofenac; Double-Blind Method; Female; Humans; Male; Middle Aged; Osteoarthritis; | 2007 |
Evaluation of the patient acceptable symptom state in a pooled analysis of two multicentre, randomised, double-blind, placebo-controlled studies evaluating lumiracoxib and celecoxib in patients with osteoarthritis.
Topics: Aged; Celecoxib; Diclofenac; Double-Blind Method; Female; Humans; Male; Middle Aged; Osteoarthritis; | 2007 |
Evaluation of the patient acceptable symptom state in a pooled analysis of two multicentre, randomised, double-blind, placebo-controlled studies evaluating lumiracoxib and celecoxib in patients with osteoarthritis.
Topics: Aged; Celecoxib; Diclofenac; Double-Blind Method; Female; Humans; Male; Middle Aged; Osteoarthritis; | 2007 |
Evaluation of the patient acceptable symptom state in a pooled analysis of two multicentre, randomised, double-blind, placebo-controlled studies evaluating lumiracoxib and celecoxib in patients with osteoarthritis.
Topics: Aged; Celecoxib; Diclofenac; Double-Blind Method; Female; Humans; Male; Middle Aged; Osteoarthritis; | 2007 |
Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Arthritis, Rheumatoid; Aspirin; Cyclooxyge | 2007 |
Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Arthritis, Rheumatoid; Aspirin; Cyclooxyge | 2007 |
Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Arthritis, Rheumatoid; Aspirin; Cyclooxyge | 2007 |
Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Arthritis, Rheumatoid; Aspirin; Cyclooxyge | 2007 |
Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Arthritis, Rheumatoid; Aspirin; Cyclooxyge | 2007 |
Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Arthritis, Rheumatoid; Aspirin; Cyclooxyge | 2007 |
Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Arthritis, Rheumatoid; Aspirin; Cyclooxyge | 2007 |
Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Arthritis, Rheumatoid; Aspirin; Cyclooxyge | 2007 |
Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Arthritis, Rheumatoid; Aspirin; Cyclooxyge | 2007 |
New developments in osteoarthritis.
Topics: Acupuncture Therapy; Anti-Inflammatory Agents, Non-Steroidal; Biomechanical Phenomena; Diclofenac; D | 2007 |
Lumiracoxib in the management of osteoarthritis and acute pain.
Topics: Acute Disease; Animals; Cardiovascular Diseases; Cyclooxygenase 2 Inhibitors; Diclofenac; Drug Appro | 2007 |
Efficacy of the newest COX-2 selective inhibitors in rheumatic disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Gouty; Arthritis, Rheumatoid; Cardiovascular Dis | 2007 |
Pain relief in osteoarthritis and rheumatoid arthritis: TENS.
Topics: Adjuvants, Immunologic; Analgesia; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; C | 2007 |
Clinical use and pharmacological properties of selective COX-2 inhibitors.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase 2 Inhibito | 2008 |
Treating the symptoms of osteoarthritis-oral treatments.
Topics: Acetaminophen; Administration, Oral; Analgesics, Non-Narcotic; Analgesics, Opioid; Anti-Inflammatory | 2008 |
[Pharmacodynamics and adverse effects of modern nonsteroid anti-inflammatory agents].
Topics: Adult; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Aspirin; Clinical Trials as Topic; Diclofena | 1981 |
[The introduction of non-steroidal antirheumatics: is there a rational therapy].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Carbazoles; Chronic Disease; Diclofe | 1982 |
Diclofenac sodium: a review of its pharmacological properties and therapeutic use in rheumatic diseases and pain of varying origin.
Topics: Adult; Animals; Arthritis, Rheumatoid; Aspirin; Cyclooxygenase Inhibitors; Diclofenac; Drug Interact | 1980 |
Nonsteroidal anti-inflammatory drug-induced colonic strictures: two cases and literature review.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Colonic Diseases; Colonoscopy; Con | 1995 |
Diclofenac/misoprostol. A review of the major clinical trials evaluating its clinical efficacy and upper gastrointestinal tolerability in rheumatoid arthritis and osteoarthritis.
Topics: Arthritis, Rheumatoid; Diclofenac; Double-Blind Method; Drug Combinations; Humans; Misoprostol; Oste | 1993 |
Review of the safety of diclofenac/misoprostol.
Topics: Arthritis, Rheumatoid; Diclofenac; Drug Combinations; Humans; Misoprostol; Osteoarthritis; Safety; S | 1993 |
A study to determine the efficacy and safety of tenoxicam versus piroxicam, diclofenac and indomethacin in patients with osteoarthritis: a meta-analysis.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Double-Blind Method; Female; Humans; Indo | 1993 |
Meta-analysis of three double-blind comparative trials with sustained-release etodolac in the treatment of osteoarthritis of the knee.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Anti-Inflammatory Agents, Non-Steroidal; Delay | 1993 |
Differential effects of diclofenac and aspirin on serum glutamic oxaloacetic transaminase elevations in patients with rheumatoid arthritis and osteoarthritis.
Topics: Arthritis, Rheumatoid; Aspartate Aminotransferases; Aspirin; Diclofenac; Humans; Osteoarthritis | 1993 |
Hyaluronan as a drug delivery system for diclofenac: a hypothesis for mode of action.
Topics: Animals; Carcinoma, Basal Cell; Carotid Stenosis; Diclofenac; Drug Delivery Systems; Humans; Hyaluro | 1995 |
Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs.
Topics: Adult; Aged; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Butanones; Cyclooxyg | 1999 |
[Reducing pain by oral enzyme therapy in rheumatic diseases].
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Bromelains; Clinical Tr | 1999 |
Celecoxib clinical profile.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Celec | 2000 |
Nimesulide, a balanced drug for the treatment of osteoarthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials as Topic; Diclofenac; Etodolac; Humans; Nap | 2001 |
Simple approach to predict the maximal effect elicited by a drug when plasma concentrations are not available or are dissociated from the effect, as illustrated with chondroitin sulfate data.
Topics: Chondroitin Sulfates; Diclofenac; Half-Life; Humans; Osteoarthritis; Predictive Value of Tests; Stat | 2001 |
[What is the role of aceclofenac in the therapeutic arsenal against chronic osteoarthritis pathologies?].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cartilage; Chronic Disease; Diclofen | 2001 |
Clinical evidence for osteoarthritis as an inflammatory disease.
Topics: Acetaminophen; Adult; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Drug Combinations; Humans | 2001 |
Overall safety of Arthrotec.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Arthritis, Rheumatoid; Constipation; Diarrhea; | 1992 |
A global safety evaluation of etodolac.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Clinical Tr | 1989 |
Diclofenac sodium.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Diclofenac; Humans; Osteoar | 1989 |
168 trials available for diclofenac and Osteoarthritis
| Article | Year |
|---|---|
Comparison of the Efficacy and Safety of Ketoprofen Plaster and Diclofenac Plaster for Osteoarthritis-Related Knee Pain: A Multicenter, Randomized, Active-Controlled, Open-Label, Parallel-Group, Phase III Clinical Trial.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Double-Blind Method; Humans; Ketoprofen; | 2021 |
Diclofenac-hyaluronate conjugate (diclofenac etalhyaluronate) intra-articular injection for hip, ankle, shoulder, and elbow osteoarthritis: a randomized controlled trial.
Topics: Ankle; Diclofenac; Double-Blind Method; Elbow; Humans; Hyaluronic Acid; Injections, Intra-Articular; | 2022 |
Topics: 3T3-L1 Cells; A Kinase Anchor Proteins; Acetates; Achilles Tendon; Acute Kidney Injury; Acute Pain; | 2022 |
Greater efficacy of a combination of conservative therapies for thumb base OA in individuals with lower radial subluxation - a pre-planned subgroup analysis of the COMBO trial.
Topics: Administration, Topical; Aged; Anti-Inflammatory Agents, Non-Steroidal; Carpometacarpal Joints; Comb | 2021 |
B-vitamin mixture improves the analgesic effect of diclofenac in patients with osteoarthritis: a double blind study.
Topics: Aged; Analgesics; Diclofenac; Double-Blind Method; Drug Synergism; Female; Humans; Male; Middle Aged | 2013 |
Safety and efficacy of long-term esomeprazole 20 mg in Japanese patients with a history of peptic ulcer receiving daily non-steroidal anti-inflammatory drugs.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Diclofenac; Esomeprazole; Fema | 2013 |
[Impact of combined therapy using glucosamine sulfate and anti-inflammatory agent on pain severity in patients with osteoarthritis: prospective, non-controlled postmarketing study].
Topics: Aged; Anti-Inflammatory Agents; Cardiovascular Agents; Diclofenac; Drug Therapy, Combination; Escin; | 2013 |
Effect on blood pressure of lumiracoxib versus ibuprofen in patients with osteoarthritis and controlled hypertension: a randomized trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Blood Pressure; Blood Pressure Monitoring, Ambulatory | 2008 |
A 6-week, multicentre, randomised, double-blind, double-dummy, active-controlled, clinical safety study of lumiracoxib and rofecoxib in osteoarthritis patients.
Topics: Aged; Arthralgia; Blood Pressure; Cyclooxygenase 2 Inhibitors; Diclofenac; Dose-Response Relationshi | 2008 |
Lower gastrointestinal events in a double-blind trial of the cyclo-oxygenase-2 selective inhibitor etoricoxib and the traditional nonsteroidal anti-inflammatory drug diclofenac.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Confidence Intervals; Cyclooxygenase Inhibitors; Dicl | 2008 |
Lower gastrointestinal events in a double-blind trial of the cyclo-oxygenase-2 selective inhibitor etoricoxib and the traditional nonsteroidal anti-inflammatory drug diclofenac.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Confidence Intervals; Cyclooxygenase Inhibitors; Dicl | 2008 |
Lower gastrointestinal events in a double-blind trial of the cyclo-oxygenase-2 selective inhibitor etoricoxib and the traditional nonsteroidal anti-inflammatory drug diclofenac.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Confidence Intervals; Cyclooxygenase Inhibitors; Dicl | 2008 |
Lower gastrointestinal events in a double-blind trial of the cyclo-oxygenase-2 selective inhibitor etoricoxib and the traditional nonsteroidal anti-inflammatory drug diclofenac.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Confidence Intervals; Cyclooxygenase Inhibitors; Dicl | 2008 |
Lower gastrointestinal events in a double-blind trial of the cyclo-oxygenase-2 selective inhibitor etoricoxib and the traditional nonsteroidal anti-inflammatory drug diclofenac.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Confidence Intervals; Cyclooxygenase Inhibitors; Dicl | 2008 |
Lower gastrointestinal events in a double-blind trial of the cyclo-oxygenase-2 selective inhibitor etoricoxib and the traditional nonsteroidal anti-inflammatory drug diclofenac.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Confidence Intervals; Cyclooxygenase Inhibitors; Dicl | 2008 |
Lower gastrointestinal events in a double-blind trial of the cyclo-oxygenase-2 selective inhibitor etoricoxib and the traditional nonsteroidal anti-inflammatory drug diclofenac.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Confidence Intervals; Cyclooxygenase Inhibitors; Dicl | 2008 |
Lower gastrointestinal events in a double-blind trial of the cyclo-oxygenase-2 selective inhibitor etoricoxib and the traditional nonsteroidal anti-inflammatory drug diclofenac.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Confidence Intervals; Cyclooxygenase Inhibitors; Dicl | 2008 |
Lower gastrointestinal events in a double-blind trial of the cyclo-oxygenase-2 selective inhibitor etoricoxib and the traditional nonsteroidal anti-inflammatory drug diclofenac.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Confidence Intervals; Cyclooxygenase Inhibitors; Dicl | 2008 |
How common is diclofenac-associated liver injury? Analysis of 17,289 arthritis patients in a long-term prospective clinical trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Chemical and Drug Induced Live | 2009 |
How common is diclofenac-associated liver injury? Analysis of 17,289 arthritis patients in a long-term prospective clinical trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Chemical and Drug Induced Live | 2009 |
How common is diclofenac-associated liver injury? Analysis of 17,289 arthritis patients in a long-term prospective clinical trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Chemical and Drug Induced Live | 2009 |
How common is diclofenac-associated liver injury? Analysis of 17,289 arthritis patients in a long-term prospective clinical trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Chemical and Drug Induced Live | 2009 |
How common is diclofenac-associated liver injury? Analysis of 17,289 arthritis patients in a long-term prospective clinical trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Chemical and Drug Induced Live | 2009 |
How common is diclofenac-associated liver injury? Analysis of 17,289 arthritis patients in a long-term prospective clinical trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Chemical and Drug Induced Live | 2009 |
How common is diclofenac-associated liver injury? Analysis of 17,289 arthritis patients in a long-term prospective clinical trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Chemical and Drug Induced Live | 2009 |
How common is diclofenac-associated liver injury? Analysis of 17,289 arthritis patients in a long-term prospective clinical trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Chemical and Drug Induced Live | 2009 |
How common is diclofenac-associated liver injury? Analysis of 17,289 arthritis patients in a long-term prospective clinical trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Chemical and Drug Induced Live | 2009 |
Cardiovascular safety and gastrointestinal tolerability of etoricoxib vs diclofenac in a randomized controlled clinical trial (The MEDAL study).
Topics: Aged; Cardiovascular Diseases; Cyclooxygenase Inhibitors; Diclofenac; Double-Blind Method; Emergenci | 2009 |
Evaluation of topically administered diclofenac liposomal cream for treatment of horses with experimentally induced osteoarthritis.
Topics: Administration, Topical; Animals; Arthrography; Cartilage, Articular; Diclofenac; Histocytochemistry | 2009 |
A randomized, multicentric, comparative evaluation of aceclofenac-paracetamol combination with aceclofenac alone in Indian patients with osteoarthritis flare-up.
Topics: Acetaminophen; Adult; Aged; Diclofenac; Drug Therapy, Combination; Female; Humans; India; Male; Midd | 2009 |
Factors associated with blood pressure changes in patients receiving diclofenac or etoricoxib: results from the MEDAL study.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Blood Pressure; Cyclooxygenase | 2009 |
Diclofenac sodium gel in patients with primary hand osteoarthritis: a randomized, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arthralgia; Diclofenac; Dou | 2009 |
Correlation of pain relief with physical function in hand osteoarthritis: randomized controlled trial post hoc analysis.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Di | 2010 |
Correlation of pain relief with physical function in hand osteoarthritis: randomized controlled trial post hoc analysis.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Di | 2010 |
Correlation of pain relief with physical function in hand osteoarthritis: randomized controlled trial post hoc analysis.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Di | 2010 |
Correlation of pain relief with physical function in hand osteoarthritis: randomized controlled trial post hoc analysis.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Di | 2010 |
The effects of lumiracoxib 100 mg once daily vs. ibuprofen 600 mg three times daily on the blood pressure profiles of hypertensive osteoarthritis patients taking different classes of antihypertensive agents.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Cyclooxygen | 2010 |
Incidence of gastroduodenal ulcers during treatment with celecoxib or diclofenac: pooled results from three 12-week trials in Chinese patients with osteoarthritis or rheumatoid arthritis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Arthritis, Rheumatoid; Celecoxib; China; Comorbidity; Cy | 2010 |
Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthritis, Rheumatoid; Celecoxib; | 2010 |
Haemoglobin decreases in NSAID users over time: an analysis of two large outcome trials.
Topics: Adult; Aged; Anemia; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Aspirin; Celeco | 2011 |
[Dynamics of intragastric acidity in patients with osteoarthritis and rheumatoid arthritis during therapy with diclofenac sodium].
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Diclofenac; Endoscopy, Gastro | 2011 |
Potential pharmacodynamic drug-drug interaction between concomitantly administered lisinopril and diclofenac sodium: a call for appropriate management in hypertensive osteoarthritic patients.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Bloo | 2011 |
The effect of non-steroidal anti-inflammatory drugs on the endothelial function of patients with osteoarthritis in short term.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Brachial Artery; Cyclooxygenase Inhibitors; Di | 2012 |
Cardiovascular safety of lumiracoxib: a meta-analysis of randomised controlled trials in patients with osteoarthritis.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Cardiovascular System; Cyclo | 2013 |
Risk factors associated with a decrease ≥2 g/dL in haemoglobin and/or ≥10% haematocrit in osteoarthritis patients taking celecoxib or a nonselective NSAID plus a PPI in a large randomised controlled trial (CONDOR).
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; D | 2012 |
Long-term tolerability of topical diclofenac sodium 1% gel for osteoarthritis in seniors and patients with comorbidities.
Topics: Administration, Cutaneous; Adult; Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cardio | 2012 |
Incidence of gastroduodenal ulcers associated with valdecoxib compared with that of ibuprofen and diclofenac in patients with osteoarthritis.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Anti-Inflammatory Agents, Non-Steroidal; Cyclo | 2002 |
Efficacy and safety of diclofenac-cholestyramine and celecoxib in osteoarthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Celecoxib; Cholestyramine Resin; | 2002 |
Double-blind, randomised, comparative trial of etodolac SR versus diclofenac in the treatment of osteoarthritis of the knee.
Topics: Abdominal Pain; Aged; Analysis of Variance; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase | 2003 |
The efficacy and cost effectiveness of N of 1 studies with diclofenac compared to standard treatment with nonsteroidal antiinflammatory drugs in osteoarthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cost-Benefit Analysis; Diclofenac; Follow-Up Studies; Human | 2004 |
Effects of COX inhibition on blood pressure and kidney function in ACE inhibitor-treated blacks and hispanics.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Anti | 2004 |
Effect of diclofenac alone or in combination with alpha-tocopherol on the oxidative activity of polymorphonuclear leukocytes in healthy and osteoarthritic individuals.
Topics: alpha-Tocopherol; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Diclofenac; Drug Therapy, C | 2004 |
Therapeutic arthritis research and gastrointestinal event trial of lumiracoxib - study design and patient demographics.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cyclooxygenase 2; Cyclooxygenase 2 In | 2004 |
A four-week, randomized, double-blind trial of the efficacy and safety of SKI306X: a herbal anti-arthritic agent versus diclofenac in osteoarthritis of the knee.
Topics: Administration, Oral; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Delayed-Action Preparati | 2004 |
Gastroduodenal safety and tolerability of lumiracoxib compared with Ibuprofen and celecoxib in patients with osteoarthritis.
Topics: Aged; Celecoxib; Cyclooxygenase Inhibitors; Diclofenac; Female; Humans; Ibuprofen; Incidence; Male; | 2004 |
Lumiracoxib.
Topics: Administration, Oral; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase Inhibitors; Diclofenac; Doubl | 2004 |
[Proof of the pharmacodynamic activity of Flector Plaster in healthy volunteers and patients suffering from osteo-arthritis of the knee].
Topics: Administration, Topical; Adult; Diclofenac; Double-Blind Method; Female; Humans; Knee Joint; Male; O | 2004 |
Efficacy and safety of willow bark extract in the treatment of osteoarthritis and rheumatoid arthritis: results of 2 randomized double-blind controlled trials.
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheu | 2004 |
Valdecoxib is associated with improved dyspepsia-related health compared with nonspecific NSAIDs in patients with osteoarthritis or rheumatoid arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cyclooxygenase Inhibitors; Diclofena | 2005 |
Safety and efficacy of lumiracoxib compared with NSAIDs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Diclofenac; Double-Blind Method; D | 2005 |
Etoricoxib in the treatment of osteoarthritis over 52-weeks: a double-blind, active-comparator controlled trial [NCT00242489].
Topics: Administration, Oral; Aged; Cyclooxygenase Inhibitors; Diclofenac; Dose-Response Relationship, Drug; | 2005 |
Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibitors; Diclofenac; Double-Bl | 2006 |
A randomized database study in general practice yielded quality data but patient recruitment in routine consultation was not practical.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Databases, Factual; Diclofenac; Family Pr | 2006 |
Efficacy and safety of aceclofenac in the treatment of osteoarthritis: a randomized double-blind comparative clinical trial versus diclofenac - an Indian experience.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygena | 2006 |
Cardiorenal effects of celecoxib as compared with the nonsteroidal anti-inflammatory drugs diclofenac and ibuprofen.
Topics: Acid-Base Equilibrium; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, | 2006 |
Evaluation of the patient acceptable symptom state in a pooled analysis of two multicentre, randomised, double-blind, placebo-controlled studies evaluating lumiracoxib and celecoxib in patients with osteoarthritis.
Topics: Aged; Celecoxib; Diclofenac; Double-Blind Method; Female; Humans; Male; Middle Aged; Osteoarthritis; | 2007 |
Evaluation of the patient acceptable symptom state in a pooled analysis of two multicentre, randomised, double-blind, placebo-controlled studies evaluating lumiracoxib and celecoxib in patients with osteoarthritis.
Topics: Aged; Celecoxib; Diclofenac; Double-Blind Method; Female; Humans; Male; Middle Aged; Osteoarthritis; | 2007 |
Evaluation of the patient acceptable symptom state in a pooled analysis of two multicentre, randomised, double-blind, placebo-controlled studies evaluating lumiracoxib and celecoxib in patients with osteoarthritis.
Topics: Aged; Celecoxib; Diclofenac; Double-Blind Method; Female; Humans; Male; Middle Aged; Osteoarthritis; | 2007 |
Evaluation of the patient acceptable symptom state in a pooled analysis of two multicentre, randomised, double-blind, placebo-controlled studies evaluating lumiracoxib and celecoxib in patients with osteoarthritis.
Topics: Aged; Celecoxib; Diclofenac; Double-Blind Method; Female; Humans; Male; Middle Aged; Osteoarthritis; | 2007 |
Gastrointestinal side effects of etoricoxib in patients with osteoarthritis: results of the Etoricoxib versus Diclofenac Sodium Gastrointestinal Tolerability and Effectiveness (EDGE) trial.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Cyclooxygenase Inhibitors; Diclofe | 2007 |
Cardiovascular outcomes in high risk patients with osteoarthritis treated with ibuprofen, naproxen or lumiracoxib.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Cyclooxygenase 2 In | 2007 |
Effect of risk factors on complicated and uncomplicated ulcers in the TARGET lumiracoxib outcomes study.
Topics: Age Distribution; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase 2 Inhibitors; Diclof | 2007 |
Comparative efficacy and tolerability of two sustained-release formulations of diclofenac: results of a double-blind, randomised study in patients with osteoarthritis and a reappraisal of diclofenac's use in this patient population.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Dosage Forms; Double-Blind Method; Humans | 2007 |
Long-term retention on treatment with lumiracoxib 100 mg once or twice daily compared with celecoxib 200 mg once daily: a randomised controlled trial in patients with osteoarthritis.
Topics: Aged; Arthralgia; Canada; Cardiovascular Diseases; Celecoxib; Chemical and Drug Induced Liver Injury | 2008 |
Effectiveness of leech therapy in women with symptomatic arthrosis of the first carpometacarpal joint: a randomized controlled trial.
Topics: Aged; Animals; Anti-Inflammatory Agents, Non-Steroidal; Carpometacarpal Joints; Diclofenac; Female; | 2008 |
Diclofenac gel for osteoarthritis.
Topics: Administration, Topical; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Drug Administration Sc | 2008 |
Diclofenac sodium and occlusal splint therapy in TMJ osteoarthritis: a randomized controlled trial.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Female; Follow-Up Studies; Humans; | 2008 |
Bioequivalence and pharmacokinetic evaluation of two branded formulations of aceclofenac 100 mg: a single-dose, randomized, open-label, two-period crossover comparison in healthy Korean adult volunteers.
Topics: Administration, Oral; Adult; Anti-Inflammatory Agents, Non-Steroidal; Chromatography, High Pressure | 2008 |
[Evaluation of the efficacy of a single daily administration of slow-release diclofenac in the treatment of degenerative and non-degenerative arthropathies. Multicenter study concerning 643 patients].
Topics: Adolescent; Adult; Aged; Arthritis, Rheumatoid; Clinical Trials as Topic; Diclofenac; Drug Administr | 1984 |
Treatment of osteoarthrosis of the spine: a comparison of flurbiprofen and diclofenac.
Topics: Adult; Aged; Clinical Trials as Topic; Diclofenac; Double-Blind Method; Drug Administration Schedule | 1983 |
A short-term, double-blind comparison between indoprofen and diclofenac in osteoarthritis.
Topics: Adult; Aged; Clinical Trials as Topic; Diclofenac; Double-Blind Method; Female; Humans; Indoprofen; | 1983 |
A multicentre study of diclofenac sodium slow-release (Voltaren Retard) in the treatment of rheumatic disorders in the Kingdom of Saudi Arabia.
Topics: Adult; Arthritis, Rheumatoid; Clinical Trials as Topic; Delayed-Action Preparations; Diclofenac; Fem | 1984 |
[Pharmacodynamics and adverse effects of modern nonsteroid anti-inflammatory agents].
Topics: Adult; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Aspirin; Clinical Trials as Topic; Diclofena | 1981 |
Double-blind comparative clinical trial of carprofen versus diclofenac-Na in patients with coxarthrosis.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Carbazoles; Clinical Trials as Topic; Diclofen | 1982 |
Diclofenac and ibuprofen in rheumatoid arthritis and osteoarthritis.
Topics: Arthritis, Rheumatoid; Clinical Trials as Topic; Diclofenac; Double-Blind Method; Female; Humans; Ib | 1980 |
Once daily dose treatment with a non-steroidal anti-rheumatic drug (diclofenac) in osteoarthrosis.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Clinical Trials as Topic; Delayed-Action Preparations | 1980 |
[Short-term controlled clinical studies with sodium diclofenac in patients with "painful" osteoarthrosis].
Topics: Adult; Aged; Clinical Trials as Topic; Diclofenac; Female; Humans; Male; Middle Aged; Osteoarthritis | 1981 |
Diclofenac suppositories in osteoarthrosis. A double-blind comparison with indomethacin.
Topics: Aged; Clinical Trials as Topic; Diclofenac; Double-Blind Method; Female; Humans; Indomethacin; Male; | 1981 |
[Comparative double-blind trial of diclophenac-sodium and naproxen in hip arthrosis].
Topics: Aged; Clinical Trials as Topic; Diclofenac; Double-Blind Method; Hip Joint; Humans; Middle Aged; Nap | 1981 |
A study of the efficacy and tolerability of diclofenac and ibuprofen in osteoarthritis of the hip.
Topics: Aged; Clinical Trials as Topic; Diclofenac; Double-Blind Method; Female; Hip Joint; Humans; Ibuprofe | 1981 |
Diclofenac sodium and thyroid function tests.
Topics: Adult; Aged; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Clinical Trials as Topic; Diclofenac; | 1982 |
A comparative study of naproxen with diclofenac sodium in osteoarthrosis of the knees.
Topics: Adult; Aged; Clinical Trials as Topic; Diclofenac; Double-Blind Method; Female; Humans; Knee Joint; | 1982 |
Double-blind study evaluating by endoscopy the tolerability of nimesulide and diclofenac on the gastric mucosa in osteoarthritic patients.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Double-Blind Method; Endoscopy; Female; Gastric | 1994 |
Efficacy and tolerability of diclofenac dispersible in painful osteoarthrosis.
Topics: Diclofenac; Double-Blind Method; Female; Hip Joint; Humans; Knee Joint; Male; Middle Aged; Osteoarth | 1993 |
Diclofenac/misoprostol. A review of the major clinical trials evaluating its clinical efficacy and upper gastrointestinal tolerability in rheumatoid arthritis and osteoarthritis.
Topics: Arthritis, Rheumatoid; Diclofenac; Double-Blind Method; Drug Combinations; Humans; Misoprostol; Oste | 1993 |
Efficacy and upper GI safety of diclofenac/misoprostol, piroxicam and naproxen in patients with osteoarthritis.
Topics: Diclofenac; Double-Blind Method; Drug Combinations; Female; Gastrointestinal Diseases; Humans; Male; | 1993 |
Review of the safety of diclofenac/misoprostol.
Topics: Arthritis, Rheumatoid; Diclofenac; Drug Combinations; Humans; Misoprostol; Osteoarthritis; Safety; S | 1993 |
Misoprostol coadministered with diclofenac for prevention of gastroduodenal ulcers. A one-year study.
Topics: Arthritis, Rheumatoid; Diclofenac; Endoscopy, Gastrointestinal; Female; Humans; Incidence; Life Tabl | 1995 |
Comparative studies with tolfenamic acid in rheumatic disorders.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Diclofenac; Double-Blind Method; Dru | 1994 |
A comparative study of signal versus aggregate methods of outcome measurement based on the WOMAC Osteoarthritis Index. Western Ontario and McMaster Universities Osteoarthritis Index.
Topics: Aged; Data Interpretation, Statistical; Diclofenac; Double-Blind Method; Health Status Indicators; H | 1994 |
Long-term effect of nonsteroidal anti-inflammatory drugs on the production of cytokines and other inflammatory mediators by blood cells of patients with osteoarthritis.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Cytokines; Diclofenac; Dino | 1994 |
n of 1 trials comparing a non-steroidal anti-inflammatory drug with paracetamol in osteoarthritis.
Topics: Acetaminophen; Adult; Aged; Aged, 80 and over; Analgesia; Capsules; Diclofenac; Double-Blind Method; | 1994 |
A placebo-controlled study of the efficacy and tolerability of a nonsteroidal anti-inflammatory drug, DHEP plaster, in inflammatory peri- and extra-articular rheumatological diseases.
Topics: Administration, Cutaneous; Adult; Aged; Arthritis, Rheumatoid; Diclofenac; Double-Blind Method; Fema | 1993 |
DHEP plasters as a topical treatment of knee osteoarthritis--a double-blind placebo-controlled study.
Topics: Administration, Cutaneous; Aged; Diclofenac; Double-Blind Method; Female; Humans; Knee Joint; Male; | 1993 |
DHEP plasters as a topical treatment of knee osteoarthritis--a double-blind placebo-controlled study.
Topics: Administration, Cutaneous; Aged; Diclofenac; Double-Blind Method; Female; Humans; Knee Joint; Male; | 1993 |
DHEP plasters as a topical treatment of knee osteoarthritis--a double-blind placebo-controlled study.
Topics: Administration, Cutaneous; Aged; Diclofenac; Double-Blind Method; Female; Humans; Knee Joint; Male; | 1993 |
DHEP plasters as a topical treatment of knee osteoarthritis--a double-blind placebo-controlled study.
Topics: Administration, Cutaneous; Aged; Diclofenac; Double-Blind Method; Female; Humans; Knee Joint; Male; | 1993 |
Worldwide experience with etodolac (Lodine) 300 mg b.i.d. in the treatment of osteoarthritis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Delayed-Action Preparations; Diclofenac; Double-Blind Me | 1993 |
Sulglycotide in the prevention of nonsteroidal anti-inflammatory drug-induced gastroduodenal mucosal injury. A controlled double-blind, double-dummy, randomized endoscopic study versus placebo in rheumatic patients.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthritis, Rheu | 1993 |
Double-blind comparison of efficacy and gastroduodenal safety of diclofenac/misoprostol, piroxicam, and naproxen in the treatment of osteoarthritis.
Topics: Adult; Aged; Aged, 80 and over; Diclofenac; Double-Blind Method; Drug Combinations; Drug Therapy, Co | 1993 |
A two-year, placebo-controlled trial of non-steroidal anti-inflammatory therapy in osteoarthritis of the knee joint.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Delayed-Action Preparations | 1993 |
A multicenter study of tenoxicam and diclofenac in patients with osteoarthritis of the knee.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Double-Blind Method; Drug Tolerance; Fema | 1993 |
Safety experience with nabumetone versus diclofenac, naproxen, ibuprofen, and piroxicam in osteoarthritis and rheumatoid arthritis.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Butanones; Diclofenac; | 1993 |
Efficacy and safety of nabumetone versus diclofenac, naproxen, ibuprofen, and piroxicam in the elderly.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Butanones; | 1993 |
Efficacy of nabumetone versus diclofenac, naproxen, ibuprofen, and piroxicam in osteoarthritis and rheumatoid arthritis.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Butanones; Diclofenac; | 1993 |
Differential effects of diclofenac and aspirin on serum glutamic oxaloacetic transaminase elevations in patients with rheumatoid arthritis and osteoarthritis.
Topics: Arthritis, Rheumatoid; Aspartate Aminotransferases; Aspirin; Diclofenac; Humans; Osteoarthritis | 1993 |
A multicenter study of nabumetone and diclofenac SR in patients with osteoarthritis.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Butanones; Diclofenac; Dose | 1995 |
Comparison of aceclofenac with diclofenac in the treatment of osteoarthritis.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Double-Blind Method; F | 1995 |
Meloxicam in osteoarthritis: a 6-month, double-blind comparison with diclofenac sodium.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase Inhibitors; Diclofenac; Double-Blind M | 1996 |
Comparison of the antiinflammatory efficacy of chondroitin sulfate and diclofenac sodium in patients with knee osteoarthritis.
Topics: Acetaminophen; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Chondroitin | 1996 |
Comparison of the antiinflammatory efficacy of chondroitin sulfate and diclofenac sodium in patients with knee osteoarthritis.
Topics: Acetaminophen; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Chondroitin | 1996 |
Comparison of the antiinflammatory efficacy of chondroitin sulfate and diclofenac sodium in patients with knee osteoarthritis.
Topics: Acetaminophen; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Chondroitin | 1996 |
Comparison of the antiinflammatory efficacy of chondroitin sulfate and diclofenac sodium in patients with knee osteoarthritis.
Topics: Acetaminophen; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Chondroitin | 1996 |
[Drug therapy of activated arthrosis. On the effectiveness of an enzyme mixture versus diclofenac].
Topics: Adjuvants, Immunologic; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Dic | 1996 |
A controlled clinical investigation of 3% diclofenac/2.5% sodium hyaluronate topical gel in the treatment of uncontrolled pain in chronic oral NSAID users with osteoarthritis.
Topics: Administration, Oral; Administration, Topical; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; | 1995 |
A multicenter, randomized, double blind study comparing lornoxicam with diclofenac in osteoarthritis.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Double-Blind Method; D | 1996 |
Prevention with sucralfate gel of NSAID-induced gastroduodenal damage in arthritic patients.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthritis, Rheumatoid; Diclofenac; Doubl | 1996 |
Comparative efficacy and tolerability of two diclofenac formulations in the treatment of painful osteoarthritis.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthralgia; Diclofenac; Double-Bli | 1996 |
Comparative study of diclofenac sodium and flurbiprofen in osteoarthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Female; Flurbiprofen; Humans; Male; Osteoarthri | 1996 |
Ibuprofen and diclofenac sodium in the treatment of osteoarthritis: a comparative trial of two once-daily sustained-release NSAID formulations.
Topics: Activities of Daily Living; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; | 1996 |
Comparison of aceclofenac with piroxicam in the treatment of osteoarthritis.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Double-Blind Me | 1997 |
[Double-blind comparative study of the effectiveness and tolerance of 900 mg dexibuprofen and 150 mg diclofenac sodium in patients with painful gonarthrosis].
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Dose-Response Relationship, Drug; | 1997 |
Aceclofenac is a well-tolerated alternative to naproxen in the treatment of osteoarthritis.
Topics: Administration, Oral; Aged; Anti-Inflammatory Agents, Non-Steroidal; Chi-Square Distribution; Diclof | 1997 |
[Efficacy and safety of nabumetone in the treatment of knee osteoarthritis: a comparative clinical trial versus aceclofenac. Study Group of Nabumetone for Osteoarthritis of the Knee].
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Butanones; Diclofenac; Female; Humans; Knee Joint; Ma | 1997 |
Local NSAID gel (eltenac) in the treatment of osteoarthritis of the knee. A double blind study comparing eltenac with oral diclofenac and placebo gel.
Topics: Administration, Oral; Administration, Topical; Aniline Compounds; Anti-Inflammatory Agents; Anti-Inf | 1997 |
A double-blind, randomized trial to compare meloxicam 15 mg with diclofenac 100 mg in the treatment of osteoarthritis of the knee.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Double-Blind Method; Female; Humans; Knee | 1997 |
Therapeutic equivalence of diclofenac sustained-released 75 mg tablets and diclofenac enteric-coated 50 mg tablets in the treatment of painful osteoarthritis.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Delayed-Action Preparations; Diclo | 1997 |
[A clinical study on the anti-inflammatory activity and gastrointestinal tolerability of amtolmetin guacyl, a new NSAID, compared with diclofenac in aged patients with osteoarticular diseases].
Topics: Administration, Oral; Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; Data Interpretatio | 1997 |
Diclofenac/misoprostol: the European clinical experience.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthritis, Rheumatoid; Diclofenac; Doubl | 1998 |
[Oxaprozin versus diclofenac retard in treated of activated arthrosis].
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Delayed-Action Preparations; Diclofenac; Dose- | 1998 |
[Functional manifestations of osteoarthritis: key points to the clinical efficacy of diacerhein].
Topics: Anthraquinones; Anti-Inflammatory Agents, Non-Steroidal; Cross-Over Studies; Diclofenac; France; Hum | 1998 |
NSAIDs and faecal blood loss in elderly patients with osteoarthritis: is plasma half-life relevant?
Topics: Aged; Aged, 80 and over; Analysis of Variance; Anti-Inflammatory Agents, Non-Steroidal; Cross-Over S | 1998 |
Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients. International MELISSA Study Group. Meloxicam Large-scale International Study Safety Assessment.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase Inhibitors; Diclofenac; Double-Blind M | 1998 |
Comparison of the upper gastrointestinal safety of Arthrotec 75 and nabumetone in osteoarthritis patients at high risk for developing nonsteroidal anti-inflammatory drug-induced gastrointestinal ulcers.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Butanones; Diclofenac; Double-Blind Method; Dr | 1999 |
Improving medication adherence through patient education distinguishing between appropriate and inappropriate utilization. Patient Education Study Group.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Computer-Assisted Instruction; Dec | 1999 |
Comparison of therapeutic efficacy of nimesulide and diclofenac in patients with degenerative joint diseases.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Dou | 1999 |
[Reducing pain by oral enzyme therapy in rheumatic diseases].
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Bromelains; Clinical Tr | 1999 |
Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.
Topics: Aged; Analysis of Variance; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Aspirin; | 2000 |
Safety and efficacy of meloxicam in the treatment of osteoarthritis: a 12-week, double-blind, multiple-dose, placebo-controlled trial. The Meloxicam Osteoarthritis Investigators.
Topics: Adult; Aged; Cyclooxygenase Inhibitors; Diclofenac; Double-Blind Method; Female; Gastrointestinal Di | 2000 |
Tolerability profiles of rofecoxib (Vioxx) and Arthrotec. A comparison of six weeks treatment in patients with osteoarthritis.
Topics: Abdominal Pain; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygen | 2001 |
Treatment of elderly patients with nabumetone or diclofenac: gastrointestinal safety profile.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Anti-Inflammatory Agents, Non-Steroidal; Butanones; D | 2001 |
A comparison of the efficacy and tolerability of meloxicam and diclofenac in the treatment of patients with osteoarthritis of the lumbar spine.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase Inhibitors; Diclofenac; Double- | 2001 |
Effects of non-steroidal anti-inflammatory drugs on hypertension control using angiotensin converting enzyme inhibitors and thiazide diuretics.
Topics: Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive | 2001 |
Dyspepsia tolerability from the patients' perspective: a comparison of celecoxib with diclofenac.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Diclofenac; Double-Blind | 2002 |
Diclofenac (Voltaren) for the treatment of osteo-arthrosis: a double-blind comparison with naproxen.
Topics: Aged; Clinical Trials as Topic; Diclofenac; Dose-Response Relationship, Drug; Female; Humans; Male; | 1977 |
[Experiences with the use of sodium diclofenac (Voltaren) in rheumatic diseases].
Topics: Adult; Aged; Arthritis, Rheumatoid; Clinical Trials as Topic; Diclofenac; Drug Evaluation; Drug Tole | 1978 |
A long-term study of diclophenac sodium in the treatment of rheumatoid arthritis and osteo-arthrosis.
Topics: Adult; Aged; Arthritis, Rheumatoid; Blood Cell Count; Blood Sedimentation; Chronic Disease; Clinical | 1978 |
A double-blind multicentre comparison of diclofenac sodium and naproxen in osteoarthrosis of the hip.
Topics: Adult; Clinical Trials as Topic; Diclofenac; Double-Blind Method; Drug Evaluation; Female; Hip Joint | 1978 |
[Use of vol'taren in rheumatological practice].
Topics: Arthritis, Rheumatoid; Clinical Trials as Topic; Diclofenac; Drug Evaluation; Humans; Middle Aged; O | 1978 |
How long should long be? Long-term trials in rheumatic diseases.
Topics: Arthritis, Rheumatoid; Clinical Trials as Topic; Diclofenac; Drug Evaluation; Humans; Indomethacin; | 1979 |
Diclofenac sodium (Voltarol) and indomethacin: a multicentre comparative study in rheumatoid arthritis and osteoarthritis.
Topics: Arthritis, Rheumatoid; Clinical Trials as Topic; Diclofenac; Double-Blind Method; Hemoglobins; Human | 1979 |
Analysis of the Brazilian literature on diclofenac sodium (Voltarol).
Topics: Arthritis, Rheumatoid; Brazil; Clinical Trials as Topic; Diclofenac; Drug Tolerance; Female; Humans; | 1979 |
An open assessment of the efficacy and tolerability of diclofenac sodium (Voltarol) in patients with rheumatic disease and a comparative study of diclofenac sodium (Voltarol) with indomethacin in patients with osteoarthritis and rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Clinical Trials as Topic; Diclofenac; Drug Evaluation; Drug Tolerance; Female | 1979 |
[A new anti-rheumatic drug in orthopedics].
Topics: Adolescent; Adult; Aged; Arthritis; Child; Clinical Trials as Topic; Diclofenac; Female; Humans; Joi | 1979 |
[A clinical comparison of sulindac and diclofenac in the treatment of osteoarthritis (author's transl)].
Topics: Adult; Aged; Diclofenac; Double-Blind Method; Female; Humans; Indenes; Male; Middle Aged; Osteoarthr | 1979 |
Double-blind, randomized and parallel comparison between droxicam and diclofenac sodium in patients with coxarthrosis and gonarthrosis.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Double-Blind Method; Female; Human | 1991 |
The efficacy of Arthrotec in the treatment of osteoarthritis.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Diclofenac; Dose-Response Relationship, Drug; | 1992 |
The safety of Arthrotec in patients with rheumatoid arthritis or osteoarthritis: an assessment of the upper gastrointestinal tract by endoscopy.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Arthritis, Rheumatoid; Diclofenac; Digestive S | 1992 |
Overall safety of Arthrotec.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Arthritis, Rheumatoid; Constipation; Diarrhea; | 1992 |
The gastroduodenal safety and efficacy of the fixed combination of diclofenac and misoprostol in the treatment of osteoarthritis.
Topics: Adult; Aged; Diclofenac; Double-Blind Method; Drug Combinations; Duodenum; Female; Gastrointestinal | 1992 |
Double-blind randomized controlled trial of flurbiprofen-SR (ANSAID-SR) and diclofenac sodium-SR (Voltaren-SR) in the treatment of osteoarthritis.
Topics: Adolescent; Adult; Aged; Diclofenac; Double-Blind Method; Flurbiprofen; Humans; Middle Aged; Osteoar | 1992 |
Double-blind comparison of etodolac SR and diclofenac SR in the treatment of patients with degenerative joint disease of the knee.
Topics: Aged; Delayed-Action Preparations; Diclofenac; Double-Blind Method; Etodolac; Female; Hematocrit; He | 1992 |
Clinical evaluation of a new NSAID applied topically (BPAA gel) vs. diclofenac emulgel in elderly osteoarthritic patients.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Gels; Humans; Middle A | 1992 |
Double blind randomized controlled trial of sodium meclofenamate (Meclomen) and diclofenac sodium (Voltaren): post validation reapplication of the WOMAC Osteoarthritis Index.
Topics: Adult; Diclofenac; Double-Blind Method; Female; Humans; Male; Meclofenamic Acid; Middle Aged; Osteoa | 1992 |
Efficacy and tolerability of diclofenac dispersible in elderly patients with osteoarthritis.
Topics: Administration, Oral; Aged; Aged, 80 and over; Diclofenac; Double-Blind Method; Drug Administration | 1991 |
[Clinical experiences with tenoxicam. Preliminary results of a multicenter study].
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Double-Blind Method; Female; Human | 1991 |
Relationship between severity and clinical importance of symptoms in osteoarthritis.
Topics: Clinical Trials as Topic; Diclofenac; Double-Blind Method; Female; Flurbiprofen; Humans; Male; Middl | 1991 |
A microcomputer-assisted study of nabumetone and slow release diclofenac in osteoarthritis.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Butanones; Delayed-Action P | 1990 |
A controlled comparison of piroxicam and diclofenac in patients with osteoarthritis.
Topics: Activities of Daily Living; Diclofenac; Double-Blind Method; Gastrointestinal Diseases; Humans; Midd | 1990 |
Flurbiprofen versus diclofenac for the treatment of osteoarthritis of the knee.
Topics: Adult; Aged; Diclofenac; Double-Blind Method; Female; Flurbiprofen; Humans; Knee Joint; Male; Middle | 1990 |
Controlled-release indomethacin and sustained-release diclofenac sodium in the treatment of osteoarthritis: a comparative controlled clinical trial in general practice.
Topics: Adult; Aged; Delayed-Action Preparations; Diclofenac; Double-Blind Method; Female; Humans; Indometha | 1990 |
Recent clinical experience with etodolac in the treatment of osteoarthritis of the knee.
Topics: Activities of Daily Living; Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Clinic | 1989 |
A global safety evaluation of etodolac.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Clinical Tr | 1989 |
[Double-blind randomized multicenter study with tenoxicam, piroxicam and diclofenac sodium retard in the treatment of ambulatory patients with arthroses and soft tissue rheumatism].
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Delayed-Action Preparations; Diclofenac; Doubl | 1989 |
[Piroxicam gel versus diclofenac gel in active gonarthroses].
Topics: Adult; Aged; Aged, 80 and over; Clinical Trials as Topic; Diclofenac; Female; Gels; Humans; Knee Joi | 1989 |
A double-blind randomised multicentre study with tenoxicam, piroxicam and diclofenac sodium retard in the treatment of ambulant patients with osteoarthritis and extra-articular rheumatism.
Topics: Aged; Ambulatory Care; Anti-Inflammatory Agents, Non-Steroidal; Delayed-Action Preparations; Diclofe | 1989 |
Mefenamic acid compared with diclofenac sodium in elderly patients with osteoarthritis.
Topics: Aged; Aged, 80 and over; Clinical Trials as Topic; Diclofenac; Double-Blind Method; Female; Follow-U | 1988 |
Tenoxicam or diclofenac in the treatment of gonarthrosis.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials as Topic; Diclofenac; Double-Blind Me | 1987 |
International experiences with diclofenac in osteoarthritis.
Topics: Aspirin; Clinical Trials as Topic; Diclofenac; Diflunisal; Double-Blind Method; Gastrointestinal Dis | 1986 |
Efficacy of diclofenac in osteoarthritis. Experience in the United States.
Topics: Adult; Aged; Aspirin; Clinical Trials as Topic; Diclofenac; Double-Blind Method; Hip Joint; Humans; | 1986 |
Mefenamic acid and diclofenac sodium in osteoarthritis of the weight bearing joints: a double blind comparison.
Topics: Adult; Aged; Clinical Trials as Topic; Diclofenac; Double-Blind Method; Female; Humans; Male; Mefena | 1985 |
A comparison of naproxen and diclofenac sodium in the treatment of osteoarthritis in elderly patients.
Topics: Aged; Clinical Trials as Topic; Diclofenac; Double-Blind Method; Female; Humans; Male; Naproxen; Ost | 1985 |
Double-blind preference and compliance multicentre study in osteoarthritis: once-a-day treatment.
Topics: Adult; Aged; Aspirin; Clinical Trials as Topic; Diclofenac; Double-Blind Method; Drug Administration | 1985 |
[Comparative open study between proglumetacin and diclofenac in the treatment of arthrosis of the hip and the knee].
Topics: Adult; Aged; Anti-Inflammatory Agents; Clinical Trials as Topic; Diclofenac; Female; Hip Joint; Huma | 1985 |
Worldwide clinical safety experience with diclofenac.
Topics: Aspirin; Clinical Trials as Topic; Diclofenac; France; Humans; Ibuprofen; Japan; Osteoarthritis; Rhe | 1985 |
[Double blind comparison between imidazole-2-hydroxybenzoate and diclofenac sodium in the treatment of osteoarthrosis in geriatric patients].
Topics: Aged; Anti-Inflammatory Agents; Clinical Trials as Topic; Diclofenac; Double-Blind Method; Female; H | 1985 |
128 other studies available for diclofenac and Osteoarthritis
| Article | Year |
|---|---|
Selective cannabinoid receptor type 2 (CB2) agonists: optimization of a series of purines leading to the identification of a clinical candidate for the treatment of osteoarthritic pain.
Topics: Animals; Dogs; Guanosine 5'-O-(3-Thiotriphosphate); HEK293 Cells; Humans; Male; Osteoarthritis; Puri | 2013 |
Discovery of N-(4-Fluoro-3-methoxybenzyl)-6-(2-(((2S,5R)-5-(hydroxymethyl)-1,4-dioxan-2-yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide. A Highly Selective and Orally Bioavailable Matrix Metalloproteinase-13 Inhibitor for the Potential Treat
Topics: Animals; Cartilage, Articular; Collagenases; Dogs; Drug Design; Humans; Kidney; Macaca fascicularis; | 2016 |
Substituted Indazoles as Nav1.7 Blockers for the Treatment of Pain.
Topics: Analgesics; Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Electrophysiology; Ev | 2016 |
NSAID-Induced Colopathy.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Colonic Diseases; Colonoscopy; Diclofenac; Humans; Ma | 2021 |
Hyaluronan injection versus oral glucosamine and diclofenac in the treatment of temporomandibular joint osteoarthritis.
Topics: Cohort Studies; Diclofenac; Glucosamine; Humans; Hyaluronic Acid; Osteoarthritis; Retrospective Stud | 2022 |
Association of tramadol with all-cause mortality, cardiovascular diseases, venous thromboembolism, and hip fractures among patients with osteoarthritis: a population-based study.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Codeine; Cohort Studies; Cyc | 2022 |
[Evaluation of topical therapy of patients with osteoarthritis of small joints of the hands with Voltaren® Emulgel® 2% (diclofenac diethylamine 2%)].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthralgia; Diclofenac; Female; Humans; Male; Osteoarthriti | 2021 |
Does cartilage ERα overexpression correlate with osteoarthritic chondrosenescence? Indications from
Topics: Aging; Animals; Bone Development; Cartilage; Chondrocytes; Diclofenac; Disease Models, Animal; Estro | 2019 |
Association of tramadol with risk of myocardial infarction among patients with osteoarthritis.
Topics: Aged; Aged, 80 and over; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Codeine; Diclo | 2020 |
Thermoresponsive Hyalomer intra-articular hydrogels improve monoiodoacetate-induced osteoarthritis in rats.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Experimental; Cartilage, Articular; Dic | 2020 |
Comparison of diclofenac with apigenin-glycosides rich Clinacanthus nutans extract for amending inflammation and catabolic protease regulations in osteoporotic-osteoarthritis rat model.
Topics: Administration, Oral; Animals; Apigenin; Cytokines; Diclofenac; Disease Models, Animal; Dose-Respons | 2020 |
[Residual Property of SI-613, a Novel Drug for Osteoarthritis, in Knee Joint].
Topics: Animals; Cartilage; Diclofenac; Disease Models, Animal; Hyaluronic Acid; Injections, Intra-Articular | 2020 |
Reinforced Supramolecular Hydrogels from Attapulgite and Cyclodextrin Pseudopolyrotaxane for Sustained Intra-Articular Drug Delivery.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Bone Regeneration; Cyclodextrins; Diclofenac; Dise | 2021 |
Mistletoe fig (Ficus deltoidea Jack) leaf extract prevented postmenopausal osteoarthritis by attenuating inflammation and cartilage degradation in rat model.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Apigenin; Cartilage; Collagen Type II; Diclofenac; | 2017 |
NSAIDs relieve osteoarthritis (OA) pain, but cardiovascular safety in question even for diclofenac, ibuprofen, naproxen, and celecoxib: what are the alternatives?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Diclofenac; Humans; Ibuprofen; Naproxen; Network | 2017 |
Efficacy and safety of diclofenac in osteoarthritis: Results of a network meta-analysis of unpublished legacy studies.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Female; Humans; Ibuprofen; Male; Middle Aged; N | 2017 |
Java Tea (Orthosiphon stamineus) protected against osteoarthritis by mitigating inflammation and cartilage degradation: a preclinical study.
Topics: Animals; Arthritis, Experimental; Cartilage, Articular; Diclofenac; Dose-Response Relationship, Drug | 2018 |
Risk of myocardial infarction with use of selected non-steroidal anti-inflammatory drugs in patients with spondyloarthritis and osteoarthritis.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Case-Control Studies; Diclo | 2018 |
Etoricoxib and Diclofenac Might Reduce the Risk of Dementia in Patients with Osteoarthritis: A Nation-Wide, Population-Based Retrospective Cohort Study.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cohort Studies; Dementia; Diclofenac; Etoricoxib; Fem | 2018 |
Effect of diclofenac etalhyaluronate (SI-613) on the production of high molecular weight sodium hyaluronate in human synoviocytes.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cell Adhesion Molecules; Cells, Cult | 2019 |
Lower gastrointestinal adverse effects of NSAIDS: an extreme example of a common problem.
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Colectomy; Colon; Colonic Diseases; D | 2013 |
Nonsteroidal anti-inflammatory drugs and their risk: a story still in development.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthralgia; Arthritis, Rheumatoid; Cardiovascular Diseases; | 2013 |
[Topical therapy of arthritis with diclofenac is safe].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Evidence-Based Medicine; Gastrointestinal Disea | 2014 |
A cost-effectiveness analysis of celecoxib compared with diclofenac in the treatment of pain in osteoarthritis (OA) within the Swedish health system using an adaptation of the NICE OA model.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cost-Benefit Analysis; Cyclooxygenase 2 Inhibito | 2014 |
Aceclofenac-loaded chondroitin sulfate conjugated SLNs for effective management of osteoarthritis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Chondroitin Sulfates; Delayed-Action Preparations; | 2014 |
How to mechanistically explain the CONDOR study data.
Topics: Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Humans; Intestinal Mucosa | 2015 |
Clinical inquiry: does topical diclofenac relieve osteoarthritis pain?
Topics: Administration, Cutaneous; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Humans; Osteoarthrit | 2015 |
Nonsteroidal anti-inflammatory drugs in-vitro and in-vivo treatment and Multidrug Resistance Protein 4 expression in human platelets.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Platelets; Case-Control Studies | 2016 |
Diclocor is superior to diclofenac sodium and quercetin in normalizing biochemical parameters in rats with collagen-induced osteoarthritis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Collagen; Diclofenac; Disease Models, Animal; Drug | 2016 |
Thermoresponsive nanospheres with independent dual drug release profiles for the treatment of osteoarthritis.
Topics: Anilides; Cell Differentiation; Chitosan; Chondrocytes; Diclofenac; Drug Carriers; Female; Humans; M | 2016 |
[Articular cartilage in osteoarthritic patients: effects of diclofenac, celecoxib and glucosamine sulfate on inflammatory markers].
Topics: Aged; Analysis of Variance; Anti-Inflammatory Agents, Non-Steroidal; Biomarkers; Cartilage, Articula | 2007 |
A novel Diclofenac-carrier for local treatment of osteoarthritis applying live-animal MRI.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Collagen Type I; Delayed-Action Preparations; Dicl | 2009 |
Treating osteoarthritis topically: Voltaren Gel for pain relief.
Topics: Administration, Topical; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Female; Humans; Osteoa | 2009 |
[Effect of protracted therapy with chondroprotectors and non-steroidal anti-inflammatory drugs on the quality of life in patients with osteoarthrosis].
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Chondroitin Sulfates; Diclofenac; Female; Huma | 2009 |
Photoallergic contact dermatitis due to diclofenac with cross-reaction to aceclofenac: two case reports.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Dermatitis, Photoallergic; Diclofenac; Female; Humans; Male | 2009 |
Capsule endoscopy and nonsteroidal anti-inflammatory drugs (NSAID)-induced enteropathy--a bit of light in a long, dark tunel.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Capsule Endoscopy; Clinical Trials as To | 2010 |
Macroscopic small bowel mucosal injury caused by chronic nonsteroidal anti-inflammatory drugs (NSAID) use as assessed by capsule endoscopy.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Capsule Endoscopy; Cyclooxygenase 2 Inhibitors | 2010 |
Nonopioid analgesics for osteoarthritis: availability of topical NSAIDs.
Topics: Administration, Cutaneous; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Drug Approval; Human | 2010 |
NSAIDs and risk of lower gastrointestinal bleeding.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthritis, Rheumatoid; Celecoxib; Coloni | 2010 |
Local application of the endocannabinoid hydrolysis inhibitor URB597 reduces nociception in spontaneous and chemically induced models of osteoarthritis.
Topics: Action Potentials; Afferent Pathways; Age Factors; Animals; Arthralgia; Benzamides; Carbamates; Dicl | 2011 |
Are traditional NSAIDs prescribed appropriately among French elderly with osteoarthritis? Results from the CADEUS cohort.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Cohort Studies; Diclofenac; Drug I | 2011 |
Evaluation of NT-proBNP and high sensitivity C-reactive protein for predicting cardiovascular risk in patients with arthritis taking longterm nonsteroidal antiinflammatory drugs.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Biomarkers; C-Reactive Protein | 2011 |
[Topical treatment with diclofenac with improved effect (Diclo Duo spray)].
Topics: Administration, Cutaneous; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Humans; Nebulizers a | 2010 |
Severe acute liver injury associated with lumiracoxib.
Topics: Acute Disease; Autoantibodies; Chemical and Drug Induced Liver Injury; Cyclooxygenase 2 Inhibitors; | 2012 |
The cost-effectiveness of celecoxib vs diclofenac in the treatment of osteoarthritis in the UK; an update to the NICE model using data from the CONDOR trial.
Topics: Advisory Committees; Aged; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cost-Benefit Analysis | 2012 |
Tolerability of topical diclofenac sodium 1% gel for osteoarthritis in seniors and patients with comorbidities.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Co | 2012 |
Efficacy test of Polycan, a beta-glucan originated from Aureobasidium pullulans SM-2001, on anterior cruciate ligament transection and partial medial meniscectomy-induced-osteoarthritis rats.
Topics: Administration, Oral; Animals; Anterior Cruciate Ligament; Anti-Inflammatory Agents, Non-Steroidal; | 2012 |
Analgesic effects of lidocaine, morphine and diclofenac on movement-induced nociception, as assessed by the Knee-Bend and CatWalk tests in a rat model of osteoarthritis.
Topics: Administration, Oral; Analgesics; Animals; Arthralgia; Diclofenac; Disease Models, Animal; Injection | 2012 |
Pooled safety analysis of diclofenac sodium topical solution 1.5% (w/w) in the treatment of osteoarthritis in patients aged 75 years or older.
Topics: Administration, Topical; Aged; Aged, 80 and over; Analysis of Variance; Anti-Inflammatory Agents, No | 2012 |
Causation: Recurrent collagenous colitis following repeated use of NSAIDs.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Colitis; Collagen; Diarrhea; Diclo | 2002 |
Modelling therapeutic strategies in the treatment of osteoarthritis: an economic evaluation of meloxicam versus diclofenac and piroxicam.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials as Topic; Decision Support Techniques; Dicl | 2003 |
Preoperative irradiation for prevention of heterotopic ossification following prosthetic total hip replacement results of a prospective study in 462 hips.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arthroplasty, Replacement, | 2003 |
Celecoxib has a positive effect on the overall metabolism of hyaluronan and proteoglycans in human osteoarthritic cartilage.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cartilage, Articular; Celecoxib; Diclofenac; Dose-Res | 2003 |
Risk factors of adverse drug reaction from non-steroidal anti-inflammatory drugs in Shanghai patients with arthropathy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheu | 2004 |
Effect of diclofenac alone or in combination with alpha-tocopherol on the oxidative activity of polymorphonuclear leukocytes in healthy and osteoarthritic individuals.
Topics: alpha-Tocopherol; Antioxidants; Case-Control Studies; Diclofenac; Dose-Response Relationship, Drug; | 2004 |
Evidence in practice--number 3: Cox 2 inhibitors.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase Inhibitors; Diclofenac; Evidence-Based Medic | 2004 |
COX-2 drug may help treat osteoarthritis.
Topics: Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Humans; Isoenz | 2004 |
Lumiracoxib in the treatment of osteoarthritis, rheumatoid arthritis and acute postoperative dental pain: results of three dose-response studies.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Arthritis, Rheumatoid; Clinical Trials, Phase II as T | 2005 |
Tolerance of diclofenac after hypersensitivity to celecoxib and to nabumetone.
Topics: Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Butanones; Celecoxib; Cyclooxygenase Inh | 2006 |
Clinical trial design and patient demographics of the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) study program: cardiovascular outcomes with etoricoxib versus diclofenac in patients with osteoarthritis and rheumatoid arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Aspirin; Cyclooxygenase Inhibitors; | 2006 |
Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Cyclo | 2006 |
Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Cyclo | 2006 |
Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Cyclo | 2006 |
Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Cyclo | 2006 |
Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Cyclo | 2006 |
Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Cyclo | 2006 |
Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Cyclo | 2006 |
Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Cyclo | 2006 |
Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Cyclo | 2006 |
Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Cyclo | 2006 |
Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Cyclo | 2006 |
Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Cyclo | 2006 |
Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Cyclo | 2006 |
Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Cyclo | 2006 |
Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Cyclo | 2006 |
Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Cyclo | 2006 |
[By what means does the rheumatic patient with gastrointestinal risks fare best?].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Controlled Clinical Trials as Topic; | 2007 |
An economic model of long-term use of celecoxib in patients with osteoarthritis.
Topics: Age Factors; Analysis of Variance; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cost-Benefit | 2007 |
[Coronary risks with NSAID and coxibs. The end of hysteria].
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Cause | 2006 |
[3 questions about gastrointestinal risk. Are coxibs here clearly better than NSAID?]].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Cyclooxygen | 2006 |
Treating osteoarthritis in the elderly: should recent data on NSAIDs change our way of practice?
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase 2 Inhibitors; Databases, Factual; Dicl | 2007 |
Australian drugs regulator cancels registration of COX 2 inhibitor.
Topics: Australia; Cyclooxygenase 2 Inhibitors; Diclofenac; Drug Approval; Humans; Osteoarthritis | 2007 |
Advice for nurses on drug withdrawal.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Australia; Cyclooxygenase 2 Inhibitors; Diclofenac; Drug Ap | 2007 |
Diclofenac sodium: blood concentration of the slow-release form and influence on the metabolism of kallikrein.
Topics: Adult; Delayed-Action Preparations; Diclofenac; Female; Humans; Kallikreins; Male; Osteoarthritis; P | 1984 |
Anaphylactic shock induced by diclofenac.
Topics: Aged; Anaphylaxis; Diclofenac; Humans; Male; Osteoarthritis; Phenylacetates | 1983 |
Osteoarthritis and non-steroidal and anti-inflammatory drugs: a multi-centre comparative study.
Topics: Aged; Diclofenac; Female; Hip Joint; Humans; Ibuprofen; Indenes; Knee Joint; Male; Naproxen; Osteoar | 1982 |
Voltarol 50mg in arthritis: a dosage study.
Topics: Adolescent; Adult; Aged; Arthritis, Rheumatoid; Diclofenac; Drug Administration Schedule; Drug Toler | 1982 |
An interim report on a multicentre general practice study of Voltarol. 2) Osteoarthritis.
Topics: Adolescent; Adult; Aged; Diclofenac; Family Practice; Female; Humans; Male; Middle Aged; Osteoarthri | 1980 |
[Therapy of degenerative arthropathies with sodium diclofenac].
Topics: Adult; Aged; Bone Diseases; Diclofenac; Female; Humans; Indomethacin; Joint Diseases; Male; Middle A | 1980 |
Effects of tenidap on canine experimental osteoarthritis. I. Morphologic and metalloprotease analysis.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Cartilage; Collagenases; Dic | 1995 |
Histological findings in gastric mucosa in patients treated with non-steroidal anti-inflammatory drugs.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Chronic Disease; Diclofenac; Female; Gastric M | 1995 |
Safety profile of etodolac in the elderly population.
Topics: Age Factors; Aged; Arthritis, Rheumatoid; Clinical Trials as Topic; Delayed-Action Preparations; Dic | 1994 |
Pharmacokinetics of diclofenac hydroxyethylpyrrolidine (DHEP) plasters in patients with monolateral knee joint effusion.
Topics: Administration, Cutaneous; Adult; Aged; Diclofenac; Female; Humans; Knee Joint; Male; Middle Aged; O | 1993 |
In vitro release of prostaglandins and leukotrienes from synovial tissue, cartilage, and bone in degenerative joint diseases.
Topics: Arthritis; Arthritis, Rheumatoid; Bone and Bones; Cartilage, Articular; Chondrocalcinosis; Culture T | 1993 |
Arthrotec for all?
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Drug Combinations; Female; Humans; Misopr | 1993 |
Prolonged effect of iodoacetate on articular cartilage and its modification by an anti-rheumatic drug.
Topics: Animals; Cartilage, Articular; Diclofenac; Iodoacetates; Iodoacetic Acid; Knee Joint; Male; Osteoart | 1993 |
Tenidap reduces the level of interleukin 1 receptors and collagenase expression in human arthritic synovial fibroblasts.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Blotting, Northern; Cells, Cultured; | 1996 |
Modulation of murine osteoarthritis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cartilage; Densitometry; Diclofenac; Disease Model | 1996 |
Effects of diacerhein on granuloma induced cartilage breakdown in the mouse.
Topics: Animals; Anthraquinones; Anti-Inflammatory Agents, Non-Steroidal; Cartilage, Articular; Cytokines; D | 1998 |
[Diclofenac/orphenadrine infusion therapy in patients with active arthrosis].
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Drug Administration Schedule; Drug Combin | 1998 |
[Vitamin E in rheumatic disease therapy?].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Arthritis, Rheumatoid; Diclofenac; Humans; Os | 1998 |
Economic evaluation of nimesulide versus diclofenac in the treatment of osteoarthritis in Greece.
Topics: Ambulatory Care; Anti-Inflammatory Agents, Non-Steroidal; Cost-Benefit Analysis; Diclofenac; Greece; | 1998 |
Diclofenac-associated hepatitis.
Topics: Alanine Transaminase; Alkaline Phosphatase; Anti-Inflammatory Agents, Non-Steroidal; Aspartate Amino | 1999 |
Aceclofenac: is the antiinflammatory effect really due to cyclooxygenase inhibition?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cells, Cultured; Chondrocytes; Diclo | 1999 |
Re: Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients (C. Hawkey et al., Br J Rheumatol 1998;37:937-45)
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase Inhibitors; Diclofenac; Humans; Meloxicam; O | 1999 |
Preference for nonsteroidal antiinflammatory drugs versus acetaminophen and concomitant use of both types of drugs in patients with osteoarthritis.
Topics: Acetaminophen; Aged; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Data Collect | 2000 |
Recurrence of Arthrotec-associated nephrotic syndrome with re-challenge.
Topics: Acute Kidney Injury; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Drug Combinations; Humans; | 2000 |
Effects of diclofenac, aceclofenac and meloxicam on the metabolism of proteoglycans and hyaluronan in osteoarthritic human cartilage.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cartilage, Articular; Culture Techniques; Diclofenac; Dose- | 2000 |
[Economic evaluation of the use of diclofenac/misoprostol in the treatment of osteoarticular diseases].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthritis, Rheumatoid; Cost-Benefit Anal | 2000 |
Inhibition of the nitrosothiol production of cultured osteoarthritic chondrocytes by rhein, cortisol and diclofenac.
Topics: Aged; Anthraquinones; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Chondrocyte | 2001 |
Iatrogenic cost factors incorporating mild and moderate adverse events in the economic comparison of aceclofenac and other NSAIDs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Diclofenac; Health Care Costs; Human | 2001 |
Photoallergic contact dermatitis from aceclofenac.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Dermatitis, Photoallergic; Diclofe | 2001 |
Celecoxib in osteoarthritis and rheumatoid arthritis: new preparation. As disappointing as rofecoxib.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Clinical Trials as Topic; Diclofenac | 2001 |
Anaphylactoid reaction to a cyclooxygenase-2 inhibitor in a patient who had a reaction to a cyclooxygenase-1 inhibitor.
Topics: Anaphylaxis; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxyge | 2001 |
Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs (ibuprofen, diclofenac, and nabumetone).
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Butanones; Cardiovascular Diseases; Clinical T | 2002 |
[Impact of the education of a patient with arthrosis].
Topics: Aged; Aged, 80 and over; Cyclooxygenase Inhibitors; Diclofenac; Drug Therapy, Combination; Exercise | 2002 |
Gastrointestinal medications and procedures in osteoarthritis patients treated with rofecoxib compared with nonselective NSAIDs.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Butanones; Clinical Trials | 2001 |
[Arthrosis drugs critically evaluated. Emphasis on cartilage protection].
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cartilage, Articular; Cyclooxygenase 2; Cyclooxygenas | 2002 |
A comparison of adverse renovascular experiences among osteoarthritis patients treated with rofecoxib and comparator non-selective non-steroidal anti-inflammatory agents.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Butanones; Clinical Trials, Phase II as Topic; Clinic | 2002 |
[Evaluation of parameters of inflammation in the clinical trial of sodic diclofanac in rheumatology].
Topics: Adult; Aged; Arthritis, Rheumatoid; Diclofenac; Drug Evaluation; Female; Humans; Middle Aged; Osteoa | 1977 |
[Effect of anti-inflammatory treatment by diclofenac on blood sedimentation especially during arthroses].
Topics: Adolescent; Adult; Aged; Aging; Blood Sedimentation; Diclofenac; Female; Humans; Joint Diseases; Mal | 1978 |
Factors affecting the pharmacokinetics of diclofenac sodium (Voltarol).
Topics: Absorption; Adult; Age Factors; Aged; Biological Availability; Diclofenac; Dosage Forms; Drug Intera | 1979 |
Anti-inflammatory efficacy versus gastrointestinal safety: a dilemma resolved? Introduction.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Diclofenac; Drug Combinations; Gastr | 1992 |
Chondrocytic monoamine oxidase activity in the development of natural murine osteoarthritis.
Topics: Animals; Cartilage, Articular; Diclofenac; Epinephrine; Knee Joint; Male; Mice; Mice, Inbred Strains | 1992 |
Chondroprotection, myth or reality: an experimental approach.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cartilage, Articular; Cells | 1990 |
Prevalence of mucosal lesions in the stomach and duodenum due to chronic use of NSAID in patients with rheumatoid arthritis or osteoarthritis, and interim report on prevention by misoprostol of diclofenac associated lesions.
Topics: Alprostadil; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthritis, Rheumatoid; Dicl | 1991 |
Reversible hepatitis associated with diclofenac.
Topics: Aged; Biopsy; Chemical and Drug Induced Liver Injury; Diclofenac; Female; Humans; Liver; Microscopy, | 1991 |
Diclofenac-associated hepatotoxicity.
Topics: Aged; Arthritis, Rheumatoid; Chemical and Drug Induced Liver Injury; Diclofenac; Female; Fibromyalgi | 1990 |
Ketoprofen vs naproxen or diclofenac sodium in osteoarthritis.
Topics: Diclofenac; Humans; Ketoprofen; Multicenter Studies as Topic; Naproxen; Osteoarthritis | 1990 |
Spontaneous osteo-arthritis of the knee-joint in C57BL mice receiving chronic oral treatment with NSAID's or prednisone.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Indomethacin; Joints; Male; Mice; Mice | 1990 |
Selective effect of diclofenac in the treatment of osteoarthritis versus dysmenorrhea.
Topics: Adult; Diclofenac; Dysmenorrhea; Female; Half-Life; Humans; Liver Function Tests; Osteoarthritis | 1990 |
[Efficacy of sucralfate in the prevention of stomach diseases induced by non-steroidal anti-inflammatory drugs].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Drug Evaluation; Drug Therapy, Combination; Fem | 1989 |
Histomorphological and lectin-histochemical confirmation of the antidegenerative effect of diclofenac in experimental osteoarthrosis.
Topics: Animals; Cartilage; Concanavalin A; Diclofenac; Histocytochemistry; Lectins; Male; Osteoarthritis; R | 1989 |
Quantitative criteria for evaluating the early development of osteoarthritis and the effect of diclofenac sodium.
Topics: Animals; Cartilage; Diclofenac; Glucosephosphate Dehydrogenase; Magnesium; Magnesium Chloride; Male; | 1989 |
Pathogenesis of osteoarthritis and use of diclofenac in the treatment of experimental models.
Topics: Animals; Anti-Inflammatory Agents; Cartilage, Articular; Diclofenac; Disease Models, Animal; Dogs; E | 1985 |
NSAID induced avascular necrosis and arthropathy of femoral head.
Topics: Aged; Aged, 80 and over; Diclofenac; Female; Femur Head Necrosis; Hip Prosthesis; Humans; Osteoarthr | 1987 |
Effects of Voltaren on arachidonic acid metabolism in arthritis patients.
Topics: Arachidonic Acid; Arachidonic Acids; Arthritis, Rheumatoid; Diclofenac; Dinoprostone; Humans; Hydrox | 1985 |
Severe reversible autoimmune haemolytic anaemia and thrombocytopenia associated with diclofenac therapy.
Topics: Aged; Anemia, Hemolytic, Autoimmune; Autoantibodies; Complement C3; Diclofenac; Erythrocytes; Female | 1986 |
Effects of sodium diclofenac on glycosaminoglycan metabolism in experimental osteoarthritis in rabbits.
Topics: Animals; Cartilage, Articular; Diclofenac; Glycosaminoglycans; Hyaluronic Acid; Immobilization; Oste | 1985 |
[Efficacy and tolerance of dexindoprofen compared with diclofenac sodium in the treatment of osteoarthrosis patients].
Topics: Adult; Aged; Anti-Inflammatory Agents; Diclofenac; Drug Tolerance; Female; Humans; Indoprofen; Male; | 1985 |
Synovial fluid concentrations of diclofenac in patients with rheumatoid arthritis or osteoarthritis.
Topics: Adult; Aged; Arthritis, Rheumatoid; Diclofenac; Humans; Kinetics; Metabolic Clearance Rate; Middle A | 1985 |
Worldwide experience with diclofenac in rheumatoid arthritis and osteoarthritis.
Topics: Arthritis, Rheumatoid; Aspirin; Diclofenac; Double-Blind Method; Humans; Indomethacin; Naproxen; Ost | 1985 |
Diclofenac sodium in the treatment of rheumatoid arthritis and osteoarthritis.
Topics: Arthritis, Rheumatoid; Aspirin; Diclofenac; Double-Blind Method; Female; Humans; Ibuprofen; Male; Mi | 1985 |